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Early detection of Barrett’s oesophagus and associated neoplasia is key to 
preventing progression to oesophageal adenocarcinoma. Improving 
surveillance and introducing population screening for Barrett’s are major goals 
of current research: this project aimed to apply emerging techniques in 
vibrational spectroscopy to these problems. 
Fourier transform infrared (FTIR) mapping was used to develop an automated 
histology tool for detection of Barrett’s and Barrett’s neoplasia in tissue biopsies. 
45 FTIR maps were measured from 22 tissue samples from 19 patients. 
Principal component analysis (PCA) fed linear discriminant analysis (LDA) was 
used to build classification models based on spectral differences, tested using 
leave one sample out cross validation (LOSOCV). Classification of normal 
squamous samples versus ‘abnormal’ samples (any stage of Barrett’s) was 
performed with 100% sensitivity and specificity. Using a 3-group model to 
differentiate normal squamous, non-dysplastic Barrett’s and neoplastic Barrett’s 
(dysplasia or adenocarcinoma), neoplastic Barrett’s was identified with 95.6% 
sensitivity and 86.4% specificity.  
Non-endoscopic cell collection devices have recently been developed for 
population screening for Barrett’s oesophagus. A further aim of this project was 
to evaluate FTIR for classification of oesophageal cells. Cytology brushings 
were collected at endoscopy, cytospun onto slides and FTIR maps measured. 
Cytology review and contemporaneous histology was used to inform a training 
dataset containing 141 cells from 17 patients. A classification model was 
constructed using PCA-fed LDA. Applying this training model to the entire 
dataset of 115 FTIR maps from 66 patients, whole samples were classified with 
v 
 
sensitivity and specificity respectively as follows: normal squamous 79.0% and 
77.0%, non-dysplastic Barrett’s 31.3% and 100%, and neoplastic Barrett’s 
83.3% and 54.2%.  
Raman spectroscopy was also evaluated as a tool for tissue diagnosis, but 
several strands of enquiry were limited by instrument problems.  
FTIR mapping could be used as an accurate, automated tool for processing 
biopsies in Barrett’s surveillance. Analysis of oesophageal cell samples can be 
performed using FTIR with reasonable sensitivity for Barrett’s neoplasia, though 
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RESEARCH CONTEXT AND AIMS 
Early diagnosis is the key to improving outcomes from oesophageal 
adenocarcinoma: although Barrett’s oesophagus is a recognised pre-malignant 
condition with established surveillance programmes for identified patients, over 
90% of oesophageal adenocarcinomas present as symptomatic tumours. 
Improving early detection is a major goal of current research: the two main 
approaches to achieving this goal are: 
1. Development of a non-endoscopic screening tool. 
2. Improvement of detection of dysplasia within current surveillance 
programmes to allow endotherapy and prevent progression. 
This research project addresses both of these aims using emerging techniques 
from vibrational spectroscopy. The use of infrared spectroscopy to classify 
oesophageal pathology is investigated, with the goal of applying infrared 
spectroscopy to oesophageal cells collected using a non-endoscopic cell 
collection device. This would allow screening amongst the general population, 
and revolutionise models of surveillance for patients known to have Barrett’s 
oesophagus.  
Raman spectroscopy is investigated with the goal of developing a Raman probe 
designed for use within the instrument channel of a conventional endoscope. 
This technique could potentially improve endoscopic detection of dysplasia, and 
enable targeted endotherapy. 
Both infrared and Raman spectroscopy are investigated as tools for automated 
histopathology: this could improve detection of dysplasia and reduce the 
workload of pathology departments in processing samples for Barrett’s 
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SECTION A: LITERATURE REVIEW 
CHAPTER 1: BARRETT’S OESOPHAGUS 
1. Barrett’s oesophagus 
1.1. Definitions 
Barrett’s oesophagus owes its eponym to Norman Barrett, a British thoracic 
surgeon who first described the condition in 1950 (Barrett 1950). He proposed 
that the condition resulted from a congenitally short oesophagus, with the 
stomach extending into the mediastinum (Barrett 1950). It was subsequently 
recognised that the condition was in fact acquired, with an oesophageal origin 
for the columnar mucosa, and an association with gastro-oesophageal reflux 
(Allison and Johnstone 1953). Barrett himself accepted this view, and later 
referred to it as ‘lower oesophagus lined by columnar epithelium’ (Barrett 1957). 
Barrett’s is now well-recognised as representing a metaplastic change from the 
normal squamous epithelial lining of the oesophagus to a columnar epithelium, 
predisposing to an increased risk of oesophageal adenocarcinoma, though 
there is variation among expert opinion on the precise defining characteristics. 
The British Society of Gastroenterology (BSG) guidelines include both 
endoscopic and histological criteria for diagnosis: 
‘Barrett’s oesophagus is defined as an oesophagus in which any portion of the 
normal distal squamous epithelial lining has been replaced by metaplastic 
columnar epithelium, which is clearly visible endoscopically (≥1cm) above the 
gastro-oesophageal junction and confirmed histopathologically from 
oesophageal biopsies’ (Fitzgerald et al. 2014). 
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Meanwhile for the American Gastroenterological Association the only criterion is 
the presence of intestinal metaplasia (IM) on biopsy, whilst the American 
College of Gastroenterology also requires IM and an endoscopically visible 
segment of columnar mucosa (but do not have a minimum length requirement 
in their definition) (Spechler et al. 2011; Wang and Sampliner 2008). 
The clinical significance of intestinal metaplasia is that it is the only histological 
subtype with strong evidence for risk of malignant progression – this is 
discussed in further detail, along with the other histological subtypes of 
columnar mucosa, in the section on histology (Fitzgerald et al. 2014; Spechler 
et al. 2011; Wang and Sampliner 2008).  
 
1.2. Epidemiology of oesophageal adenocarcinoma 
The incidence of oesophageal adenocarcinoma has shown a dramatic rise 
amongst Western populations during the latter portion of the 20th century 
(Edgren et al. 2013; Pera et al. 2005; Powell et al. 2002; Trivers, Sabatino, and 
Stewart 2008). Population data from the US and the UK showed a marked rise 
beginning in the 1960-70s (Powell and McConkey 1990; Yang and Davis 1988); 
this trend has continued and similar rises have been seen from Western Europe 
and Australia (Edgren et al. 2013). To date, the underlying cause of this rapid 
rise in incidence has not been fully explained (Edgren et al. 2013; Pera et al. 
2005). Whilst strong associations with  gastro-oesophageal reflux and obesity 
have been demonstrated, both of which have increased in Western populations 
in the late 20th century, these factors do not fully account for the changing 
epidemiology of this disease either alone or in combination, as population 
databases suggest an inflection point which precedes the increase in these risk 
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factors (Edgren et al. 2013; Pera et al. 2005). The rise in oesophageal 
adenocarcinoma also parallels the decreasing prevalence of Helicobacter Pylori 
infection in developed countries, suggesting the bacterium may have a 
protective effect (Labenz and Malfertheiner 1997). Data from the US suggest 
that the rate of increase has slowed, and incidence is reaching a plateau: 
national data show a yearly rate of increase of 8.2% from 1973 to 1996, 
followed by a 1.3% rise from 1996 to 2006 (Pohl, Sirovich, and Welch 2010). 
 
Figure 1-1 UK incidence of oesophageal cancer (all types), 1975-2010 
Reproduced from Cancer Research: http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/oesophagus/survival/#Trends (Accessed May 2014). 
There are now over 8000 cases of oesophageal cancer in the UK each year, 
but survival rates remain poor: only 20-30% of oesophageal cancers are 
potentially curable at presentation, and overall 5-year survival rate in the UK 




















Figure 1-2 UK survival from oesophageal cancer (all types) over time, 1971-
2009. Reproduced from Cancer Research: http://www.cancerresearchuk.org/ 
cancer-info/cancerstats/types/oesophagus/survival/#Trends (Accessed May 
2014). 
 
1.3. Epidemiology of Barrett’s oesophagus 
The majority of patients with Barrett’s oesophagus (BO) are asymptomatic and 
remain undiagnosed, and thus the true population prevalence is uncertain 
(Cameron et al. 1990; Dulai et al. 2002; de Jonge et al. 2013). The population 
who become symptomatic and present may represent a subpopulation which 
could further confound epidemiological data (de Jonge et al. 2013).  
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Estimates have been derived from population studies, autopsy findings and 
studies undertaking endoscopy in volunteer populations (both symptomatic and 
asymptomatic groups).  
Rex et al. (2003) offered upper gastrointestinal (GI) endoscopy to patients 
scheduled for colonoscopy with no prior history of 
oesophagogastroduodenoscopy (OGD) and found 6.8% overall had Barrett’s 
oesophagus. Heartburn symptoms did not significantly increase the risk of 
Barrett’s, but were associated with an increased risk of long-segment Barrett’s 
(Rex et al. 2003). In a similar study in a group of patients all over the age of 65, 
an even higher prevalence of 16.7% was reported (Ward et al. 2006). However 
it is likely that the selection bias from including older patients with pre-existing 
indications for colonoscopy gives a significant over-estimate.  
Population based studies in unselected patients have reported lower 
prevalences of BO, with a study in 1000 volunteers in Sweden finding a 
prevalence of 1.6%, and subsequent studies in Italy and China 1.3% and 1.9% 
respectively (Ronkainen et al. 2005; Zagari et al. 2008; Zou et al. 2011). 
Extrapolating these estimates from unselected patients to the UK population 
would suggest there are in the region of 1 million people with Barrett’s 
oesophagus in the UK.  
 
1.4. Risk factors for Barrett’s oesophagus 
Gastro-oesophageal reflux disease (GORD) is the key risk factor for developing 
BO (Lagergren et al. 1999) and as such BO can be viewed as a response to 
chronic injury: a protective effect from frequent acid reflux. A meta-analysis of 
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26 studies found GORD to be associated with long segment BO, but the 
association for short segment BO (SSBO) was less clear (Taylor and 
Rubenstein 2010). In one cohort, 25% of patients undergoing endoscopy for 
symptoms of gastro-oesophageal reflux were found to have endoscopic 
columnar-lined oesophagus (Balasubramanian et al. 2012). This study also 
found heartburn duration >5 years, and hiatus hernia to be risk factors for BO 
(Balasubramanian et al. 2012). Hiatus hernia is often associated with symptoms 
of GORD, and has also been identified as a risk factor for BO in an earlier study 
(Avidan et al. 2002). A number of other conditions are less-commonly 
associated with a risk of BO and are shown in Table 1-1 below. 
 
Table 1-1 Conditions associated with the development of Barrett’s oesophagus 
Chronic oesophageal reflux (>60% of cases) 
Congenital retardation syndromes (1%) 
Non-steroidal anti-inflammatory drugs (1%) 
Chemotherapy (<1%) 
Viral oesophagitis (<1%) 
Reproduced from Jankowski et al. 2010. 
 
Male gender and older age are the major demographic factors which 
predispose to BO, and Caucasian race has also been implicated 
(Balasubramanian et al. 2012; Cook, Wild, and Forman 2005; Edelstein et al. 
2009; Eloubeidi and Provenzale 2001; Gerson et al. 2001). Central obesity 
appears to be a risk factor (both waist-to-hip ratio and abdominal 
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circumference) (Corley et al. 2007; Edelstein et al. 2007, 2009), but studies 
based on BMI have led to conflicting results (Anderson et al. 2007; Corley et al. 
2007; Edelstein et al. 2007; El-Serag et al. 2005). A number of studies have 
implicated smoking as a risk factor for Barrett’s but this has not been 
demonstrated in every study (Anderson et al. 2007; Edelstein et al. 2009; Kubo 
et al. 2009; Smith et al. 2005).  
A recent study by Liu et al. attempted to risk stratify those referred for upper 
gastrointestinal endoscopy on demographic risk factors for BO (Liu et al. 2014). 
Their training model included 1,603 patients and determined the following 
factors predictive of BO (any length of columnar lined oesophagus): age, male 
sex, acid reflux (classified as ‘never or sometimes’ or ‘often and daily’), and anti-
reflux medication. Among this cohort of patients referred for endoscopy, 
abdominal pain and chest pain were negative predictors of BO. Smoking was 
not an independent risk factor once other risk factors were accounted. 
As mentioned earlier, there is epidemiological evidence that Helicobacter pylori 
(H. pylori) infection may have a protective effect against oesophageal cancer 
(Labenz and Malfertheiner 1997). It has been posited that long term H. pylori 
infection leads to multifocal atrophic gastritis, and consequently reduced gastric 
acid secretion, as a possible mechanism of protecting against Barrett’s 
oesophagus, and adenocarcinoma (Molloy and Sonnenberg 1997).   
A positive family history for HGD or OAC increases the risk of developing BO, 
with one study calculating a 28% risk for first-degree relatives (Juhasz et al. 
2011). Much recent work has focused on identifying genetic markers that are 
associated with an increased risk of BO and OAC.  In a genome-wide 
association study comparing 1852 patients with Barrett’s against 5172 controls 
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run by the Esophageal Adenocarcinoma Genetics Linkage consortium 
(EAGLE), 2 genetic loci were identified that were strongly associated with a 
small increased risk of Barrett’s (6p21 and 16q24) (Su et al. 2012). 
 
1.5. Natural history 
Whilst the sequence of progression from metaplasia to low grade, then high 
grade dysplasia, followed by carcinoma, is well characterised (Jankowski et al. 
1999), the exact risk of progression has been the subject of debate. The 
historically quoted cancer risk of 0.5% per patient per year was derived largely 
from small case series (Fitzgerald et al. 2014): more recent, population-based 
studies have revised this figure down. A study in Northern Ireland followed 
8,522 patients with Barrett’s oesophagus for a mean 7 years, and found risk of 
progression to high grade dysplasia (HGD) or adenocarcinoma was 0.22% per 
year, with a risk of 0.16% per year for adenocarcinoma alone (Bhat et al. 2011). 
A Danish study which identified patients with IM-type Barrett’s oesophagus from 
the Danish Pathology Registry followed up 11,028 patients for median 5.2 years 
(Hvid-Jensen and Pedersen 2011). This group found progression to HGD or 
adenocarcinoma in 0.26% per year, and 0.12% for adenocarcinoma alone. 
Examining non-dysplastic Barrett’s in isolation, the risk of adenocarcinoma was 
0.10% per year.  
A similar population-wide study carried out in the Netherlands followed up 
42,207 patients with a histological diagnosis of Barrett’s oesophagus, of whom 
16,333 underwent surveillance endoscopy (though the clinical reasons for 
choosing surveillance were not recorded in this retrospective study) (de Jonge 
et al. 2010). In those who entered surveillance, after excluding patients with a 
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diagnosis of HGD or adenocarcinoma within 12 months of the first endoscopy, 
the risk of progression to HGD or adenocarcinoma was 0.58%, and 0.43% for 
adenocarcinoma alone. Examining the group as a whole and including those 
who did not receive surveillance endoscopy, the risk of progression to 
adenocarcinoma was lower at 0.14%.  
A large meta-analysis totalling 58,547 patient-years of follow up reported an 
incidence of adenocarcinoma of 0.33% per patient per year (Desai et al. 2012). 
However there is significant geographical variation in incidence of oesophageal 
adenocarcinoma, and it is possible that the risk for patients with Barrett’s varies 
between regions. One meta-analysis of data exclusively from the UK (prior to 
the study by Bhat et al. in 2011) suggested the risk for UK patients is around 
1.0% (Jankowski, Provenzale, and Moayyedi 2002). 
One study suggested that the risk of progression to adenocarcinoma reduces 
with length of time in surveillance (Gaddam et al. 2013). Stratifying patients by 
number of endoscopies under surveillance (and hence time), those patients with 
persistent Barrett’s but no progression to dysplasia had a reducing risk of 
progression with time under surveillance. This suggests that those who are 
going to progress are more likely to do so early in the course of disease, and 
the authors conclude that endoscopy intervals could be lengthened for patients 
under surveillance for several years with stable pathology. 
There is further variation in the reported incidence of progression of low grade 
dysplasia (LGD). The Danish group found the risk of progression to 
adenocarcinoma if LGD was detected at index endoscopy was 1.27% per year 
(Hvid-Jensen and Pedersen 2011). Similarly, a study of 210 patients with LGD 
followed up for mean 6.2 years found a combined risk of HGD/oesophageal 
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adenocarcinoma (HGD/OAC) of 1.86% per year (Wani et al. 2011). However 
this study also noted significant inter-observer disagreement on diagnosis of 
LGD even by experienced pathologists. Other studies have suggested a higher 
rate of progression. A large multi-centre cohort study followed 156 patients with 
LGD for a mean 4.1 years and found progression to HGD/OAC in 13% 
(Sharma, Falk, et al. 2006). A recent RCT of radiofrequency ablation (RFA) 
versus surveillance for LGD reported a rate of progression to HGD/OAC of 
26.5% over 3 years in the control arm, with progression to OAC in 8.8% (Phoa 
et al. 2014). 
The variation in reported risk may reflect the difficulties in achieving consensus 
pathology with LGD: over diagnosis may result in underestimates for the true 
risk of progression.  
For patients diagnosed with HGD on biopsies there is a significant risk that 
intra-mucosal adenocarcinoma may be present but has not been identified on 
the initial biopsies. A number of studies have examined oesophagectomy 
specimens performed for HGD. A systematic review of these studies calculated 
a pooled average of 39.9% for the occurrence of either intra-mucosal or 
invasive OAC (Konda et al. 2008). The risk of invasive OAC was 11% in those 










1.6.1.1. The normal oesophagus: squamous epithelium 
In cross section the oesophageal wall is composed of mucosa, which is 
separated from submucosa by the muscularis mucosae, with circular and 
longitudinal muscle layers outside the submucosa, all surrounded by a thick 
covering of connective tissue, the adventitia (Shepherd 2013). 
 
Figure 1-3 Microanatomy of the wall of the oesophagus. A Normal squamous 
epithelium-lined mucosa; B Muscularis mucosae; C Submucosa; D Submucosal 
glands. Figure reproduced from Shepherd 2013. 
The mucosa consists of a non-keratinising stratified squamous epithelial lining, 
approximately 500-800μm thick (Shepherd 2013). This lies on a lamina propria, 
a loose connective tissue layer which separates the mucosa from a layer of 
muscle fibres, the muscularis mucosae. The submucosa contains gland 
structures, nerves and lymphatic vessels within a loose connective tissue 
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network. This rich lymphatic plexus contributes to the high rates of lymph node 
metastasis with oesophageal cancers invading the submucosa. 
 
Figure 1-4 Normal squamous epithelium of the oesophagus. Figure reproduced 
from Shepherd 2013. 
The extracellular matrix is composed of structural proteins such as collagen and 
fibronectin, and enzymes including the matrix metalloproteinases. This 
microenvironment can play a role in the dysplastic progression of Barrett’s 
oesophagus, provide support for developing tumours and promote tumour 
invasion (Picardo et al. 2012). Changes to its composition may occur with 
neoplasia and a number of matricellular proteins have been identified with 
altered expression in Barrett’s oesophagus or adenocarcinoma. Secreted 
protein acidic and rich in cysteine (SPARC) has multiple effects such as cell 
cycle modulation and antiproliferative functions, and is increased in BO and 
OAC (Botelho et al. 2010). Thrombospondin-1 (TSP-1) has an anti-angiogenic 
action and regulates growth factors, and is differentially expressed in OAC 
(Saadi et al. 2010). Osteopontin is another matricellular protein known to 
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promote metastasis that has been found to upregulated in OAC (Miller et al. 
2006). The matrix metalloproteinase (MMP) enzymes have a major role in 
turnover and remodelling of the extracellular matrix, along with tissue growth 
and angiogenesis. A number of MMPs (particularly MMP-1, -2, -3, -7 and -9) 
have been found to be increased along the progression from BO to OAC 
(Grimm et al. 2010; Groblewska et al. 2012; Herszenyi et al. 2007; Keld et al. 
2010; Lagarde et al. 2007; Miller et al. 2006; Salmela et al. 2001), suggesting 
that these changes occur early in the metaplasia-dysplasia-adenocarcinoma 
sequence. A study by Lagarde et al. (2007) identified MMP-1, -3, -7 and -9 as 
prognostic biomarkers for OAC.  
 
1.6.1.2. Barrett’s oesophagus 
As discussed earlier, BO is the replacement of the normal squamous epithelium 
with columnar epithelium through metaplastic change. This is thought to be 
chiefly a response to gastro-oesophageal reflux, with both the high acid content, 
and the reflux of bile and alkali from the duodenum thought to play a part in the 
development of neoplasia (Dixon et al. 2001; Lagergren et al. 1999; Vaezi and 
Richter 1996). Using a canine model, replacement of squamous epithelium with 
columnar epithelium was seen following high acid exposure (Gillen et al. 1988). 
This was demonstrated in the presence of squamous barriers to proximal 
migration of gastric columnar epithelium, thus highlighting that alternative 
mechanisms are involved other than simply proximal extension of gastric 
epithelium. A further argument against gastric migration has been the absence 
of goblet cells in non-metaplastic gastric epithelium. Other proposed candidates 
include pluripotent basal stem cells in squamous epithelium, or columnar cells 
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lining oesophageal gland ducts (Nicholson et al. 2012). However it has been 
recently argued that the evidence from non-animal models may be misleading, 
and the evidence from human studies points most strongly towards a cellular 
origin in the proximal columnar gastric or cardiac epithelium (McDonald et al. 
2015a). It thus seems most likely that development of Barrett’s oesophagus is a 
two-stage process, with migration of gastric epithelium followed by metaplastic 
change to intestinalisation with goblet cells (McDonald et al. 2015a;McDonald et 
al. 2015b). 
 
Figure 1-5 The structure of a typical Barrett’s gland. Haematoxylin and eosin 
shown in A, with corresponding protein expression highlighted in the schematic 
diagram in B. Reproduced from  McDonald et al. 2015b. 
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The stem cells which form the metaplastic glandular epithelium in Barrett’s arise 
in the neck of the gland and exhibit bidirectional migration (Lavery et al. 2014). 
Recent research has shown clonality of metaplastic glands in Barrett’s, 
indicating a common derivation from a single progenitor cell (Nicholson et al. 
2012). Multiple differentiated cell lineages have demonstrated clonality, 
indicating that pluripotent stem cells can populate large areas of epithelium 
(Nicholson et al. 2012). In the work by Nicholson et al. (2012), one patient 
exhibited a common clonal mutation in both glandular metaplastic tissue and 
regenerating squamous epithelium, suggesting a common cellular origin and 
therefore indicating plasticity in the undifferentiated precursor cell.  
Thus the current theory is that Barrett’s glands are clonal units sustained by 
multiple stem cells derived from a single (multipotent) common progenitor 
(McDonald et al. 2015b). 
There are three main types of epithelium that form columnar-lined oesophagus 
(CLO): cardiac, fundic and intestinal metaplasia (IM). A definitive histological 
diagnosis of CLO can only be made in the presence of native oesophageal 
structures such as submucosal glands or their associated ducts, or islands of 
squamous epithelium amongst the metaplastic glandular mucosa, which are 
invariably associated with submucosal glands (Coad et al. 2005). These 
features confirm that the columnar epithelium is unequivocally in the 
oesophagus, but are only present in around 10-15% of biopsy sets (Srivastava 
et al. 2007; Takubo, Nixon, and Jass 1995). Typically, a ‘patchwork’ of the three 
different subtypes of CLO is seen on biopsy samples (Shepherd 2013). 
Cardiac and fundic-type metaplasias are so named because of their 




Figure 1-6 Cardiac-type mucosa. Figure reproduced from 
http://www.barrettsinfo.com/content/3b_what _is_histology.cfm, (accessed 
20/01/15). 
 
Figure 1-7 Fundic-type mucosa. Figure reproduced from 




the stomach (cardia and fundus). Cardiac-type metaplasia contains glands but 
no oxyntic cells or goblet cells. Fundic-type metaplasia contains oxyntic cells 
but no goblet cells. Correlation with the site of biopsy at endoscopy is essential 
for correct classification here. 
The characteristic feature of intestinal metaplasia is the presence of goblet 
cells. Another feature which may be seen is non-goblet cells which stain 
positively with Alcian blue and indeed these ‘blue cells’ may be more prevalent 
than goblet cells (Shepherd 2013).  
 
 
Figure 1-8 Intestinal metaplasia.  
Figure reproduced from http://www.barrettsinfo.com/content/3b_what 
_is_histology.cfm, (accessed 20/01/15). 
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The role of IM in the diagnosis of BO is controversial. There is evidence to 
suggest that the risk of malignant progression associated with BO is much 
higher in those with identified IM than those with CLO without IM (Bhat et al. 
2011; Skinner et al. 1983). Difficulty arises, firstly, in identifying the presence of 
IM due to sampling error from mucosal biopsies. One study looked at long-
segment BO in 125 patients with a total of 1646 biopsies and concluded that, to 
demonstrate goblet cells in 67.9% of endoscopies required 8 biopsies, but if 
only 4 were taken goblet cells were identified in only 34.7% (Harrison et al. 
2007). Thus the absence of IM on biopsy does not reliably preclude the 
presence of IM. A further study followed patients with (612 patients) and without 
IM (322 patients) at index biopsy (Gatenby et al. 2008). They found that over 
50% of patients without IM were found to have IM at 5-year follow up, and over 
90% had IM at 10 years, though the extent to which this represents sampling 
error or new development of IM is not clear. The rates of progression to 
dysplasia and cancer were similar between groups.  
There is also emerging evidence that CLO that does not contain goblet cells 
may still show ‘intestinalisation’, and harbour molecular changes that suggest 
potential for malignant progression (Chaves et al. 2007; Hahn et al. 2009; Liu et 
al. 2009; Romagnoli et al. 2001). 
Despite these difficulties, the current US management guidelines all require IM 
as a necessary component of BO diagnosis (Spechler et al. 2011; Wang and 
Sampliner 2008). Historically, pathological opinion in the UK has successfully 
argued that IM should not be a defining feature of BO (Shepherd 2013; Watson, 
Heading, and Shepherd 2005), but this argument continues (Riddell and Odze 
2009). The most recent BSG guidelines have taken an intermediate position in 
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which IM is not required for the diagnosis of BO, but patients with biopsy-proven 
IM are managed differently from those without (discussed in section 1.9 below) 
(Fitzgerald et al. 2014). Commenting on the presence of IM is therefore a key 
component of the pathological reporting terms advocated in the updated BSG 
guidelines (see Table 1-2). 
 
Table 1-2 Pathological reporting of specimens  
‘Barrett’s oesophagus with gastric metaplasia only’ (glandular epithelium with 
cardiac/fundic metaplasia) 
‘Barrett’s oesophagus with IM’ 
‘No evidence of Barrett’s oesophagus’ (squamous epithelium without glandular 
tissue) 
Adapted from BSG guidelines (Fitzgerald et al. 2014). 
 
1.6.1.3. Dysplasia 
Dysplasia in BO is classified using the Riddell-type classification, as ‘indefinite 
for dysplasia’, low grade dysplasia (LGD), and high-grade dysplasia (HGD) 
(Shepherd 2013). The Vienna classification attempted to standardise diagnostic 
terminology worldwide, and resolve some of the differences between Western 
and Japanese classifications (Schlemper et al. 2000). Although both cytological 
and architectural features of dysplasia are well-described, there are no definitive 
criteria for dysplasia, and the distinction between grades of dysplasia is even 







Figure 1-9 Examples of A) low grade dysplasia and B) high grade dysplasia. 
Figures reproduced from Shepherd 2013. 
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The diagnosis of LGD is made largely on the basis of cytological atypia, with 
relative preservation of tissue architecture. HGD generally has abnormal 
glandular architecture and more marked cytological atypia (Shepherd 2013). A 
number of features are described that can help differentiate the two, and these 
are presented in Tables 1-3 and 1-4 below. 
 
Table 1-3 Pathological characteristics of low and high grade dysplasia 
Low Grade Dysplasia High Grade Dysplasia 
Cytology approximates to that of mild 
and moderate adenomatous dysplasia 
Nuclei enlarged, crowded, 
hyperchromatic and ovoid 
 
Mitotic activity may be substantial and 
atypical mitoses may be present 
Stratification is often present 
 
 
Architectural change, including villosity, 
may be present but in the appropriate 
cytological setting there is loss of the 
basal-luminal maturation/differentiation 
axis 
Cytology approximates to that of severe 
adenomatous dysplasia 
Nuclei enlarged, usually spheroidal, 
may have open chromatin pattern with 
nucleoli 
Mitotic activity may be substantial and 
atypical mitoses usually present 
Stratification may be present but there is 
usually pronounced cellular 
disorganization 
Architectural change, including villosity, 
glandular budding and complex 
glandular structures, is often present. 
There is loss of the basal-luminal 
maturation/differentiation axis 
 
Table adapted from Fléjou and Svrcek 2007 in Shepherd 2013. 
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It is important to appreciate that the distinctions between LGD and HGD are 
arbitrary cut-offs along a biological continuum, and as such strict definitions are 
not possible. Difficulties with poor inter-observer reliability in classifying 
dysplasia are well recognised (Kaye et al. 2009; Kerkhof et al. 2007; 
Montgomery et al. 2001; Reid et al. 1988; Shepherd 2013). This is particularly 
true for indefinite for dysplasia, and LGD (Shepherd 2013). A number of studies 
have shown that the prediction of progression is more accurate with consensus 
pathology (Curvers, ten Kate, et al. 2010; Skacel et al. 2002), and this has led 
to the current guidance for all dysplastic specimens in BO to be reported by a 
second gastrointestinal pathologist (Fitzgerald et al. 2014). 
Immunohistochemical biomarkers can be used by pathologists to provide further 
information for diagnosis. The most widely studied in BO is p53. The ability of 
p53 to stain positively for dysplasia has been variably reported (Kaye et al. 
2009, 2010; Khan et al. 1998; Murray et al. 2006) but there is evidence that it 
may improve interobserver agreement between pathologists (Kaye et al. 2009; 
Skacel et al. 2002) and serve as a marker of risk of progression (Kastelein et al. 
2013; Murray et al. 2006). The current BSG guidelines advise that it should be 
considered as an adjunct to improve diagnostic reliability, but some authors still 





Table 1-4 Comparison of cytological and architectural features of low and high 
grade dysplasia 
Feature LGD HGD 
Cytology 
Increased nuclear:cytoplasm ratio 
Loss of cell polarity 
Mitosis 
Atypical mitosis 
Full-thickness nuclear stratification 
Decreased goblet cells (+/- dystrophic) 
Hyperchromasia 
Multiple nucleoli 
Large irregular nucleoli 






Crowded (back-to-back) crypts 
Irregular crypt shapes 
Intraluminal papilla/ridges 














































1.6.1.4. Indefinite for dysplasia 
There are several reasons why it may not be possible for the pathologist to give 
a certain diagnosis of dysplasia based on the biopsy samples obtained from a 
patient. Significantly, this term may be used both for high quality samples where 
there is a low degree of suspicion of LGD, but may also be used for samples of 
low quality that contain possible features of dysplasia, which could include 
HGD. Clarification by the pathologist when using this term is helpful to guide 
further patient management. 
Difficulties in interpretation may be caused by technical factors such as crush 
artefact, poor staining or tangential sectioning (Shepherd 2013). Alternatively, 
other pathology or treatment artefacts can alter appearances, e.g. inflammatory 
and regenerative change can be hard to differentiate from dysplasia, so areas 
of oesophagitis or ulceration may preclude a confident diagnosis of dysplasia. 
‘Surface maturation’ describes the loss of atypia seen as cells migrate from 
gland bases to the surface, and is recognised as a feature differentiating 
normal, regenerating mucosa from true dysplasia (Shepherd 2013). Cytological 
atypia in basal crypts is not an uncommon finding, having been reported in up to 
7.3% of cases of BO (Lomo et al. 2006). However, some argue for a distinct 
case in which a focus of low/high-grade cytological atypia in a crypt stands out 
as markedly different from surrounding crypts, and that this ‘crypt dysplasia’ (or 
‘basal crypt dysplasia-like atypia’) is a subtype of true dysplasia (Coco et al. 
2011).The argument is that this represents an early stage in the development of 
dysplasia. There is controversy over the existence/significance of ‘crypt 
dysplasia’, with some authors remaining to be convinced that this is a form of 
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dysplasia (Shepherd 2013). Consequently this may be reported as LGD/HGD 
depending on the degree of dysplasia present, or ‘indefinite for dysplasia’ by 
those who do not recognise it as a form of dysplasia, and who argue that only 
this labelling will lead to the correct management for patients (Fitzgerald et al. 
2014; Shepherd 2013). 
 
1.6.1.5. Oesophageal adenocarcinoma 
Once there is evidence of invasion beyond the basement membrane this 
signifies a carcinoma.  
 
 
Figure 1-10 Oesophageal adenocarcinoma: intramucosal carcinoma. Figure 
reproduced from http://pathology2.jhu.edu/beweb/fig7.htm, accessed 20/01/15). 
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The tumour-node-metastasis (TNM) staging system is the most widely used 
classification system for oesophageal cancers, which reports the stage in terms 
of primary tumour (T), nodal spread (N) and distant metastases (M) (Raimes 
2009). A table outlining current TNM staging for oesophageal cancer is 
presented in Appendix I.  
 
 
Figure 1-11 Classification of early oesophageal cancer in columnar lined 
oesophagus. Figure reproduced from Pech et al. 2008. Mucosal depth is shown 




In recognition of the clinical significance of invasion of certain layers of the 
submucosa, (discussed further in section 1.10 below), there is further 
subdivision for early cancers, and the following terms may be used in the 
context of early oesophageal cancer: 
Intramucosal carcinoma Intramucosal carcinoma (IMC) is defined as 
penetration of the epithelial basement membrane into the lamina propria or 
muscularis mucosae, but without invasion of the submucosa.  
Submucosal invasion by adenocarcinoma Any oesophageal 
adenocarcinoma that has invaded into or beyond the submucosa.  
Classification is based on the depth of invasion of either the mucosa (m1-4) or 
submucosa (sm1-3) as shown in Figure 1-11. 
 
1.6.2. Oesophageal cytology 
Oesophageal cytology was performed relatively frequently in the era before 
flexible endoscopy as a means of diagnosing oesophageal cancer (Rubin 
1960). Following the introduction of the flexible endoscope, some continued to 
advocate brush cytology as a complementary part of routine assessment for 
Barrett’s surveillance, in addition to biopsy (Falk 2003). However, cytological 
assessment does not form part of the current Barrett’s guidelines from the BSG 
(Fitzgerald et al. 2014), the AGA (Spechler et al. 2011) or the ACG (Wang and 
Sampliner 2008). 
Diagnosis of Barrett’s with intestinal metaplasia can be made on brush cytology 
by the recognition of goblet cells (Conrad, Cobb, and Raza 2012).  Key features 
of adenocarcinoma cells are enlarged, pleomorphic nuclei, irregular nuclear 
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membranes and prominent nucleoli. The cytoplasm is variable in amount and 
may contain vacuoles. Cells appear in small overlapping clusters with loss of 
polarity (Conrad et al. 2012). High grade dysplasia appears similar to 
adenocarcinoma but without the tumour diathesis (necrotic  debris, fibrin and 
inflammatory cells) and lacks the cellular dispersion and discohesion of 
adenocarcinoma (Conrad et al. 2012). Low grade dysplasia can be difficult to 
differentiate from reactive changes, which show nuclear enlargement and an 
inflammatory background (Conrad et al. 2012). 
 
 
Figure 1-12 Examples of oesophageal cytology A) Barrett’s oesophagus, 
glandular epithelium with goblet cells, B) adenocarcinoma with enlarged nuclei, 
prominent nucleoli and necrotic background. Figure adapted from Conrad et al. 
2012. 
Hughes and Cohen (1998) reviewed a number of studies comparing cytology 
and histology, and found the range of reported correlation between the two 
techniques in patients with dysplasia was 50-100% (Hughes and Cohen 1998). 
Of the larger studies which have compared brush cytology and histology among 
patients with known or suspected Barrett’s neoplasia, Geisinger et al. found 
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agreement of 72% between the techniques (Geisinger, Teot, and Richter 1992), 
and Hardwick et al. reported sensitivity and specificity of 89% for brush cytology 
versus endoscopy and biopsy (Hardwick et al. 1997).  
Oesophageal cytology can be difficult to interpret, particularly in the presence of 
inflammation or ulceration, and some authors advise that management 
decisions should not be made on the evidence of cytology alone as benign 
Barrett’s in the presence of ulceration may appear malignant (Hardwick et al. 
1997). 
Non-endoscopic balloon cytology technique has been used to collect cells. This 
technique has been used as a screening tool in populations with a high 
prevalence of squamous cell carcinoma. This has been implemented in clinical 
practice in China for several decades (Dawsey et al. 1997; Shu 1983; Spechler 
1997). 
A study examining balloon cytology in Barrett’s-associated neoplasia compared 
it against brush cytology, using endoscopy and biopsy as the gold standard, 
among a population of patients with suspected Barrett’s oesophagus (Falk et al. 
1997). Adequate collection of columnar epithelium was achieved in 52/63 cases 
(83%) for balloon cytology, versus 59 of 61 (97%) cases with brush cytology. 
Balloon cytology had sensitivity 80% for HGD and adenocarcinoma, but 
sensitivity of LGD was 25% (Falk et al. 1997). Brush cytology had sensitivity of 
100% in HGD and adenocarcinoma but only 22% in LGD (Falk et al. 1997). 
Whilst these results imply that balloon cytology is not a suitable screening test 
for Barrett’s neoplasia with this device, it suggests that brush cytology has the 
potential to collect a representative sample, but the difficulty of interpretation of 
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low grade dysplasia may limit the sensitivity using conventional cytological 
assessment. 
 
1.6.3. Endoscopic diagnosis 
White-light high-resolution endoscopy remains the gold standard for diagnosing 
Barrett’s oesophagus. Accurate identification of the gastro-oesophageal junction 
(GOJ) is essential for diagnosis and measurement of BO. It is essential to 
differentiate an irregular squamocolumnar junction (‘Z-line’) from tongues of 
columnar-lined oesophagus, and recognise a hiatus hernia rather than mislabel 
this as BO. The squamocolumnar junction normally delineates the GOJ, but in 
the presence of Barrett’s columnar mucosa will line the lower oesophagus. The 
‘diaphragmatic pinch’ can also be helpful, but in the presence of a hiatus hernia 
the stomach may be in the thorax. Therefore the most reliable endoscopic 
indicator of the GOJ is the upper limit of the longitudinal gastric folds (Amano et 
al. 2006), but this can only be reliably assessed with sufficient air insufflation. 
Palisade vessels are present in the oesophagus and continue to the lower 
oesophageal sphincter (Shepherd 2013) and may be identifiable 
endoscopically. Some units, particularly in Japan, use the lower limit of palisade 
vessels to define the GOJ, but this has not shown good inter-observer 




Figure 1-13 Identification of the gastro-oesophageal junction. File adapted from 
http://www.drleith.co.za/anti-reflux-surgery.php, accessed 20/01/15. 
 
Endoscopic findings of BO should be reported in accordance with the Prague 
C&M classification, as agreed by the International Working Group for 
Classification of Oesophagitis (Sharma, Dent, et al. 2006). This advises that the 
length of the Barrett’s segment is recorded as the circumferential (C) and 
maximal (M) lengths in centimetres. This classification system has been shown 
to have good inter-observer reliability for Barrett’s lengths to within 2cm (rates of 
agreement for C and M 97% and 95% respectively), though exact agreement 




Figure 1-14 Reporting Barrett’s length using Prague C&M criteria. Figure 
adapted from Nguyen-Tang, Frossard, and Dumonceau 2011. 
 
Islands of BO should be described in terms of distance from the incisors and the 
length of the segment (Fitzgerald et al. 2014). The position of visible lesions 
should also be described in terms of their distance from the incisors, and their 
appearance using the Paris classification (see Table 1-5).  
As discussed earlier, the diagnosis depends on both endoscopic and 
histological findings. In recognition of the need for confirmatory tissue diagnosis, 
along with the difficulties in accurately identifying dysplastic change at 
endoscopy, the Seattle biopsy protocol has been developed (Levine et al. 
2000). This involves taking four-quadrant biopsies at 2cm intervals throughout 
the entire Barrett’s segment, preferably with ‘jumbo’ biopsy forceps, in addition 
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to sampling any visible lesions. For long segments this can be a lengthy 
procedure: a 10cm circumferential segment of Barrett’s requires 24 biopsies 
(assuming there are no visible lesions), and this number of specimens 
generates a significant workload for pathology services.  
 
Table 1-5 Paris classification of superficial lesions (type ‘0’ lesions) in the upper 
GI tract 
0-Ip Protruded, pedunculated 
0-Is Protruded, sessile 
0-IIa Superficial, elevated 
0-IIb Flat 
0-IIc Superficial, depressed 
0-III Excavated 
Adapted from Endoscopic Classification Review Group 2005. 
The limitations of conventional endoscopy and biopsy have led to the 
development of a number of advanced techniques for detection of dysplasia in 





1.7. Surveillance for Barrett’s oesophagus 
1.7.1. Guidelines 
Patients with Barrett’s oesophagus may be offered routine endoscopic 
surveillance with the aim of early detection of dysplastic or malignant change, to 
enable curative intervention. Any malignant change should ideally be detected 
prior to invasion of the submucosa, with its concomitant risk of lymphatic 
metastases.  
To achieve this effectively requires accurate endoscopic and pathological 
recognition of such changes, along with a sufficiently short interval between 
endoscopies to monitor progression. These factors must be balanced against 
the acceptability and risks to the patient of multiple endoscopies, and the costs 
of implementing such a programme, particularly given the natural history of the 
condition which suggests a risk of progression to cancer below 0.5% per year 
(Bhat et al. 2011; Desai et al. 2012; Hvid-Jensen and Pedersen 2011).  
Surveillance endoscopy programmes are now widely practised in many 
countries, however there remains uncertainty over the optimal surveillance 
strategy and this is reflected in the differing guidelines produced by a number of 
gastroenterological societies. A summary of the different societal guidelines for 
Barrett’s surveillance is included in Appendix II. 
The interval of surveillance endoscopy depends largely on the presence or 
absence of dysplastic change, but cases must be considered individually to 





1.7.2. Efficacy of surveillance and cost-effectiveness 
Evidence that endoscopic surveillance for Barrett’s leads to improved outcomes 
(such as reduced mortality from oesophageal adenocarcinoma) is weak, and 
remains the subject of debate. The current evidence-base is derived from 
retrospective cohort studies and comparative studies: a number of small studies 
have shown improved outcomes and/or earlier stage at diagnosis in patients in 
surveillance programmes (Cooper et al. 2002; Cooper, Kou, and Chak 2009; 
Corley et al. 2002; Fountoulakis et al. 2004; Peters et al. 1994; Rubenstein et 
al. 2008; van Sandick et al. 1998; Streitz, Andrews, and Ellis 1993). However a 
recent, large retrospective study did not demonstrate any benefit from 
surveillance and reached the opposite conclusion (Corley et al. 2013). A 
comparison is shown in Table 1-6. 
These retrospective studies are limited by a number of potential sources of bias 
and confounders, as the population presenting to medical professionals with 
symptoms or co-morbidities may be systematically different from those patients 
in whom Barrett’s is not diagnosed and kept under surveillance. A randomised-
controlled trial is needed to address this question, and a large RCT in the UK 
(Barrett’s Oesophagus Surveillance Study) is underway to assess the efficacy 
and cost-effectiveness of surveillance. 
Surveillance is a costly process, involving large numbers of patients having 
frequent endoscopies, and multiple tissue samples to be processed and 
reviewed by histopathologists. With hard data on efficacy lacking, there is a 
growing concern that surveillance is not cost-effective in its current forms (de 




Table 1-6 Comparison of retrospective studies of surveillance  
Study Total no. of 
patients with 
OAC 









Streitz et al. 1993 77 11 p=0.006 p=0.007 
Peters et al. 1994 52 17 p=0.01 p=0.05 
van Sandick et al. 
1998 
70 16 p=0.0001 p=0.0029 
Corley et al. 2002 23 15 p=0.02 p=0.01 
Cooper et al. 
2002 
1633 9.70% p<0.001 p<0.01 
Fountoulakis et 
al. 2004 
91 17 p=0.001 p=0.008 
Rubenstein et al. 
2008 
155 25 p=0.02 HR 0.82 (95% 
CI 0.52-1.29) 
Cooper et al. 
2009 
2754 8.10% p=0.001 p=0.001 
Corley et al. 2013 351 70 (not stated) HR 0.99 (95% 
CI 0.36-2.75) 
Table adapted from Fitzgerald et al. 2014. 
It must also be noted that, as a means by which to improve overall outcomes 
from oesophageal adenocarcinoma, surveillance can have only a limited 
impact, as a very small proportion of patients who develop adenocarcinoma 
have a prior diagnosis of Barrett’s oesophagus. In a large, population-based 
study in Northern Ireland, only 7.3% of cases of oesophageal adenocarcinoma 
occurred in patients known to have Barrett’s oesophagus (Bhat 2012). 
Surveillance in its current form offers uncertain benefits and is not demonstrably 
cost-effective. The goal of current research is, firstly, to assess the benefits of 
surveillance and secondly, to enable risk stratification to identify those who may 
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benefit most from targeted surveillance at an appropriate interval. This 
knowledge should then allow the design of an efficacious and cost-effective 
programme of endoscopic surveillance for patients with Barrett’s oesophagus.  
 
1.8. Screening for Barrett’s 
The key criteria for a successful screening programme were outlined by Wilson 
and Jungner in a classic public health report in 1968 (Wilson and Jungner 
1968), and have subsequently been updated in the UK by the National 
Screening Committee (National Screening Committee 2009). 
Criteria for a successful screening programme (Wilson and Jungner 1968): 
1 The condition sought should be an important health problem. 
2 There should be an accepted treatment for patients with recognized 
disease. 
3 Facilities for diagnosis and treatment should be available. 
4 There should be a recognizable latent or early symptomatic stage. 
5 There should be a suitable test or examination. 
6 The test should be acceptable to the population. 
7 The natural history of the condition, including development from latent 
to declared disease, should be adequately understood. 
8 There should be an agreed policy on whom to treat as patients. 
9 The cost of case-finding (including diagnosis and treatment of 
patients diagnosed) should be economically balanced in relation to 
possible expenditure on medical care as a whole. 
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10 Case-finding should be a continuing process and not a “once and for 
all” project. 
For oesophageal cancer, Barrett’s oesophagus represents the ‘recognizable 
latent or early symptomatic stage’ outlined above, and as such is a potential 
target for screening. However there are several criteria that are not met: the 
current gold-standard test is endoscopy and biopsy, which is neither 
‘acceptable’ given that the small risk of morbidity would not be justified unless 
there was a sufficiently high prevalence amongst the screened population, nor a 
cost-effective means of case-finding.  
These obstacles could be overcome in one of two ways: identification of ‘high-
risk’ groups in which the associated morbidity and cost of endoscopy is justified, 
or through developing an alternative test with lower morbidity and lower cost.  
To target those most at risk of having Barrett’s oesophagus several groups 
have examined the possibility of screening patients with chronic symptoms of 
gastro-oesophageal reflux disease (GORD) with endoscopy. The prevalence of 
Barrett’s in patients with chronic GORD is 5-15% (Shaheen and Ransohoff 
2002). A meta-analysis by Taylor and Rubenstein (2010) found that, whilst there 
was a strongly increased risk of long-segment Barrett’s oesophagus with GORD 
symptoms (OR 4.92, 95% CI 2.01-12.0), there was no association between 
short-segment Barrett’s oesophagus and GORD (OR 1.15, 95% CI 0.76-1.73) 
(Taylor and Rubenstein 2010). 
These symptoms are common amongst the general population however, with 
around 20% of the population having symptoms up to once a week (Shaheen 
and Ransohoff 2002), and around 6% of the population over the age of 45 
experiencing chronic symptoms (Camilleri et al. 2005). To screen all of these 
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individuals would require huge resources: estimates from the US suggest that 
6.6 million individuals would require endoscopy, with 1 oesophageal 
adenocarcinoma detected for every 1320 procedures (Kahrilas 2011; Vaezi and 
Kahrilas 2013). It must also be noted that 40% of patients with oesophageal 
adenocarcinoma (and 71% of patients with junctional adenocarcinoma of the 
cardia) do not experience any GORD symptoms (Lagergren et al. 1999).  
Consequently endoscopic screening in an unselected population with GORD is 
not currently recommended either in the US or the UK (Fitzgerald et al. 2014; 
Spechler et al. 2011; Wang and Sampliner 2008). However, in the presence of 
multiple risk factors (chronic GORD plus 3 out of male sex, age over 50, white 
race, obesity) the BSG guidelines advise consideration of screening, with a 
lower threshold for those with a first-degree relative with Barrett’s or 
oesophageal adenocarcinoma (Fitzgerald et al. 2014). 
There has been recent focus on using genetic markers of risk to identify those 
at increased risk of developing OAC. A genome wide association study 
identified genomic markers of risk for Barrett’s oesophagus, incorporating data 
from a number of studies of patients with Barrett’s oesophagus 
(ChemoPrevention Of Intestinal Neoplasia (ChOPIN), Aspirin Esomeprazole 
Chemoprevention Trial (AspECT), and the Esophageal Adenocarcinoma 
Genetics LinkagE (EAGLE) consortium) (Su et al. 2012). Single nucleotide 
polymorphisms (SNPs) that increase the risk of BO were identified at 
chromosome loci 6p21, rs9257809, and 16q24, rs9936833. These SNPs could 
be used in future to identify those at increased risk of developing OAC and thus 
receive targeted screening. 
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Further work on genetic biomarkers of disease progression has identified 
markers of increased risk for progression to dysplasia or adenocarcinoma (p53 
and SMAD4). This knowledge could be applied to risk stratify those with 
Barrett’s from whom tissue or cell samples show these key mutations. 
An alternative approach to screening is to use less invasive techniques to 
reduce the morbidity. Studies assessing capsule endoscopy to identify Barrett’s 
have shown a relatively low sensitivity at 60-78% (Galmiche et al. 2008; Lin et 
al. 2007; Ramirez, Akins, and Shaukat 2008). Others have used ultra-thin 
transnasal endoscopes in patients with GORD or known Barrett’s and 
demonstrated results very similar to conventional endoscopy (Jobe et al. 2006; 
Shariff et al. 2012). 
A further technology under assessment is a swallowed cytology collection 
device (Cytosponge™) (Kadri et al. 2010). The device is contained within a 
small capsule which is attached to a length of string: patients swallow the 
capsule, the gelatine capsule then dissolves in the acidic gastric secretions to 
reveal the collection device (analogous to a cytology brush), which is then 
withdrawn through the oesophagus using the string, collecting cells as it passes 
(see Figure 1-15). Cytology collection has the potential advantage over biopsy 
of sampling very large areas of epithelium, to minimise the risk of missing small 
areas of dysplasia. 
Accurate biomarkers of Barrett’s oesophagus are required due to the mixed cell 
population collected by the device, with a previous study suggesting the most 
promising as Trefoil Factor 3 (TFF3) (Lao-Sirieix et al. 2009). Furthermore, the 
acceptability of the device has been demonstrated in a primary care setting 











































































1.9. Management of Barrett’s and Barrett’s-associated neoplasia 
 
Figure 1-16 Management of non-dysplastic Barrett’s oesophagus (adapted 
from Fitzgerald et al. 2014). 
Surveillance forms the mainstay of management for patients with non-dysplastic 
Barrett’s oesophagus: the current BSG guidelines are illustrated in the algorithm 
in Figure 1-16 above. Endotherapy is not currently indicated for these patients, 




There is increasing evidence for the use of certain drugs as chemoprevention 
for patients with Barrett’s oesophagus. A number of cohort studies have shown 
a significantly reduced risk of progression to high grade dysplasia (HGD) or 
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oesophageal adenocarcinoma (OAC) for patients taking proton pump inhibitors 
(PPIs) versus no therapy or on histamine-2 receptor antagonists (H2RA) (El-
Serag et al. 2004; Nguyen et al. 2009). However data from randomised 
controlled trials (RCT) are still awaited, and the BSG guidelines advise that 
‘there is not yet sufficient evidence to advocate acid suppression drugs as 
chemopreventive agents’ (Fitzgerald et al. 2014).  
Evidence for a protective effect from non-steroidal anti-inflammatory drugs 
(NSAIDs) comes from large meta-analyses of patients taking aspirin as primary 
or secondary prevention for cardiovascular disease (Corley et al. 2003; Liao et 
al. 2012; Rothwell et al. 2011). In the largest of these, incorporating data from 
23,535 patients, those followed up for 10-20 years after starting aspirin, and 
having taken aspirin daily for 5 years or more, had a significant reduction in risk 
of OAC, hazard ratio 0.36 (95% CI 0.18-0.71) (Rothwell et al. 2011).  
Once again there are no data from randomised trials, and given the risks of 
NSAIDs such as gastrointestinal bleeding and cerebral haemorrhage, this will 
be crucial in informing management decisions for patients with Barrett’s (Cuzick 
et al. 2009). 
Aspirin and Esomeprazole for Chemoprevention in Barrett’s metaplasia 
(AspECT) is a large, multi-centre RCT (NCT00357682), which aims to address 
the lack of randomised data and evaluate the risks and benefits of both PPIs 
and NSAIDs as chemoprevention in Barrett’s (ClinicalTrials.gov 2013). The trial 
has 4 arms, with patients randomised to low-dose or high-dose PPI 
(esomeprazole) +/- aspirin.  
There is some evidence from observational studies for a protective effect from 
statins against oesophageal cancer. A recent meta-analysis reviewed the 
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effects of statins in a patients with Barrett’s (Beales, Hensley, and Loke 2013),  
including 11 observational studies with a total of 1999 patients, and found an 
OR for progressing to OAC was 0.57 (95%CI 0.43-0.75) for those on a statin.  
Whilst the absence of randomised data limits current recommendations for 
chemoprevention, this paradigm may become a key component of management 
of Barrett’s oesophagus in future. 
 
1.9.2. Endotherapy for Barrett’s-associated neoplasia 
Endoscopic treatments aim to remove or destroy areas of neoplasia in the 
oesophagus, either through resection or ablation, and promote re-growth of the 
normal squamous lining. The goal of ablative techniques is to achieve complete 
eradication of dysplasia, along with complete eradication of intestinal 
metaplasia (Leggett, Gorospe, and Wang 2013). These minimally invasive 
treatments can offer treatment without recourse to radical surgery and thus can 
be considered in patients with earlier stage disease and those for whom major 
surgery would be a very high risk.  
The BSG guidelines advise the following algorithm (see Figure 1-17) for 





Figure 1-17 Algorithm for management of dysplastic Barrett’s oesophagus 
(adapted from Fitzgerald et al. 2014). LGD low grade dysplasia; HGD high 
grade dysplasia; OGD oesophago-gastroduodenoscopy; MDT multidisciplinary 
team 
 
1.9.2.1. Low grade dysplasia 
In the 2014 BSG guidelines, as shown in figure 1-17 above, patients found to 
have LGD are advised to have 6-monthly OGD surveillance until biopsy 
confirms regression to non-dysplastic BO on successive OGDs, or progression 
to HGD occurs (Fitzgerald et al. 2014). However, a recent randomised 
controlled trial from European centres  reported a highly significant reduction in 
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progression for patients with LGD treated with RFA (Phoa et al. 2014). The rate 
of progression to HGD or cancer over 3 year follow up was 1.5% in the ablation 
group versus 26.5% in the untreated group (p<0.001), with progression to 
cancer 1.5% versus 8.8% respectively (p=0.03).  
It must be noted that the rate of progression in the control arm in this trial 
(26.5%) was high over 3 years, which may limit its applicability in other settings. 
This rate is much higher than might be expected from the natural history of LGD 
reported in other studies, with a recent meta-analysis calculating a risk of 
progression to HGD or cancer of around 1% per year (Almond, Hodson, and 
Barr 2014). The use of an expert pathology panel for consensus diagnosis, with 
a very robust classification of LGD, is likely to have influenced the composition 
of the group seen in the study by Phoa et al.  Of 511 patients with an initial 
diagnosis of LGD screened for entry to the trial, only 247 were confirmed to 
have LGD after review by the expert panel, and 140 went on to be randomised 
(Phoa et al. 2014). 
In light of these findings it seems likely that historical overdiagnosis of LGD has 
led to an underestimation of the true risk of progression with LGD (Almond et al. 
2014). This suggests the need for consensus reporting of all Barrett’s dysplasia 
specimens, and the question of whether to offer intervention in the absence of 
consensus is difficult.   
The recently published National Institute for Health and Care Excellence (NICE) 
guidelines now support the use of RFA for the ablation of low grade dysplasia 




1.9.2.2. High grade dysplasia 
The diagnosis of HGD has serious implications for patients – not only do they 
have a high risk of progression to adenocarcinoma, but there is a significant risk 
that a small focus of cancer may already be present, but not yet detected. For 
this reason, historically, the treatment of HGD was radical oesophagectomy for 
those considered fit for surgery. The advent of endotherapy led to great debate 
over whether these treatments could offer oncologically sound treatment. 
Although there have not been any randomised trials directly comparing surgery 
with endotherapies, the growing body of evidence for endotherapies over the 
past 20 years or so has resolved this debate, and endoscopic resection is now 
considered the treatment of choice for patients with macroscopically visible 
HGD or T1a adenocarcinoma (Fitzgerald et al. 2014). The management of HGD 
and early oesophageal cancer is shown in the algorithm in Figure 1-18 below. 
For visible lesions, endoscopic resection (ER) is preferred over ablative therapy 
alone because it provides the most accurate staging information. Depth of 
invasion can be accurately assessed: data from stepwise ER of entire Barrett’s 
segments have confirmed that the most advanced disease is located in visible 
lesions (Pouw et al. 2010). A meta-analysis of studies in which patients have 
undergone oesophagectomy for HGD found the risk of invasive OAC to be 11% 
in those with visible lesions, compared to 3% in those with no visible lesion 





Figure 1-18 Algorithm for managing HGD and early oesophageal 
adenocarcinoma (adapted from Fitzgerald et al. 2014).  ER endoscopic 
resection; HGD high grade dysplasia; EC early oesophageal adenocarcinoma; 
MDT multidisciplinary team; OGD oesophagogastroduodenoscopy; RFA 
radiofrequency ablation 
There are now numerous ablative techniques for HGD: each of these 
techniques has its strengths and weaknesses, and some key features are 
presented in Table 1-7 below. RCT data are available for some of these 
modalities, and includes direct comparison of certain techniques. Currently, 
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there is a large scale trial (Barrett’s Radiofrequency Intervention for Dysplasia 
by Endoscopy, BRIDE, NCT017337) under way aiming to compare outcomes 
between RFA and argon plasma coagulation (APC) (ClinicalTrials.gov 2012). 
This pilot study has just closed to recruitment and initial data will be available 
soon. On the basis of currently available RCT data and taking account of the 
side effect profiles of each treatment, RFA is recommended as the first-line 
therapy for HGD outside of the context of RCTs (Fitzgerald et al. 2014). 
The first major RCT of RFA randomised 127 patients on a 2:1 allocation to RFA 
or a sham procedure (Shaheen et al. 2009). Complete eradication of HGD was 
seen in 81.0% of treated patients versus 19.0% of controls (p<0.001). In a later 
report on extended follow up of this group, 96% of those achieving eradication 
of HGD remained free of HGD at 3 year follow up (Shaheen et al. 2011). Risk of 
any disease progression was reduced in the ablation group (3.6% vs. 16.3%, 
p=0.03) as was the risk of cancer (1.2% vs. 9.3%, p=0.045). 
A meta-analysis of RFA for BO calculated pooled estimates for complete 
eradication of dysplasia of 91% (87-95%, 95% CI), and complete eradication of 
IM 78% (70-86%, 95% CI) (Orman, Li, and Shaheen 2013). The commonest 










    
Step-wise 
radical ER 
97-100% Accurate diagnosis 
Low costs 
High risk of stenosis 
Only feasible <5cm Barrett’s 
 
APC 67-86% Widely available 
Low costs 
Buried glands 
Feasible for short segments 
only 
 
PDT 40-77% RCT data 
Treatment of nodular 
dysplasia 




RFA 80-98% RCT data 
High response rate 
Low complication rate 
High costs 
Minimal long-term follow up 
data 
 
Cryotherapy 68-88% Good safety profile No RCT data 
No long-term follow up data 
 
Adapted from Fitzgerald et al., 2014. APC, argon plasma coagulation; ER 
endoscopic resection; PDT photodynamic therapy; RCT Randomised controlled 
trial; RFA radiofrequency ablation.  
 
1.9.2.3. Intra-mucosal adenocarcinoma 
The low risk of nodal metastasis with T1a cancer (0-10%) (Alvarez Herrero et 
al. 2010; Barbour et al. 2010; Buskens et al. 2004; Liu et al. 2005; Prasad et al. 
2009; Sepesi et al. 2010; Stein et al. 2005; Westerterp et al. 2005) has resulted 
in very good tumour free and overall survival with endoscopic resection for T1a 
cancers in high-volume centres. One recent large series reported tumour free 
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survival of 93.8% at mean follow up 56.6 months (Pech et al. 2014). ER for T1b 
tumours is associated with poorer outcomes, with 5 year tumour free and 
overall survival 60% and 58% respectively, likely due to increased depth and 
higher risk of nodal involvement (up to 46%) (Alvarez Herrero et al. 2010; 
Barbour et al. 2010; Buskens et al. 2004; Liu et al. 2005; Prasad et al. 2009; 
Sepesi et al. 2010; Stein et al. 2005; Westerterp et al. 2005). For upper third 
tumours of the submucosa (T1bsm1) the risk of lymph node metastasis is 
relatively low (around 10%) and some series report good outcomes treating 
T1bsm1 tumours endoscopically (Alvarez Herrero et al. 2010; Pech et al. 2014; 
Westerterp et al. 2005). Decision making may be further influenced by 
pathological indicators of good prognosis, such as R0 resection, or absence of 
vascular and lymphatic invasion (Estrella et al. 2011). The use of ER for 
T1bsm1 cancer remains debated however, and the current BSG guidance 
advises surgery for patients who are fit enough, but that ER should be offered 
with curative intent in patients who are high-risk surgical candidates (see Figure 
1-18 above) (Fitzgerald et al. 2014). 
Whilst ER is effective at removing Barrett’s-associated intra-mucosal lesions, 
these patients have a high rate of metachronous lesions after ER alone, 
affecting around 15-20% (Pech et al. 2008, 2014). The risk of developing further 
lesions can be reduced significantly with ablative therapy to the remaining 
Barrett’s segment (Pech et al. 2008; Pouw et al. 2010). Current guidance 
advises removal of all visible lesions with ER, followed by ablative therapy 
(currently RFA is preferred method) to all residual areas of Barrett’s (Fitzgerald 




1.10. Advanced endoscopic diagnosis 
1.10.1. Wide-Field detection techniques (‘red-flag’) 
A number of techniques have been developed to increase the sensitivity of 
detecting areas of dysplasia or neoplasia during wide-field endoscopic 
examination, as opposed to those techniques which aid histological recognition 
on a point-by-point basis, analysing small areas of tissue at a time. 
 
1.10.1.1. High Resolution Endoscopy 
The increasing resolution of cameras (>1,000,000 pixels) and high definition 
display screens has improved detection over conventional equipment. Current 
systems allow magnification up to x150 depending on equipment (Subramanian 
and Ragunath 2013). High resolution endoscopes (HRE) and monitors increase 
sensitivity, with some studies reporting HRE to be as good as NBI and 
chromoendoscopy, with no additional benefit from the enhanced imaging 
techniques (W. Curvers et al. 2008). It is also widely available in clinical use. 
However there are a number of weaknesses compared to alternative advanced 
imaging techniques: sensitivity for dysplasia can be variable (79-90%) and 
shows interobserver variability (W. Curvers et al. 2008; Kara et al. 2005), plus 
longer inspection times are required to achieve these higher detection rates 
(Gupta et al. 2012).  
 
1.10.1.2. Chromoendoscopy  
Applying a ‘stain’ (most commonly acetic acid or methylene blue) via the 
endoscope to the oesophageal mucosa enables enhanced visualisation, 
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highlights surface topography and mucosal irregularities. Acetic acid particularly 
accentuates villi and pits and can increase detection of intestinal metaplasia 
and dysplasia compared to white light endoscopy (WLE) (Fortun et al. 2006). 
Methylene blue highlights intestinal metaplasia and dysplasia but not squamous 
epithelium. Reported sensitivity for identifying IM ranges from 53-98%, with 
specificity 32-97% (Saxena and Canto 2013). This wide range is likely to be due 
to study heterogeneity, different administration techniques and methods of 
interpretation when performing chromoendoscopy. The low specificity, interuser 
variability, and practicalities of administration of stains (additional catheter and 
messy dye) have limited the adoption of this technique, particularly as it has 
largely been overtaken by virtual chromoendoscopy. 
 
1.10.1.3. Narrow Band Imaging 
The addition of an extra light filter to endoscopic white light narrows the 
bandwith of blue and green light, and increases the intensity of the blue light 
(Saxena and Canto 2013). The blue light does not penetrate mucosa, and the 
blue wavelength corresponds to the peak absorption of haemoglobin, therefore 
highly vascular structures appear darker, contrasting with the surrounding 
mucosa (Subramanian and Ragunath 2013). Some studies have shown high 
accuracy in experienced hands, with a meta-analysis of 8 studies showing high 
sensitivity (96%) and specificity (94%) for HGD, high sensitivity (0.95) but poor 
specificity (0.65) for IM (Mannath et al. 2010). There is also evidence for 
equivalent detection rate to WLE but achieved with fewer biopsies (Wolfsen et 
al. 2008). However there are wide-ranging figures quoted on real-time 
sensitivity and specificity depending on methodology used: one multi-centre 
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study with expert endoscopists showed sensitivity for HGD 83% and specificity 
33% (Curvers, Herrero, et al. 2010). A further multi-centre study reported 
sensitivity for dysplasia 47% and specificity 72% (Singh et al. 2011), and noted 
that interobserver agreement was better amongst experts (k=0.63 for mucosal 
changes, k=0.58 for vascularity and k=0.68 for predicted histology) than non-
experts. One of the causes for interobserver variability is the use of multiple 
classification systems, all of which have their own limitations (Silva et al. 2011; 
Singh et al. 2011). It is also relatively time-consuming compared to standard 
endoscopy (Curvers, Herrero, et al. 2010). 
 
1.10.1.4. FICE (Fuji Intelligent Chromo Endoscopy)/i-scan (Pentax) 
This system is analogous to NBI but use post-processing techniques to 
enhance the image rather than light filters to improve visualisation of mucosal 
and vascular patterns. The strengths are likely to be similar to NBI, but whilst 
some work has been done in the colon, there have been few studies examining 
its role in Barrett’s to date. One study showed FICE and acetic acid 
chromoendoscopy identified irregular mucosal patterns in 100% of patients in a 
small pilot study (Camus et al. 2012). 
 
1.10.1.5. Autofluorescence 
Autofluorescence imaging (AFI) produces real-time pseudocolour images based 
on detection of fluorescence from endogenous fluorophores when exposed to 
short wavelength light (370-470nm) (Saxena and Canto 2013; Subramanian 
and Ragunath 2013). Neoplastic tissues have different autofluorescence 
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characteristics, allowing their differentiation: a barrier filter shows normal tissue 
as green and dysplastic/cancerous tissue as magenta. It appears to be highly 
sensitive, with several authors reporting sensitivity >90% (Curvers et al. 2008a; 
Kara et al. 2006). The major weakness has been poor specificity, with a high 
number of false positives (difficulty discriminating dysplasia and inflammation) 
(Curvers et al. 2008a). Attempts have been made to improve imaging 
techniques but poor specificity remains a problem for ‘third-generation’ as well 
as ‘second-generation’ AFI (Boerwinkel et al. 2013). This combination of 
characteristics lends itself to use with other imaging modalities as a ‘red-flag’ 
technique, sampling large fields which can then be analysed further with more 
specific techniques. 
Future developments may include multimodal systems, attempts to address the 
low-resolution  image and jerky video because of low frame rate of current 
systems (Subramanian and Ragunath 2013), or attempts to correlate AFI with 
biomarkers, though this has not been very successful to date (Boerwinkel et al. 
2012). 
 
1.10.1.6. Labelling of biomarkers 
The concept of labelled biomarkers has excited a lot of interest: the aim is to 
use visually tagged probe molecules that selectively bind neoplastic cells. If 
reliable biomarkers could be identified, there are a number of potential 
techniques that could be used to visualise the markers and thus highlight areas 
of neoplasia.  
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Probe molecules that would target such biomarkers may either be antibodies 
against specific proteins on neoplastic cells, or less specific molecules that 
selectively bind to, or concentrate in, neoplastic cells. Probe molecules could be 
labelled in a number of ways, including fluorescence, or binding to nanoparticles 
which carry a label e.g. Surface Enhanced Raman Scattering (SERS) using a 
metallic nanoparticle with a chemiadsorbed Raman reporter molecule (Kong et 
al. 2015).  
One example of fluorescence in Barrett’s oesophagus is lectins – alterations in 
cell surface glycans cause changes in lectin binding to selectively target 
neoplasia, with the use of fluorescent lectins allowing visualisation (Bird-
lieberman et al. 2012). 
These techniques have the potential to rapidly identify areas of dysplasia and 
neoplasia, with many putative targets. However, to date, although there has 
been some in vivo work to demonstrate proof of concept, sensitive and specific 
markers are lacking (Lu and Wang 2008). 
 
1.10.1.7. Multimodal imaging 
To utilise the different advantages of differing imaging modalities, there has 
been much work on multimodal imaging systems, whereby a combination of 
techniques can be used concurrently to aid diagnosis. 
Whilst a number of combinations have been tried, the most successful to date 
has been the Endoscopic TriModal Imaging system (Olympus). This 
incorporates high-resolution endoscopy, AFI and NBI. The aim is to use AFI 
initially, which has a high sensitivity for dysplasia, to identify suspicious lesions, 
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followed by NBI which has greater specificity to characterise them further and 
reduce false positives (the main problem associated with AFI alone) (Curvers, 
Herrero, et al. 2010; W. L. Curvers et al. 2008). The theory follows that AFI 
should avoid missing any suspicious lesions, and NBI should prevent a high 
number of unnecessary biopsies. However, a recent randomised controlled trial 
in the Netherlands found that although there was a greater yield of targeted 
biopsies, NBI appeared to add little, and the overall diagnostic yield was not 
significantly different from conventional endoscopy (Curvers, Herrero, et al. 
2010). 
Certain other weaknesses also remain – it does not define the histology and 
therefore still requires biopsy confirmation, use of multiple modalities is time 
consuming, and there is the increased cost of a multimodal system.  
Another possible multimodal technique combined cross-polarized imaging 
(CPI), vital dye fluorescence imaging (VFI) and high resolution microendoscopy 
(HRME) (Thekkek et al. 2013). CPI shows vascularity (like NBI), VFI shows 
glandular structures. After these wide-field techniques they applied point 
measurement with HRME. This demonstrated in vivo feasibility, but there are no 
published data on sensitivity and specificity.  
 
1.10.2. Point measurement techniques 
1.10.2.1. Confocal laser endomicroscopy 
Confocal laser endomicroscopy (CLE) magnifies mucosa x1000, making it 
possible to visualise cellular structures in real-time. The microscope may be 
integrated into the endoscope (Pentax systems) or incorporated into a probe 
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which is passed via the instrument channel (Cellvizio™). In experienced hands 
the technique can have accuracy as high as 96.8% for IM and 92.9% for 
intraepithelial neoplasia in the oesophagus (Goetz and Kiesslich 2008). It 
defines tissue histology, and consequently may allow a reduction in the number 
of biopsies required (Canto et al. 2013). In one recent study, compared to WLE 
alone, CLE altered the patient’s management plan in 36% of cases (Canto et al. 
2013). Weaknesses of this technique include interuser variability, subjective 
interpretation, and it is time-consuming as small areas are sampled. It is also 
comparatively expensive and requires intravenous fluorescein. 
The similar technique of endocytoscopy uses a contact light microscope to give 
up to x1400 magnification. Recent ex vivo work in BO has shown high accuracy 
(83-100%) and high interobserver agreement for this technique (Tomizawa et 
al. 2013).  
 
1.10.2.2. Optical Coherence Tomography 
Optical coherence tomography (OCT) is analogous to ultrasound using 
electromagnetic waves: it produces its image from infrared light and optical 
scattering based on differences in tissue composition (Lightdale 2013). 
Techniques used have included a balloon catheter system (Suter et al. 2009) or 
a tethered capsule (Gora et al. 2013). In addition to defining the histology, OCT 
provides cross-sectional imaging, which could potentially be useful for 
assessing depth of invasion of a lesion, or detecting buried glands following 
ablative treatment in the oesophagus (Lightdale 2013). However it has poor 
image contrast, comparatively low sensitivity and specificity (one study found 
the sensitivity for HGD/IMC to be  83%, specificity 75% (Evans et al. 2006), and 
61 
 
a further study by the same group reported sensitivity 81% and specificity 57-
66% for IM) (Evans et al. 2007). This may in part be due to the difficulties and 
somewhat subjective interpretation required.  
 
1.10.2.3. Elastic Scattering Spectroscopy (ESS) 
This technique is based on the elastic scattering of white light: light scattering 
from epithelial surfaces provides information about cellular organelles e.g. 
nuclear size. Development of a fibre-optic probe has been the aim, with 
advantages being a short acquisition time, relatively low cost, and an 
intermediate field of measurement at around 0.5mm.  High signal interference 
from deep structures has proved a limitation on accuracy, but the technique has 
shown sensitivity for HGD (92%) though not specificity (60%) (Lovat et al. 
2006).  
 
1.10.2.4. Endoscopic polarised scanning spectroscopy (EPSS) 
EPSS is similar to ESS above, depending on elastically scattered light, but this 
technique uses a filter to remove signal from deeper tissue to allow epithelial 
analysis (light backscattered from the epithelial surface retains its linear 
polarisation, unlike light backscattered from the submucosal layers) (Qiu et al. 
2010). This may achieve higher accuracy than ESS: Qiu et al. report sensitivity 
of 92% and specificity of 96% for all pathologies in a study of 8 patients in vivo, 




1.10.2.5. Angle-resolved low coherence interferometry 
This is a further optical technique based on angular scattering from cell nuclei at 
various tissue depths, which provides a measure of the size of cell nuclei, with 
larger nuclei implying dysplasia. A small in vivo feasibility study has 
demonstrated some promise for identification of dysplasia (Wax et al. 2011). 
A summary table comparing advanced endoscopic imaging techniques is 




CHAPTER 2: VIBRATIONAL SPECTROSCOPY 
 
2. Vibrational spectroscopy 
2.1. Fundamental principles 
When light is incident on matter it may be reflected, absorbed (including 
fluorescence and phosphorescence), scattered, or pass straight through.  
Incident light is absorbed by a molecule if its energy matches the energy 
required to excite the molecule from its ground state to an excited state. Only 
light of a specific wavelength (and thus a specific energy) will be absorbed by a 
given molecule. Scattering occurs when the energy from incident light raises the 
electrons of the molecule to a higher energy state, forming an unstable 
‘complex’, before releasing this energy as scattered radiation. Nearly all of this 
scattered radiation has the same wavelength (and hence energy) as the 
incident light: since the incident and scattered light has the same energy this is 
termed ‘elastic’ scattering, or known as Rayleigh scattering. Around 1 in 106-108 
of the scattered photons have a different energy from the incident light, 
corresponding to one of the vibrational energy states of the molecule: this is 
termed ‘inelastic’ scattering, or known as Raman scattering. When the molecule 
starts in its ground state, and the scattered light has a lower energy than the 
incident light, the process is known as Stokes scattering. If the molecule begins 
at an excited state and the scattered light has a greater energy than the incident 
light, it is termed Anti-Stokes scattering. The energy changes involved in these 





Figure 2-1 Changes in energy state underlying infrared absorbance, Rayleigh 
and Raman scattering. (reproduced from 
http://commons.wikimedia.org/wiki/File:Raman_energy_ levels.jpg) 
 
Changes in energy state will alter molecular vibration. A given molecule can 
vibrate in a defined number of vibrational modes: for a non-linear molecule this 
is 3N-6, where N is the number of atoms in the molecule (see Figure 2-2 
below). For infrared absorption to occur, molecular vibration must induce a 
change in the dipole moment of the molecule. For Raman scattering to occur, 
there must be polarisation of the electron cloud. Different molecules require 
different energy to alter these vibrational modes: this underpins the analytical 
technique of vibrational spectroscopy, with measurement of the energy change 
from infrared absorption or Raman scattering providing information about the 





Figure 2-2 Possible vibrational modes for a CO2 molecule. For a triatomic 
molecule such as CO2, symmetric stretch has a strong effect on the polarisation 
of the electron cloud, and hence a relatively strong Raman scattering effect.  
Bending and asymmetric stretch cause a change in the dipole moment and 
consequently a strong infrared absorption, but a weak effect on polarisation and 
correspondingly weak Raman scattering. (adapted from 
http://www.ino.it/~miomao/co2modi.jpg) 
 
2.2. Raman Spectroscopy 
2.2.1. Raman spectroscopy of biological samples 
Raman spectroscopy relies on the inelastic (Raman) scattering of light to 
interrogate samples and analyse their content. The difference in energy 
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between incident and scattered photons is known as the ‘Raman shift’. This 
‘Raman shift’ is both specific to the bond responsible for the scattering, and 
independent of the incident wavelength (Byrne, Sockalingum, and Stone 2011). 
The intensity of the scatter gives a measure of the concentration of the 
molecules containing responsible bonds in the specimen.  
Plotting the Raman shift measured in wavenumbers (1/wavelength, 
conventionally in units of cm-1) on the x-axis, against the intensity of the 
scattered light on the y-axis, gives the Raman spectrum for a given sample. 
Since the Raman shift is relative to the incident wavelength, the zero point on 
the x-axis represents the incident light, with positive values recording Stokes 
scattering, and negative values Anti-Stokes.  
 
Figure 2-3 Raman spectra of certain key biomolecules – characteristic spectral 
peaks associated with specific biochemical substrates allow identification of 
molecules based on their spectra. Reproduced from Old et al. 2014. 
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The resultant spectrum is therefore both a qualitative and quantitative measure 
of the sample biochemistry (Byrne et al. 2011). Figure 2-3 shows an example of 
the use of Raman spectroscopy to analyse a number of key biomolecules. 
Raman spectroscopy of biological samples poses a number of challenges: the 
signal is relatively weak, as only 1 in 106-109 photons are inelastically scattered 
and ambient light must be filtered to reduce unwanted spectral contributions 
(Kendall et al. 2009). Visible wavelengths excite a strong autofluorescence 
signal which can mask the weak Raman signal: near-infrared wavelengths are 
used to minimise this effect (Krafft 2009). Raman spectrometers must therefore 
be highly sensitive to Raman signal, whilst excluding all other signal through a 
series of filters. A schematic diagram of the layout of a typical laboratory Raman 
spectrometer is shown in Figure 2-4.  
 
 




The laser light is focussed onto the sample, then scattered light is filtered based 
on wavelength to remove any elastically scattered light, passes through a slit to 
remove any stray light, before a diffraction grating splits the beam based on its 
wavelength, and the light is then reflected onto a charge-coupled detector 
(CCD) device. The CCD registers the number of photons striking it at each 
region, which following diffraction corresponds to a specific wavelength, thus 
giving the intensity at each wavelength.  
The -OH vibrational modes of water molecules produce weak Raman signals, 
and thus do not contribute significantly to resultant spectra. Consequently, 
Raman spectroscopy can be used to analyse fresh tissue with no prior 
preparation, both ex vivo and in vivo without causing tissue damage.  
The use of fibre optic probes can improve tissue access for in vivo Raman 
analysis, such as through a needle probe or endoscope (Kast et al. 2007). 
Fibre-optic probes designed for in vivo use must overcome the signal-to-noise 
challenges, and face the major problem that Raman signals and 
photoluminescence are generated in the delivery fibres themselves (Day et al. 
2009). For certain applications, all this must be achieved with a probe of very 
small size to enable access to body cavities, and in a sufficiently short time to 
allow accurate measurement from a moving target organ. This will be discussed 
in further detail with regard to the Raman probe used in this project. 
Spectral analysis of biological tissue samples using vibrational spectroscopy 
has a number of potential strengths as a diagnostic tool. Data analysis 
techniques applied to the measured spectra can characterise subtle differences 
and detect biochemical changes that have been induced by disease. This 
enables identification of pathology, and classification into appropriate 
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subgroups, based upon sample biochemistry. The data analysis techniques 
used are described in section 2.4 below.  
Potential applications include use as an ‘optical biopsy’ technique for in vivo 
tissue diagnosis or to guide therapy, as a ‘digital staining’ method to assist a 
histopathologist in analysing a sample, or as an entirely automated process for 
histopathology classification.  
Developments in vibrational spectroscopic applications in the oesophagus are 
reviewed below, but it should be noted that these techniques are also being 
investigated to accurately identify a range of pathologies in a number of other 
tissue sites, including stomach (Bergholt et al. 2013; Bergholt, Zheng, Lin, Ho, 
Teh, Yeoh, Yan So, et al. 2011; Ito et al. 2013; Li et al. 2013),  colon (Lloyd et 
al., 2012), breast (Kast et al., 2007; Kong et al., 2014), lymphoma (Isabelle et 
al. 2008), lung (Gao et al. 2012; Huang et al. 2003; Krafft and Sergo 2006; 
Pijanka et al. 2013; Short et al. 2008), cervix (Bazant-Hegemark et al. 2008; 
Lyng et al. 2007; Martinho et al. 2008.; Robichaux-Viehoever et al. 2007; Wood 
et al. 2004), brain (Gajjar et al. 2012; Ji et al. 2013; Toms et al. 2006), head and 
neck (Das et al. 2006; Harris et al. 2010; Menzies et al. 2013; Singh et al. 2012; 
Stone et al. 2000), skin (Hammody et al. 2008; Nijssen et al. 2007; Tfaili et al. 
2012; Yu et al. 2013), and urological applications (Baker et al. 2009; Barman et 
al. 2012; Crow, Barrass, et al. 2005; Crow, Molckovsky, et al. 2005; Derenne, 
Gasper, and Goormaghtigh 2011; Draga et al. 2010; Grimbergen et al. 2010; 





2.2.2. Clinical applications of Raman in the oesophagus 
2.2.2.1. Raman tissue mapping: towards automated histology 
Raman spectroscopy has shown promise in differentiating pathological 
subtypes in the oesophagus, with much of the initial work performed in vitro. In 
an analysis of snap-frozen oesophageal biopsy samples, Kendall et al. showed 
the ability to discriminate between 8 pathological groups: normal squamous, 3 
subtypes of Barrett’s oesophagus (intestinal metaplasia, cardiac and fundic type 
mucosa), high-grade dysplasia, adenocarcinoma, squamous dysplasia and 
squamous cell carcinoma (Kendall et al. 2003). When analysed as a 3-subset 
model (normal vs. Barett’s vs. dysplasia/adenocarcinoma), they achieved a high 
level of agreement with consensus pathological opinion (k=0.89) (Kendall et al. 
2003). This level of agreement compared favourably with that of an independent 
pathologist analysing the same samples against consensus pathology (k=0.76), 
demonstrating the importance of consensus opinion, and underlining its value in 
training spectral models.  
Raman spectral mapping of thin oesophageal tissue sections has been used to 
characterise the biochemical changes underlying the spectral differences. 
Shetty et al. used pseudo-colour principal component score maps to identify 
altered cellular constituents associated with malignancy (Shetty et al. 2006). 
Dysplastic glandular tissue showed higher levels of DNA, actin and oleic acid, 
whereas normal squamous tissue had a higher glycogen content.  
Rapid mapping of tissue sections using Raman spectroscopy has the potential 
to be used as an automated histopathology tool. Hutchings et al. showed that 
mapping could be performed in clinically applicable timescales e.g. 2mm 
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diameter section over 30-90 minutes, and that this was sufficient to discriminate 
pathology (Hutchings et al. 2009).  
 
2.2.2.2. Raman probe: towards an ‘optical biopsy’ 
As a hollow organ which can be visualised readily with endoscopy, much work 
in the oesophagus, and elsewhere in the gastro-intestinal tract, has been aimed 
at the development of a fibre-optic Raman probe for in vivo use, with several 
probes having been designed to be compatible with medical endoscopes. The 
potential advantages of Raman as an ‘optical biopsy’ tool are outlined in Table 
2-1 below. 
 
Table 2-1 Putative advantages of an ‘optical biopsy’ 
Advantages of optical biopsy Clinical benefits 
Objective evidence for diagnosis Avoids subjectivity of histopathological assessment 
Biochemical changes may precede 
morphology 
Earlier detection of pre-malignant changes 
Reduce need for tissue biopsy Avoids risk of bleeding, risk of perforation of hollow 
viscus, cost of tissue processing, cost of analysis, 
delay to diagnosis. 
Enable targeted cancer resection Ensure resection margins are clear intra-
operatively, avoiding need for re-excision or 
uncertainty over completeness of excision. 




There are a number of design and manufacturing challenges which must be 
overcome to achieve this in the oesophagus. The probe must fit the instrument 
channel of a gastroscope, the internal diameter of which measures 2.8mm for a 
standard endoscope (though this can vary from 2.0-3.8mm) (Olympus medical 
2013; Varadarajulu et al. 2011) and a scope length of 92.5-110cm (Varadarajulu 
et al. 2011). The probe must be sufficiently durable to withstand manipulation 
through articulation of the endoscope, and resistant to degradation by both 
biological secretions and processes of disinfection. Background scattered light 
must be filtered prior to spectrometer detection, requiring multiple filters. The 
acquisition time must be short to ensure a stable reading, and to allow the 
examination to proceed in a clinically appropriate timescale.  
Using a custom-built Raman probe, designed to be compatible with standard 
medical endoscopes, Almond et al. were able to demonstrate accurate 
recognition of pathology subtypes (Almond et al. 2012, 2013). A schematic 
diagram of the probe, along with a picture of the packaged probe, is shown in 
Figure 2-5. Using spectra acquired in 1 second, with a 3 group analysis (normal 
squamous cells vs. Barrett’s oesophagus/LGD vs. high grade 
dysplasia/adenocarcinoma) gave sensitivity and specificities for normal 
squamous cells of 87% and 96% respectively, Barrett’s/LGD 72% and 91%, 
HGD/adenocarcinoma 86% and 88%. Using a 2 group model with spectra 
acquired over 5 seconds the detection rate of HGD/adenocarcinoma remained 










Figure 2-5 A) Schematic diagram of Raman probe. B) Packaged probe. 
Reproduced from Day et al. 2009. 
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A number of groups have trialled Raman probes in vivo in the oesophagus. A 
preliminary study in 2000 demonstrated the safety and feasibility of using such 
probes in the oesophagus, using an Enviva Visionex probe (Shim et al. 2000). 
This group measured 400 spectra in 20 patients using 5 second acquisition 
times, although discrimination of pathology was poor (Shim et al. 2000).  
In 2005 the same group used a custom-built probe to measure 192 spectra in 
65 patients with Barrett’s oesophagus, using 5 second acquisition times. They 
were able to discriminate Barrett’s, LGD and HGD/adenocarcinoma with 
accuracy 88%, 81% and 92% respectively. When analysed using a 2 subset 
classification, they reported sensitivity of detecting HGD/adenocarcinoma as 
88% with a specificity 89% (Wong Kee Song and Wilson 2005; Wong Kee Song 
et al. 2005).  
More recently, Bergholt et al. have used a Raman probe to identify cancer in the 
oesophagus (Bergholt, Zheng, Lin, Ho, Teh, Yeoh, So, et al. 2011). Whilst most 
of the early work by this group has been in the stomach, they have recently 
begun using their Raman probe in the oesophagus. Initially they measured 263 
oesophageal spectra in 80 patients (33 with cancer, of whom 26 were 
adenocarcinoma and 6 were squamous cell carcinoma) with acquisition times of 
0.4-0.5 seconds, reporting identification of cancer in the oesophagus with 
sensitivity 91% and specificity 94% (Bergholt, Zheng, Lin, Ho, Teh, Yeoh, So, et 
al. 2011). Prior to commencement of our project this probe had not been used 
to identify Barrett’s oesophagus.1 
As a ‘point-imaging’ technique which provides biochemical information about 
tissues, there is potential for Raman spectroscopy to be used in combination 
                                                            
1 This group has recently presented data from testing the probe in patients with Barrett’s oesophagus – 
this is discussed further in the Summative Discussion. 
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with other imaging modalities, either using initial ‘wide-field’ imaging to identify 
areas of interest to be probed by Raman, or with modalities providing different 
types of information about the tissue. Raman probes have been used in 
conjunction with a trimodal imaging system which combines high-resolution 
white light endoscopy, autofluorescence imaging and narrow-band imaging, in a 
system known as trimodal imaging (Bergholt, Zheng, Lin, Ho, Teh, Yeoh, So, et 
al. 2011). This multimodal system aims to increase detection of suspicious 
lesions using autofluorescence imaging which has a high detection rate but is 
associated with a high false positive rate (Boerwinkel et al. 2013). Narrow band 
imaging, which is more specific for dysplasia than AFI (Urquhart, DaCosta, and 
Marcon 2013), can then identify areas for biopsy, or in combination with Raman, 
‘optical biopsy’.  
Some groups have used optical coherence tomography (OCT) in conjunction 
with Raman for certain cancer types. Optical coherence tomography provides 
information about tissue architecture, and where Raman identifies malignant 
changes through biochemistry, OCT could be used to measure depth of local 
invasion, thus informing decisions about treatment e.g. whether endoscopic 
resection would result in a compete excision or more extensive surgery is 
required. Although not yet performed in the oesophagus, in vivo feasibility work 
has been done on human skin (Patil et al. 2011), and on ex vivo tissue samples 
in the colon (Ashok et al. 2013). 
2.2.3. Advanced Raman techniques 
2.2.3.1. Coherent Anti-Stokes Raman Spectroscopy (CARS) 
Coherent Anti-Stokes Raman spectroscopy (CARS) is a non-linear variant on 
Raman microspectroscopy, which provides a signal that is orders of magnitude 
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stronger than the spontaneous Raman signal from biological tissue, and 
consequently can be acquired far more rapidly (Tu and Boppart 2014). 
 
 
Figure 2-6 Comparison of energy changes in a) spontaneous Raman, b) 
Stimulated Raman and c) CARS. Reproduced from Harvard University 
Department of Chemistry and Chemical Biology 2015.  
Spontaneous Raman involves excitation from incident pump photons resulting 
in a scattered photon: if initially at ground energy state the scattered photon is 
at Stokes frequency (ωs).  If both a pump photon at frequency ωp, and a further 
photon at Stokes frequency (ωs) are incident on the sample, and the frequency 
difference matches the vibrational frequency (Ω) of a Raman-active molecule in 
the sample (i.e. Ω =ωp- ωs), stimulated excitation occurs (known as stimulated 
Raman scattering, or SRS). If a further pump (or ‘probe’) photon (ωpr) is then 
incident on the sample, a photon at Anti-Stokes frequency (ωas) is then emitted. 
This four-wave mixing process forms the basis of CARS (see Figure 2-6) 
(Harvard University Department of Chemistry and Chemical Biology 2015.; Tu 
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Figure 2-7 Schematic diagram of CARS imaging. A picosecond laser emits 
beams of different wavelengths: one passes through an optical parametric 
oscillator, the other through a delay stage before their paths rejoin to be 
focussed onto the sample using an inverted microscope. Adapted from Lei et al. 
2011. 
The resonant vibrations produced by CARS lead to a signal greater than 5 
orders of magnitude stronger than spontaneous Raman (Begley, Harvey, and 
Byer 1974). This feature of CARS is its chief advantage, with the result that 
acquisition times can be drastically reduced. This provides the possibility of 
real-time, label-free imaging, capable of video-speed analysis. Applied to 




spontaneous Raman, where a map that may take many hours can be acquired 
in just a few minutes. The major advantages of CARS over spontaneous 
Raman are outlined below (Evans and Xie 2008): 
1. The signal is orders of magnitude stronger than spontaneous Raman. 
2. Speed – the stronger signal allows much faster acquisition times. 
3. It measures intrinsic molecular vibrations so no extrinsic label (e.g. 
antibody biomarker, nanoprobe etc.) is needed. 
4. There is no interference from autofluorescence with the Anti-Stokes 
signal from CARS. 
5. The nonlinear photon beams generate CARS signal at a focal spot, 
allowing 3D tissue interrogation at varying depths; at near-infrared 
wavelength depths of up to 0.4mm may be achieved.  
6. CARS causes minimal sample photodamage (Evans et al. 2005). 
 
However there are a number of limitations with this technique. CARS measures 
predominantly in the high wavenumber range above 1800cm-1, and does not 
include most of the ‘Fingerprint region’ which is most useful in discriminating 
complex biological substrates. For this reason, much work to date has been on 
imaging lipids, which give a signal in this high wavenumber region. With such 
strong signal, video-rate imaging is possible for lipids (Evans et al. 2005).  
A further limitation of CARS is the method of measuring one frequency at a 
time. Thus for mapping applications, maps are built up from multiple sequential 
measurements, each at a different frequency, but for rapid imaging modalities, 
only a few discrete frequencies can be studied. 
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Other major challenges with CARS include the non-resonant background, which 
makes interpretation of spectra very difficult (Krafft, Dietzek, and Popp 2009), 
and the limitation that CARS is unable to provide a quantitative measure of a 
sample, since the resonant signal is not proportional to sample content (Tu and 
Boppart 2014). Finally, an obvious barrier to clinical translation is the cost and 
complexity of the instrument set up (Tu and Boppart 2014). 
 
2.2.3.2. Clinical applications of CARS 
A number of groups have investigated the use of CARS in mapping histology 
samples as a diagnostic tool for pathology. To date these have largely been 
proof of concept studies that demonstrate the ability to distinguish salient 
features of disease that may aid diagnosis.  
CARS has been used in the gastrointestinal tract to discriminate between cell 
types using samples from human colon (Krafft, Ramoji, et al. 2009), by 
identifying the mucin content of goblet cells in colonic crypts.  
Discrimination between cancer subtypes has been shown in a small, 
exploratory study by Gao et al. using a lung cancer model (Gao et al. 2012). 
They reported excellent results for differentiation between small cell and non-
small cell tumours, and for discrimination between adenocarcinoma and 
squamous cell carcinoma.  
Accurate identification of brain tumours has been demonstrated in an orthotopic 




Table 2-2 Comparison of the characteristics of CARS required for clinical 
spectroscopy and clinical imaging (adapted from Tu and Boppart 2014). 
 Clinical spectroscopy Clinical imaging 




Tissue samples Ex vivo, thin (<100µm) 
section 
In vivo tissue, thick 
Instrumentation Microscopy/micro-
spectroscopy based on free-
space optics 
Fibre-optic based devices 














CARS can also be used to highlight subcellular structures. El-Mashtoly et al. 
(El-Mashtoly et al. 2014) used a cultured pancreatic cancer cell line to delineate 
several cell organelles including the nucleus and nucleolus, mitochondria, Golgi 
apparatus, endoplasmic reticulum and intracellular lipid droplets.  
The potential for video-rate imaging has prompted development of a fibre-optic 
instrument to allow in vivo endoscopic CARS. This technique has potential for 
clear advantages over spontaneous Raman in that it could be used as a label-
free wide-field imaging technique. One of the most exciting prospects recently 
investigated is the coupling of CARS technology with scanning fibre 
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endoscopes: a single fibre is driven at its mechanical resonance frequency by a 
piezoelectric actuator to generate a 2D image (Balu et al. 2010; Gao et al. 
2012). Much work remains to refine this technique but future developments in 
fibre-optic CARS are eagerly awaited. A comparison of the characteristics 
required as a clinical imaging tool versus a spectroscopic (i.e. mapping) tool is 
shown in Table 2-2.  
 
2.2.3.3. Other advanced Raman techniques 
Standard Raman spectroscopy only has a penetration depth of a few hundred 
microns, thus restricting laser probing to the surface or near-surface area of 
samples (Matousek and Stone 2009). The development of spatially offset 
Raman spectroscopy (SORS) enables spectral measurements from areas deep 
into the sample (Matousek 2009). The technique is based on the principle that 
photons migrate. Spectra are measured through the collection of scattered 
photons from surface areas on a sample that are laterally offset at a distance 
from the excitation laser point of incidence. A range of spectra are generated 
with varying intensities relating to the surface and subsurface layers. As 
collection becomes further away from the point of laser excitation, the spectral 
contributions from the top layer of the sample decrease faster than those from 
deeper layers. This is due to the likelihood of greater lateral migration of 
photons generated deeper in the sample before they are emitted from the 
sample surface. Through processing of the dataset using multivariate analysis, 
pure spectra can be produced of the individual layers of the sample (Matousek 
et al. 2005). Clinical uses of deep Raman techniques may include applications 
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in urology, bone and breast disease (Baker et al. 2007; Matousek and Stone 
2013; Matousek 2009; Matousek et al. 2005). 
There are a number of other advanced Raman techniques including hyper-
Raman, stimulated Raman spectroscopy (SRS), surface enhanced Raman 
spectroscopy (SERS), and tip-enhanced Raman spectroscopy (TERS), that are 
beyond the scope of this review. 
 
2.3. Infrared Spectroscopy 
2.3.1. Infrared spectroscopy of biological samples 
Infrared spectroscopy depends upon the absorption of incident radiation by the 
sample tissue, with measurement of the resultant energy loss (Isabelle, Stone, 
and Barr 2008). For a photon of light to be absorbed by a molecule, the 
photon’s energy must correspond to the energy gap between the molecule’s 
current state and a higher vibrational energy state, with a consequent loss of 
energy from the incident light. The vibrational frequency of a molecule and thus 
the probability of absorption are influenced by adjacent molecular bonds, and 
consequently the wavelength (or wavenumber, 1/wavelength) of absorption 
bands provides information about the chemical composition of the tissue (Barth 
2007). By measuring the attenuation (reduction in intensity) of the transmitted 
light after passing through a sample, an absorption spectrum can be produced. 
Chemical bonds between atoms undergo various forms of vibration; most 
molecular vibration occurs at energies corresponding to the infrared region of 
the electromagnetic spectrum, and consequently infrared radiation can produce 
excitation of molecular bonds (Haris and Chapman 1992). Vibrations that cause 
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changes in the dipole moment of the molecule can be measured using infrared 
spectroscopy (Haris and Chapman 1992), with the infrared spectrum measuring 
how much energy has been absorbed at a particular wavelength. Thus for a 
large molecule such as a protein, there are many possible vibrations and a 
complex spectrum will be produced. 
The potential of infrared (IR) spectroscopy to provide information on the 
secondary structure of proteins was first described by Elliott and Ambrose in 
1950 (Elliott and Ambrose 1950) but it was not until the advent of Fourier 
Transform spectrometers in the 1980s that IR spectroscopy became 
widespread (Van de Weert, Hering, and Haris 2005). Fourier transform 
spectrometers enable rapid data collection and high light intensity at the 
detector to achieve a high signal to noise ratio (Barth 2007); virtually all modern 
IR spectroscopy is performed using Fourier Transform Infrared (FTIR) (Kendall 
et al. 2009). 
In addition to protein conformation, FTIR spectroscopy has the ability to 
characterise the structure of lipids, nucleic acids and carbohydrates (Kendall et 
al. 2009; Quaroni and Zlateva 2011). In the context of clinical diagnostics, the 
technique has also been applied to more complex biological substrates such as 
tissue samples, body fluids and cell cultures. In this setting, since many bond 
vibrations are common to many biomolecules, FTIR does not measure specific 
molecules, but rather is used to quantify classes of molecules e.g. glycogen, 
protein, nucleic acid present in a sample (Mackanos and Contag 2010). Thus 
for a given tissue sample, FTIR generates a characteristic spectrum of infrared 
absorption peaks and consequently a unique ‘biochemical fingerprint’ based on 
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the overall biochemical composition of the tissue, with varying contributions 
from each type of bond vibration (see Figure 2-8).  
 
 
Figure 2-8 Infrared spectra of selected key biomolecules – infrared absorption 
provides characteristic spectral peaks based on whole sample biochemistry, 
allowing classification of complex molecular structures or biological substrates.  
 
This ability to probe the biochemical characteristics of tissues enables the use 
of FTIR to discriminate between cells in different stages of their life cycle and 
proliferation, identify metaplastic change in cell type, and recognise cancerous 
changes (Boydston-White et al. 2006; Kendall et al. 2009; Romeo et al. 2006). 
Advantages of infrared spectroscopy include a large range of applications from 
small proteins to tissue samples, a short measuring time, a small amount of 





Historically, the use of FTIR in vivo has been limited because of the challenges 
posed by the high water content of most biological tissues, as water is highly 
absorptive in the mid-infrared range in which FTIR operates (Kendall et al. 
2009; Mackanos and Contag 2010). Consequently, much of the work has been 
performed on excised tissue specimens, which must be sectioned and dried 
before sampling. However, advances in instrumentation and sampling 
techniques are reducing the need for tissue preparation, and addressing the 
challenges of in vivo application.  
FTIR spectrometers use a radiation source with the optical path passing 
through an interferometer to provide a calibrated interferogram (see Figure 2-9) 
(Bhargava 2012); this is the Fourier transform of the spectrum. In transmission 
mode spectroscopy, after passing through the sample the signal is measured 
using a single detector, and a computer then performs a second Fourier 
transform to convert the measured data back into an infrared transmittance 
spectrum over the measured wavelengths (Barth 2007).  
Reflectance techniques can be used instead of transmission, in which the 
infrared radiation reflected from the surface of the sample is measured, or in 
transmission-reflection (or ‘transflectance’), where radiation passes through a 
sample then hits a reflective surface, passes back through the sample and to a 
detector. This requires more complex post-processing to correct for 










































































































































This technique has the major advantage of requiring little or no tissue 
preparation, as the difficulties of sample thickness and water absorption are 
overcome. ATR also enables higher spatial resolution than is possible with 
transmission IR, with micro-ATR capable of spatial resolution of around 4-5µm 
(Kazarian and Chan 2013). Disadvantages include the need for contact with the 
sample and the potential for cross-contamination of the instrument as a result. 
The development of endoscope-compatible fibre-optic probes has opened the 
door to the use of FTIR in numerous hollow organs in vivo. Flexible infrared light 
guides have been constructed from  a number of materials, with silver halide 
preferred for in vivo use since it is transparent in the mid-IR, non-toxic, flexible, 
non-hydroscopic and stable (Mackanos and Contag 2010). The ability of such 
probes to discriminate pathology from normal tissue has been demonstrated in 
ex vivo samples from multiple sites, including oral mucosa, colon and bladder 
(Mackanos and Contag 2010).  
The ability to correct for the absorption of paraffin has allowed FTIR to be used 
on formalin-fixed tissue samples, and this provides the potential to validate 
sample spectra using extensive tissue banks (Nallala et al. 2012). 
A comparison of some of the key features of Raman and FTIR spectroscopy is 




Table 2-3 Comparison of Raman and FTIR spectroscopy (adapted from Kendall 
et al., 2009).  
 Raman FTIR 
Wavenumber range 400-4000cm-1 800-4000cm-1 
Light source Monochromatic laser Polychromatic light source 
Detection method Inelastic light scattering Mid-infrared absorption 
Molecular conditions 
for activation 
Changes in polarizability Changes in dipole moment 
Molecular bond 
sensitivities 
Non-polar bonds: C-C bonds 
including double/triple/aromatic 
rings 
Strong polar bonds: hydroxyl 
(OH), carbonyl (CO) and 
amide bonds 
Signal-to-noise ratio Lower Higher over same timescales 




Point raster mapping, line and 
rapid readout mapping. Fast 
Raman imaging, ultrafast confocal 
Raman imaging, wide-field 
imaging, LCTF Raman imaging. 
Rapid scan imaging using 
focal plane/linear array 
detectors. 
Enhanced techniques SORS, CARS, SERS, TERS ATR 
Sampling challenges:   
Contact with 
sample 
Required for in vivo probes Not for transmission; 
necessary for ATR 
Sample thickness Point measurements from thick 
sections, 5-20µm for mapping 
Thick samples (>15 µm) can 
cause spectral saturation 
Water Weakly scattered Strong absorption 
Paraffin Strong peaks in fingerprint region Visible in fingerprint region, 
can be overcome by spectral 
subtraction. 
LCTF Liquid Crystal Tunable Filter; SORS Spatially Offset Raman 
Spectroscopy; CARS Coherent Anti-Stokes Raman Spectroscopy; SERS 
Surface Enhanced Raman Spectroscopy; TERS Tip-Enhanced Raman 





2.3.3. FTIR in the oesophagus 
2.3.3.1. FTIR for oesophageal histology 
The potential of FTIR to provide a rapid, objective and non-destructive 
histopathological analysis has been recognised for several decades (Quaroni, 
Zhao, and Casson 2009). In part because of the challenges posed by the strong 
absorption by water in the mid-infrared region, FTIR is less well-suited to use in 
vivo, and in the oesophagus work has focused on developing a tool as an 
adjunct to histopathology.  
In 2007, Wang et al. used ATR to study 98 fresh oesophageal specimens from 
32 patients (Wang et al. 2007). This group found that DNA, protein, glycoprotein 
and glycogen account for most absorption in the 950 to 1800cm-1 region. Using 
a system of partial least squares to classify disease states, they could identify 
dysplasia with sensitivity 92% and specificity 80% (Wang et al. 2007).  
The feasibility of FTIR in formalin-fixed, paraffin-embedded oesophageal tissue 
sections has also been demonstrated (Quaroni and Casson 2009). Spectral 
differences based on accumulation of glycoproteins were used to identify 
Barrett’s oesophagus. Synchrotron data showed that the source of these 
glycoproteins was the goblet cells which are characteristic of intestinal 
metaplasia in Barrett’s oesophagus (Quaroni and Casson 2009). 
Amrania et al. have attempted to develop an adjunct for histopathologists that 
can rapidly scan tissue sections, and then produce a composite, ‘digitally 
stained’ image which could make interpretation faster and more accurate 
(Amrania et al. 2012). This utilises FTIR to provide a measure of DNA to 
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cytoplasmic ratio across the slide, which is then used to create a false-colour 
image which can be viewed by the histopathologist. 
 
2.3.3.2. Infrared spectral cytopathology 
Applications of spectroscopy to pathology have traditionally been based on 
tissue diagnosis, and compared against histology classification: the use of FTIR 
to analyse cells has been termed Infrared Spectral Cytopathology (SCP). Initial 
work on cells using FTIR measured whole cell pellets (Wong et al. 1991), but 
advances in micro-spectrometers have made it possible to use FTIR to 
measure spectra from individual cells (Diem et al. 2002, 2015). The biochemical 
composition of the cell measured by FTIR can reflect subtle changes in the cell, 
such as stage of the cell cycle or disease. As with spectroscopic tissue analysis 
described above, chemometric methods can be used to classify cells based on 
their spectra: this can be used to characterise progression through the cell 
cycle, cell type or pathological sub-group (Bird et al. 2008; Diem et al. 2015; 
Jimenez-Hernandez et al. 2013; Papamarkakis et al. 2010; Schubert et al. 
2010) .  
Nonetheless, there are a number of challenges posed by spectral interrogation 
of individual cells, not least the fact that signal from such a small sample is 
inevitably weak, and signal to noise ratios are consequently higher than for 
tissue measurement.  
Another major challenge is the Mie-type scattering effects which occur due to 
the cells or cell components (particularly the nucleus) being of similar size to the 
incident wavelength. This causes an oscillation in the spectral baseline and can 
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affect the position and intensity of spectral peaks (Bassan et al. 2009). This 
effect is a potential confounder in any subsequent interpretation of the affected 
peaks.  A correction algorithm (extended multiplicative scatter correction, 
EMSC) has been developed to account for these spectral distortions (Kohler et 
al. 2008). 
A further scattering effect is the ‘dispersion artefact’, which can alter the 
intensity and position of the Amide I peak at around 1655cm-1, which is 
frequently an important diagnostic marker in cell spectroscopy, and also causes 
pronounced effects on peaks to the high wavenumber side of the Amide I peak 
(Bassan et al. 2009, 2010; Miljković, Bird, and Diem 2012). Bassan et al. 
demonstrated that the dispersion artefact was caused by resonant Mie 
scattering – i.e. scattering when there is simultaneous absorption, since Mie 
scattering depends on the refractive index which changes on passing through 
an absorption resonance. Algorithms have been developed to correct for this 
artefact (Bassan et al. 2009; Miljković et al. 2012): computational data pre-
processing steps will be discussed further in the appropriate methodology 
section.  
The development of such computational tools has minimised the effects of 
spectral distortion and enabled progress to be made in investigating clinical 
applications of SCP. 
 
2.3.3.3. Clinical applications of SCP 
 If SCP could be harnessed in clinical practice, it could have a role in cytological 
diagnosis for a range of disease processes. Potential advantages over 
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conventional cytology include automation and reduction in clinical staff 
resources, the potential for objective measurement based on cellular 
biochemistry, every cell is measured so no cell can be missed through human 
error, and the ability to detect biochemical change that precedes morphology. It 
also has the advantage over histology of offering a relatively less invasive 
method of diagnosis, as tissue biopsy is not required and cells can be acquired 
by a variety of means e.g. in bodily excretions such as urine, or via superficial 
scrapings from an accessible hollow viscus, plus the ability to sample large 
regions simultaneously without taking multiple biopsies.  
In countries such as the UK that have introduced cervical screening 
programmes, cervical smear cytology frequently forms the largest portion of a 
cytology departmental workload. There has been much work previously to 
introduce automation for cervical screening based on image software detection 
of DNA content and enlarged nuclei (Biscotti et al. 2005), which led to a large 
randomised controlled trial in the UK comparing manual reading against 
automated or paired (automated then manual) reading (Kitchener et al. 2011). 
Unfortunately, this showed a lower sensitivity in the automated group and an 
inconsequential rise in specificity, so its use has not been recommended.  
Consequently cervical cytology is one of the first areas that has been explored 
by SCP, and a number of groups have published work in this field. The first 
such study by Wong et al. measured signal from large numbers of cells in a cell 
pellet rather than individual cells, but were able to distinguish differences 
between normal, dysplastic and cancerous samples, using contemporaneous 
stained slides as a reference standard (Wong et al. 1991). Further work on cell 
pellets by the group led by Max Diem, demonstrated the ability to differentiate 
93 
 
stages of maturation of cervical epithelial cells (Chiriboga et al. 1998). Later 
work by the same group showed differences could be identified between normal 
and cancerous cultured cells at a single cell level (Diem et al. 2002). Analysis of 
individual cells has continued to be the focus of more recent research. Schubert 
et al. demonstrated the use of SCP to discriminate normal squamous cells from 
low grade intraepithelial lesions in a group of 12 patients, and went on to show 
the ability of SCP to correctly identify HPV infection in samples from 2 patients 
with HPV and 3 without (compared to HPV DNA testing) (Schubert et al. 2010). 
Gajjar et al. recognized that inaccuracies in manual cytology reporting could 
introduce a teaching error into the training model, and consequently attempted 
to improve the ‘gold standard’ against which to construct their dataset (Gajjar et 
al. 2014). They took contemporaneous biopsy results and used histology, rather 
than cytology, as the gold standard. They demonstrated that SCP was superior 
to manual cytology in identifying changes when compared to histology.  
A further study applied SCP to cells lining the oral mucosa (Papamarkakis et al. 
2010). This demonstrated that spectral differences between cells from different 
areas of the oral cavity could be identified in 6 healthy volunteers, and that 
these samples could be separated from a further small group of 3 samples 
showing cancerous changes. 
SCP has also been shown to accurately discriminate between different cell 
types from the urinary tract in urine samples (Bird et al. 2008). This is a first 





2.4. Interpreting spectra: chemometrics and data analysis techniques 
2.4.1. Data pre-processing 
Prior to spectral analysis, a number of techniques may be applied as pre-
processing steps to correct for measurement artefacts or to allow comparison of 
spectra, whilst minimising systematic or random errors in the measured data. 
Normalisation of spectra reduces the effect of differences in intensity of the 
measured spectra (which may occur with e.g. different tissue thickness, or 
varying incident power). In order to highlight differences between spectra, mean 
centring may be used, whereby the mean spectrum of the entire dataset is 
subtracted from each spectrum.   
Correction algorithms for scattering effects (EMSC and resonant Mie scattering) 
are discussed above in section 2.3.3.2. EMSC is also used more broadly to 
correct for any physical effect that causes differences in the measured spectra, 
using fitting techniques such as least squares may be used to remove 
differences in the baseline spectrum (Lieber and Mahadevan-Jansen 2003), 
correct for contributions from the objective lens, or correct for the presence of 
contaminants in the tissue e.g. paraffin or OCT used in tissue preparation 
(Nallala, Lloyd, and Stone 2015).  
 
2.4.2. Principles of chemometrics 
Biological spectra are composed of the spectral contributions of many 
constituent molecules: as a result of this they contain a wealth of information 
about the composition of the sample, but this makes visual interpretation of 
such spectra challenging. Furthermore, the differences between spectra from 
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similar biological samples (e.g. different pathology subtypes from the same 
tissue type) may be subtle, and not readily apparent simply by looking at the 
spectra themselves. Thus further analysis is required to characterise the 
measured spectra, the contributions from certain biomolecules with known 
spectral peaks, and any consistent differences between sample groups that 
represent a true biochemical difference. These differences between samples 
can then be used to develop classification models which predict some property 
(e.g. pathology group or cell type) of new test samples.  
A number of statistical approaches may be used to identify the spectral features 
that represent the biochemical differences between samples. Large databases 
of spectra may be used to form a training dataset, with chemometric pattern 
recognition techniques then applied, such as prinicipal component analysis 
(PCA), linear discriminant analysis (LDA), partial least squares (Lloyd et al. 
2013) and support vector machines (Sattlecker et al. 2010). If such techniques 
are applied they must then be validated using an independent test set or 
another appropriate method (e.g. leave one sample out cross validation, 
LOSOCV) to give an accurate measure of diagnostic performance. The 
techniques applied in this thesis (PCA, LDA and LOSOCV) are discussed 
further below.  
Another method of analysis is to use clustering techniques, such as hierarchical 
cluster analysis (HCA), self-organising maps (SOM) and k-means clustering 
(Lasch et al. 2004; Lloyd et al. 2012). These provide a visual representation of 





2.4.3. PCA, LDA and LOSOCV 
Multivariate analysis of large datasets is challenging due to the huge volume of 
data. PCA is a method of describing the variance within a dataset that uses 
correlation to achieve data reduction (Miller 2010). In the situation with only 2 
sources of variation, there will be 2 principal components, as shown in Figure 2-
10. It can be considered a rotation of the axes, where principal component 1 
(PC1) represents the maximum source of variation, and PC2 then represents 
the next greatest source of variation, with PC2 being at right angles to (i.e. 
orthogonal to) PC1. Applied to spectra with many variables, it identifies the 
maximal source of variance between the spectra with each sequential 
component: thus PC1 accounts for the largest difference between the spectra, 
followed by PC2, then PC3 etc.  
Analysis of variance (ANOVA) can be applied to the principal components to 
identify those PCs which describe the greatest sources of variance. These PCs 
may carry the most useful information for subsequently building classification 
models.  
PCA assumes no prior knowledge about the dataset or any groupings within it, 
and is thus considered an ‘unsupervised’ technique. Providing the data analysis 
model with ‘group membership’ information for each spectrum can improve 
classification performance, and is known as a ‘supervised’ technique.  
Linear discriminant analysis (LDA) is one such supervised technique that 
incorporates information regarding the group each datapoint comes from. It 
uses this information to identify differences between the groups to enable 




Figure 2-10 Diagram showing principal components 1 and 2 in a situation with 
only two variables. (a) The two principal components, PC1 and PC2, for the 
variables X1 and X2. (b) Datapoints referred to their principal components axes. 
Blue circles represent datapoints, white circles their projection onto the axes. 
Figure reproduced from Miller 2010. 
Linear discriminant functions aim to maximise the separation between groups, 
whilst minimising the within group variance. Each function represents a line that 
describes maximal variation between two groups: new datapoints can then be 
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classified based on their position along this line relative to the known datapoints 
from each of the two groups. This can be extended to discriminate multiple 
groups. The difference between PCA and LDA is summarised in Figure 2-11. 
 
 
Figure 2-11 Comparison of PCA and LDA. Reproduced from: 
http://sebastianraschka.com/Articles/2014_python_lda.html (accessed 
05/10/15). 
This can then be used to construct a classification model onto which new ‘test’ 
data can be projected, with the model predicting which groups the data belong 
to.  
Depending upon where the decision boundary is drawn to classify one group 
versus another, the sensitivity and specificity of the classification model can be 
adjusted. For example, for a screening test where high sensitivity is an 
important feature, classification which favours the ‘positive’ or high-risk group 
may be preferred, giving a high sensitivity at the expense of a low specificity. In 
Figure 2-12 for example, the linear decision boundary could be moved ‘lower’ 
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as plotted, to ensure that no red dots are misclassified (i.e. high sensitivity), at 
the expense of poor specificity. 
 
Figure 2-12 A linear decision boundary in LDA. Reproduced from: 
http://www.ece.umn.edu/users/cherkass/ee4389/FDA.html (accessed 05/10/15). 
The performance of the classification model can be tested using the training 
dataset, however this risks providing a falsely optimistic measure of 
performance because the data being projected onto the model is contained 
within the training dataset itself.  This ‘overfitting’ can be avoided by using 
separate training and test datasets, whereby none of the test data forms part of 
the training data used to develop the model. However, it is desirable to 
maximise the data included in the training set (particularly when tissue samples 
are scarce) to capture as much of the normal variation within groups as possible 
and build an accurate model. Consequently other techniques can be used to 
validate performance that achieve this without compromising validity by 
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2.5. Summary of potential diagnostic applications of vibrational 
spectroscopy in the oesophagus 
To date, much work has been undertaken in applying these spectroscopic 
methods to discriminate between disease states across a wide range of 
pathologies and organ systems, but as yet none have entered routine clinical 
practice.  Current histopathological analysis of tissue relies largely on changes 
in tissue structure to classify disease processes: it is possible that the 
biochemical changes detected with spectroscopy may precede such changes, 
thus paving the way for earlier detection of disease, and facilitating rapid 
treatment.  
Cancer diagnostics uses many different imaging modalities depending on the 
disease and presentation of the patient, but remains heavily reliant on tissue 
diagnosis by histopathologists to confirm malignancy. This is necessarily 
invasive, requiring removal of a biopsy sample of tissue, and usually requires 
tissue preparation involving fixation, sectioning and staining. These preparation 
processes and analysis by a skilled pathologist incur costs, and add a delay to 
the diagnosis of several days from the point of tissue sampling. 
Histopathologists analyse largely morphological information from the tissue 
specimens (sometimes with the additional benefit of immunohistochemical 
stains for specific molecules), and subjectivity in interpretation of these features 
is a recognised difficulty in certain conditions (Bennett et al. 2012; Montgomery 
et al. 2001).  
Thus, novel methods to detect cancer in its early stages, or in a pre-malignant 
phase before it becomes an invasive tumour, are highly sought after, and the 
potential of vibrational spectroscopy to achieve this has been recognised. 
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Recent developments in spectroscopic instrumentation and spectral processing 
have advanced these technologies to a point where this potential is on the 
verge of translation into clinical reality. The development of fibre-optic probes 
has enabled access to a variety of epithelial lined body cavities, whilst mapping 
techniques allow interrogation of ex vivo samples, and ‘Deep Raman’ is being 
developed for non-invasive diagnosis in solid organs. The faster throughput of 
infrared spectroscopy lends it to rapid analysis of samples in the laboratory. 
Thus possible applications include automated screening of tissue biopsy 
processing in Barrett’s surveillance, or analysis of oesophageal cell samples 




SECTION B: FTIR SPECTROSCOPY FOR DIAGNOSIS OF BARRETT’S 
OESOPHAGUS AND ASSOCIATED NEOPLASIA 
CHAPTER 3: INTRODUCTION AND OBJECTIVES 
3. Introduction and objectives 
The current BSG guidelines list several future developments that would 
‘revolutionise the care of individuals with Barrett’s oesophagus and should be 
priorities for policy makers and funders’, of which the number one item listed is 
‘a non-endoscopic test(s) for diagnosis and surveillance’ (Fitzgerald et al. 2014). 
Development of an accurate, minimally invasive, relatively low-cost test could 
radically alter current models of endoscopic surveillance, and overcomes the 
greatest obstacles to screening for Barrett’s, namely the costs and 
acceptability/risks of endoscopy.  
Swallowed cell collection devices offer a potential non-endoscopic means of 
sampling from the oesophagus. Balloon collection devices have been used in 
eastern Asia for several decades as a screening tool for squamous cell 
carcinoma of the oesophagus (Dawsey et al. 1997; Shu 1983; Spechler 1997). 
A balloon device has been trialled for Barrett’s-associated neoplasia, but 
challenges included inadequate cell collection and reduced sensitivity for 
dysplasia (Falk et al. 1997). Results from the same study suggested that brush 
cytology has the potential to collect a representative sample, but the difficulty of 
interpretation of low grade dysplasia may limit the sensitivity using conventional 
cytological assessment. 
If a swallowed cell collection device were to be used as a screening tool for 
Barrett’s this would pose a number of challenges for conventional cytological 
assessment. Firstly, oesophageal cytology is performed relatively infrequently, 
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and expertise in this field is correspondingly limited. Secondly, assessment of 
cells may be challenging and shows variable correlation with histology taken 
contemporaneously (Geisinger et al. 1992; Hardwick et al. 1997; Hughes et al. 
1998). Thirdly, a swallowed device that enters the stomach may have glandular 
cells from the stomach which must be differentiated from oesophageal glandular 
metaplasia. Fourthly, if expert cytological assessment were required for every 
sample if applied as a population screening tool, this would require a great deal 
of resources.  
The recently developed Cytosponge™ device aims to overcome a number of 
these challenges through immunostaining with TFF3 (as explained in the 
literature review, section 1.8). A large case-control study in the UK is currently 
underway to evaluate this device as a means of detecting Barrett’s 
oesophagus.2 
Infrared spectroscopy has been used to discriminate accurately between 
pathology groups in a range of pathologies and organ systems, including 
between cells in the cervix, head and neck (‘spectral cytopathology’). To date 
there have been a small number of studies investigating IR in the oesophagus. 
These studies have attempted to characterise the spectra of normal squamous, 
Barrett’s, and adenocarcinoma tissue samples using FTIR mapping in formalin-
fixed, paraffin embedded tissue (Quaroni and Casson 2009), or ATR in fresh-
frozen sections to discriminate and classify normal squamous, Barrett’s, 
dysplastic and gastric mucosa (Wang et al. 2007). Another study used FTIR 
mapping to produce spectral maps from 2 patients with oesophageal 
adenocarcinoma based on peaks at 1234cm-1 (representing the phosphodiester 
                                                            




peak, which they used as an indicator of nuclear content), and 1650cm-1 (the 
amide I peak, which they used as an indicator of cytoplasmic content) (Amrania 
et al. 2012). 
A further study used an ATR probe in fresh frozen sections to discriminate 
normal squamous from squamous cell carcinoma (Wang et al. 2003).   
As yet, no studies have investigated the use of FTIR mapping to classify 
oesophageal cells. The application of these techniques to cell samples taken 
using a cell collection device in the oesophagus could potentially show highly 
accurate discrimination between pathology groups, and provide an automated 
means of analysis. The ability to differentiate normal squamous cells from 
abnormal cells (Barrett’s metaplasia or Barrett’s-associated neoplasia) among 
screened patients would identify those who would need endoscopy. Accurate 
discrimination between Barrett’s metaplasia and Barrett’s-associated neoplasia 
could potentially be used among those with Barrett’s oesophagus in place of 
current endoscopic surveillance. 
 
3.1. Objectives 
1. Investigate the ability of FTIR mapping to classify oesophageal pathology 
using oesophageal tissue samples and elucidate key spectral differences 
between pathology subtypes.  
2. Investigate the ability of infrared spectroscopy to classify Barrett’s and 
Barrett’s neoplasia using oesophageal cell samples. 
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a. Evaluate the ability of infrared spectroscopy to discriminate 
between normal squamous, non-dysplastic Barrett’s and Barrett’s-
associated neoplasia in oesophageal cell samples. 
b. Evaluate the ability of infrared spectroscopy to discriminate 






CHAPTER 4: FTIR MAPPING OF OESOPHAGEAL TISSUE 
4. FTIR mapping of oesophageal tissue 
4.1. Ethical approval and informed consent 
All patients participating in the study provided informed consent. Each patient 
received a standardised information leaflet explaining the study (Appendix V). 
Patients had time to read the leaflet prior to a face-to-face discussion with the 
researcher, which offered an opportunity to ask any questions about the study. 
If happy to proceed, patients then provided their consent to participate, and 
signed a standardised consent form (Appendix IV).  No samples were taken 
from patients unless they had provided informed consent.  
Ethical approval for the study was in place at the start of the project, as this 
project formed part of the ongoing work in the Biophotonics Research Unit 
programme for improving diagnosis in oesophageal malignancy. Ethical 
approval had previously been obtained from the Gloucestershire Local 
Research Ethics Committee (Appendix VI).  
 
4.2. Sample collection 
Samples were collected from patients undergoing scheduled endoscopy, either 
as part of Barrett’s surveillance or indicated for other clinical grounds (e.g. 
previous finding of dysplasia) or from patients undergoing surgery for 
oesophageal cancer.  
Since serial tissue sections were required to allow accurate correlation with 
histology (discussed further in section 4.4 below), only endoscopic resection or 
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samples taken at oesophageal resection were used in this study.  Endoscopic 
resection was performed using diathermy, and a portion of the section sent for 
immediate histology with the remainder taken for research. The research 
sample was then placed into a cryovial (Thermo Scientific, Waltham, MA, USA) 
and immediately snap frozen in liquid nitrogen, before storage at -80°C. 
For the samples collected at surgery for oesophageal cancer, once the 
oesophagus was removed from the patient it was opened longitudinally, washed 
in distilled water, and samples were collected using a scalpel. Samples were 
placed in cryovials and snap frozen as above. 
 
4.3. Sample preparation  
Fresh frozen samples were cut into thin tissue sections for measurement and 
analysis. 8µm thick sections were cut and placed on calcium fluoride slides 
(CaF2) for FTIR measurement, with a contiguous tissue section being taken and 
placed on a glass slide for haematoxylin and eosin (H&E) staining, followed by 
conventional histological assessment.  
The use of glass slides for infrared analysis is limited because infrared does not 
penetrate glass in the fingerprint region, hence calcium fluoride slides are 
preferred: calcium fluoride has no absorption peaks in the measured 
wavenumber range.  






4.4. Histology correlation: identifying regions to be measured 
Taking contiguous sections ensures that the tissue section used for analysis will 
very closely match the histology of the section used for H&E staining. This 
allows accurate correlation of the histology findings with the spectroscopic data. 
Tissue sections were reviewed by a Consultant Pathologist with a special 
interest in gastrointestinal pathology. For this study, in addition to classifying the 
pathology of each tissue section, areas within that section were highlighted by 
the pathologist to identify areas of homogeneous pathology e.g. dysplastic 
epithelium. Epithelial regions of interest were identified containing 
homogeneous pathology for measurement. This allowed targeted FTIR 
mapping of the contiguous tissue section, and ensured that, as far as possible, 
only a single tissue pathology was contained in the regions measured.  
Subsequently, tissue sections were reviewed independently by a second 
Consultant Pathologist with a special interest in gastrointestinal pathology, in 
accordance with BSG guidelines on reporting of dysplasia. Appendix VII (i) 
shows the classification of each tissue sample by both pathologists. This 
showed agreement in all normal squamous, Barrett’s and adenocarcinoma 
samples. There was discrepancy over 4 of the 5 dysplasia samples, with 
disagreement over classification of HGD versus LGD, but all samples were 
classified as dysplastic by both pathologists. The overall agreement was 
therefore 81.8% if the discordance over grade of dysplasia is included, or 100% 
if using a more simple classification of ‘any dysplasia’. This high level of 
agreement between the pathologists is likely to be due to the selection of 
‘homogeneous’ regions by the first pathologist.  The effects of variation in 
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pathology classification on our results are discussed further in the discussion 
(section 4.11). 
To identify the region to be measured, the unstained tissue section was 
examined under the microscope, and this image used to identify features of the 
tissue that correspond to regions on the H&E stained section (see Figure 4-1). 
Once the region of interest had been identified on the calcium fluoride section, 
an area within that region of interest was chosen to be measured.  
 
 
Figure 4-1 Correlating H&E stained section with contiguous unstained tissue 
section (small region of normal squamous epithelium, area highlighted further in 
Figure 4-2 below). 
 
4.5. Sample measurement 
FTIR measurements were performed in the Department of Physics at the 
University of Exeter, using an Agilent® 620 FTIR microscope connected to an 
Agilent® 670 spectrometer.  
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The Agilent® system has a 128x128 pixel focal plane array detector and uses a 
high energy Globar mid-infrared light source to simultaneously acquire 
thousands of spectra. A schematic diagram of an FTIR spectrometer is shown 
in Figure 2-9 in the literature review.  
On the Agilent® system there is not an enclosed measurement chamber, but to 
minimise the presence of atmospheric water vapour the sample is continuously 
purged with anhydrous air. Prior to sample measurement the liquid nitrogen 
reservoir was filled with liquid nitrogen to ensure adequate cooling of the focal 
plane array detector.  
The tissue section on calcium fluoride was defrosted prior to measurement. 
Once the sample slide was mounted on the FTIR microscope, system 
calibration was performed by choosing a blank region of the slide, and adjusting 
the integration time and condenser objective to optimise the intensity of the IR 
beam on the sample.  
A background spectrum was measured on a blank region of the sample slide 
prior to measurement of each sample, to allow correction for absorbance from 
the atmosphere, the system and the slide. Background measurement was taken 
using 256 scans at 4cm-1 resolution for wavenumbers 800-4000cm-1.  
Regions of homogeneous pathology were identified as described above, and 
the region of interest was identified on the slide using the microscope. FTIR 
measurements were performed using the focal plane array detector of the 
Agilent 620 microscope in transmission mode, using ‘High-magnification’ mode 
which gives a pixel size of 1.1µm, with a spectral resolution of 4cm-1. The focal 
plane array allows measurement of 128x128 pixels in a single shot, so with a 
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1.1µm pixel size this gives an approximately 140µm x 140µm region of 
measurement for a single ‘tile’.  
Consequently, 2 separate 140µm x 140µm regions were selected within the 
region of interest to be measured. This size corresponds to one ‘tile’ of the 
Agilent detector, allows rapid acquisition (approximately 12 minutes per tile 
using 64 scans per pixel), and provides a large number of spectra for analysis 
(16,384 per tile), whilst being a sufficiently small region to be confident of 
measuring homogenous tissue pathology.  
 
4.6. Data pre-processing 
The spectral maps collected are stored as a hyperspectral image or hypercube. 
This can be considered as a 2-dimensional map with co-ordinates in the X and 
Y plane, with the 3rd dimension representing the complete spectral information 
for a given pixel. An example of an unprocessed spectral map with its 
corresponding white light image is shown in Figure 4-2 below. The unprocessed 
map simply plots the maximum intensity of the signal at each pixel. 
The raw spectrum measures the amount of light transmitted through the tissue, 
(transmittance) relative to a background reading taken prior to measurement: 
this is converted to the amount of light absorbed by the tissue using the Beer-
Lambert Law as follows: 
   A = -log10 (T) 
Where A= Absorbance, T= Transmittance 
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The Agilent system does this calculation automatically and the collected data is 
then stored as absorbance rather than transmittance spectra.  
 
Figure 4-2 White light image and unprocessed spectral map (sample N3), 
showing (A) region identification using 4x objective, (B) selection of region of 
interest to map using 15x objective, and (C) unprocessed FTIR spectral map.  
 
The measured wavenumber range is 800-4000cm-1. In this large dataset, to 
focus on the most discriminatory ‘fingerprint’ region and allow more rapid 
analysis, the wavenumber range was truncated to 950-1800cm-1. This risks 
losing some information contained in the higher wavenumber range, but was felt 
to be an acceptable trade off based on the key discriminatory wavenumber 
regions identified in previous work within the group. 
115 
 
To minimise differences in absolute signal intensity due to differences in tissue 
thickness, or system effects such as source or detector variations, the dataset 
was vector normalised using the Standard Normal Variate normalisation 
method. Vector normalisation is a well recognised pre-processing technique for 
reducing scaling effects in infrared microspectroscopy (Diem et al. 2004).  
The dataset is then mean centred – this is useful prior to principal component 
analysis as it ensures the principal components focus on variance from the 
mean rather than variance from the origin, giving more meaningful information 
about variance between spectra.  
 
4.7. Data analysis  
The principles underlying the techniques chosen for data analysis are described 
in greater detail in section 2.4 above.  
Principal component analysis (PCA) was used as a data reduction technique to 
identify variance between the spectra. The first 50 principal components (PCs) 
were identified: this aimed to optimise classification performance without ‘over-
fitting’ data using random noise. Analysis of variance (ANOVA) was then 
performed to identify which of those PCs provide the greatest discrimination 
between pathology groups, with a confidence threshold of 0.99 for inclusion in 
the training model.   
Linear discriminant analysis (LDA) was then performed using those PCs 
selected by ANOVA, with the samples assigned into groups according to 
consensus pathology reporting, to build diagnostic classification models.  
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A variety of diagnostic classification models were then built, as described below. 
Each of these was tested using leave one sample out cross-validation 
(LOSOCV), with each spectrum being projected onto a training model using 
data from every sample except the one being tested (i.e. n-1 samples). This 
was repeated for every spectrum in the dataset. The predicted classification 
could then be used to generate a confusion matrix showing the true and false 
predictions for each spectrum, and allowed sensitivity and specificity of the 
technique to be calculated for individual spectra.  
Once predictions had been calculated for individual spectra, it was possible to 
combine these results to generate predictions for entire sample maps. A 
‘threshold voting’ system was developed which incorporates the prediction for 
each pixel of a map and combines this data to produce a classification for the 
whole sample. This is explained further below. 
 
4.8. Summary of measurements 
A total of 737,280 spectra were measured from 22 tissue samples, collected 
from 19 patients (some patients contributed tissue of more than one pathology 
type, for example if an area of normal squamous tissue and an area of 
adenocarcinoma were collected from the same patient). 140µm x 140µm FTIR 
maps were measured over 2 regions for each tissue sample (and there was one 
‘extra’ sample region measured for one of the adenocarcinoma samples). The 
number of maps recorded and spectra measured for each pathology are shown 




Table 4-1 Summary of measured samples 
 No. of tissue 
samples 
Total no. of FTIR 
maps measured 
Total no. of spectra 
measured 
NSQ 5 10 163,840 
BE 6 12 196,608 
Dysplasia 5 10 163,840 
Adenoca. 6 13 212,992 
TOTAL 22 45 737,280 
NSQ normal squamous; BE Barrett’s oesophagus; Adenoca. adenocarcinoma. 
After pre-processing, the mean spectrum for each sample was reviewed to 
ensure all samples were valid measurements prior to inclusion as training data 
for classification models. The mean spectrum of each sample is presented in 
Figure 4-3 below.  
The mean spectra from every sample were consistent with tissue spectra, and 
every sample was included for developing classification models. There was 
significant variance seen within some groups e.g. normal squamous around 
1020cm-1, and dysplasia around 1650cm-1. Further analysis of the composition 
of these spectra, and differences between the pathology groups, is discussed in 
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4.9. Diagnostic classification models 
4.9.1. 3 group model  
For the initial analysis the low grade dysplasia, high grade dysplasia and 
adenocarcinoma groups were combined for classification purposes, thus giving 
a ‘3 group model’ with classification as either ‘Normal squamous’, ‘Barrett’s’, or 
‘Dysplasia/adenocarcinoma’. This is for two reasons: firstly if FTIR mapping 
were to be used in practice for Barrett’s surveillance, this classification would 
highlight the ‘high risk’ samples which would benefit from intervention. Current 
guidelines advise dual reporting of all samples containing dysplasia or 
adenocarcinoma, so one potential role for FTIR would be to act as the ‘first 
pathologist’ in screening samples to identify those high risk specimens requiring 
a second review.  
Secondly, this project was intended to act as a preliminary study for cytology 
classification: cytology classification is more limited than histology and can only 
discriminate between normal, glandular (i.e. consistent with Barrett’s) and 
dysplastic cells (for either dysplasia or adenocarcinoma). Consequently the 
biochemical differences between these groupings would be most useful in 
demonstrating feasibility to inform the cytology study.  
PCA was used to identify the sources of variance within the dataset, with up to 
50 principal components (PCs) chosen by ANOVA. The contribution of each of 
those PCs in describing the variance within the dataset is shown by the F ratio 
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and 45,500 Barrett’s spectra (23.1%) misclassified as dysplasia/ 
adenocarcinoma.   
Table 4-2 Performance of the 3 group model: (A) confusion matrix showing 
classification of individual spectra (with correctly classified spectra in bold), and 
(B) sensitivity and specificity of the model for classifying individual spectra. NSQ 











To further test the validity of these results, a further analysis was performed for 
each sample which excluded other samples taken from the same patient, i.e. a 
leave one patient out cross-validation (LOPOCV). This goes a step further than 
LOSOCV to ensure that any patient-specific differences (rather than pathology-
specific differences) are not included in the training model. The results are 
shown in Table 4-3. 





(no. of spectra) 
BE 
(no. of spectra) 
DYS/AC 
(no. of spectra) 
NSQ 153358 221 583 
BE 4680 150887 57645 
DYS/AC 5802 45500 318604 
 Tissue pathology 
Performance of 
3 group model 
NSQ BE DYS/AC 
Sensitivity (%) 93.6 76.8 84.6 
Specificity (%) 99.9 88.5 85.8 
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Table 4-3 Performance of the 3 group model after LOPOCV: (A) confusion 
matrix showing classification of individual spectra (with correctly classified 
spectra in bold), and (B) sensitivity and specificity of the model for classifying 
individual spectra. NSQ = normal squamous, BE = Barrett’s oesophagus, DYS 










The results in Table 4-3 show a very slightly poorer performance for normal 
squamous and dysplasia/adenocarcinoma, but a larger drop in the Barrett’s 
sensitivity from 76.8% to 63.2%. The confusion matrix indicates that many more 
Barrett’s spectra are misclassified as dysplasia/adenocarcinoma, but very few 
as normal squamous. This suggests that between patient differences 
contributed a small amount to the training model overall, but that this may have 
been a greater source of discrimination between the Barrett’s and 
dysplasia/adenocarcinoma groups than the others. 





(no. of spectra) 
BE 
(no. of spectra) 
DYS/AC 
(no. of spectra) 
NSQ 148668 340 593 
BE 8710 124191 76117 
DYS/AC 6462 72077 300122 
 Tissue pathology 
Performance of 
3 group model 
NSQ BE DYS/AC 
Sensitivity (%) 90.7 63.2 79.6 
Specificity (%) 99.9 84.3 78.2 
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Ultimately the purpose of FTIR mapping would be to classify each sample 
rather than individual pixels within a given sample. Consequently a system was 
required to convert the individual pixel classification into a prediction for the 
whole sample. In a theoretical situation where pixel classification was 100% 
accurate, then it might be logical to classify a sample with even 1 pixel 
containing evidence of adenocarcinoma as cancer, or at least ‘high risk’ for 
cancer. However, it was clear from the pixel classification performance that this 
level of accuracy was unrealistic with 2500 pixels per sample, and greater 
flexibility was required.  
Projecting the pixel classification back onto the maps shows the distribution of 
the prediction within the sample. Although sample regions had been carefully 
selected to show a single pathology, in some cases the spectral predictions 
were different across a sample, so did not all match the histology classification. 
Projections of these predictions onto the maps could show if a region within a 
map was classified differently as shown in Figure 4-7. 
There is a strong analogy with the methodology used by pathologists here – 
when reviewing specimens if a tiny area of cancer is seen then the sample is 
classified as showing cancer (even though the majority of the sample may be 
benign). Similarly, if a sample shows a region of Barrett’s mucosa and a region 
of normal squamous mucosa, the specimen (and therefore the patient) will be 
classified as having Barrett’s oesophagus. Effectively the ‘worst’ pathology 
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Table 4-4 Performance of the 30% threshold voting 3 group model: (A) 
confusion matrix showing classification of samples (with correctly classified 
samples in bold), and (B) sensitivity and specificity of the model for classifying 
samples. (C) List of samples misclassified by the model. NSQ = normal 
squamous, BE = Barrett’s oesophagus, DYS = dysplasia, AC = 
adenocarcinoma.  
A 
 True pathology classification 
Predicted NSQ BE DYS/AC 
NSQ 10 0 0 
BE 0 9 1 
DYS/AC 0 3 22 
 
B 
Sample pathology Sensitivity Specificity 
NSQ 100 100 
BE 75.0 96.7 
DYS/AC 95.7 86.4 
 
C 
Sample no. True pathology Predicted pathology 
B1(1) BE DYS/AC 
B3(2) BE DYS/AC 
B4(2) BE DYS/AC 
D4(2) DYS BE
 
Looking at the 4 samples which were misclassified (see Table 4-4 C), it is 
noticeable that each of these samples was rather poorly preserved, as can 
happen with fresh frozen sections. This results in slight loss of tissue structure 
and the presence of small holes within the tissue, and it is possible that this may 
have contributed to the failure to classify these sections correctly. However, 
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there were 2 other tissue sections which were equally poorly preserved (B5 and 
D5) where the classification model uniformly predicted the correct pathology.  
One other sample, A2(1), although classified correctly, showed heterogeneity in 
its spectral classification. This sample had a tear in the tissue section making 
correlation of the region of interest with H&E more challenging, and it is possible 
that imprecise selection of the measurement region contributed to this.  
Table 4-5 Performance of the 30% threshold voting 3 group model using 
LOPOCV: (A) confusion matrix showing classification of samples (with correctly 
classified samples in bold), and (B) sensitivity and specificity of the model for 
classifying samples. (C) List of samples misclassified by the model. NSQ = 
normal squamous, BE = Barrett’s oesophagus, DYS = dysplasia, AC = 
adenocarcinoma.  
A 
 True pathology classification 
Predicted NSQ BE DYS/AC 
NSQ 10 0 0 
BE 0 7 1 
DYS/AC 0 5 22 
 
B 
Sample pathology Sensitivity Specificity 
NSQ 100 100 
BE 58.3 97.0 
DYS/AC 95.7 77.3 
 
C 
Sample no. True pathology Predicted pathology 
B1(1) BE DYS/AC 
B3(2) BE DYS/AC 
B4(2) BE DYS/AC 
B5(1) BE DYS/AC 




The threshold voting system was then repeated using the LOPOCV results, 
shown in Table 4-5. As with the individual spectra results the sensitivity for 
Barrett’s is lower than for LOSOCV, with several samples misclassified as 
dysplasia/adenocarcinoma, and the specificity of the dysplasia/adenocarcinoma 
group is correspondingly reduced.  
An alternative approach to the threshold voting system is to use a very high 
threshold, and accept that a proportion of the samples will therefore not be 
classified and the model will return a result of ‘unknown pathology’. This could 
be useful as a clinical application if sole diagnosis were to be performed by 
FTIR mapping, with only those samples labelled as unknown by FTIR then 
needing review.  
Table 4-6 Performance of the 90% threshold voting 3 group model: (A) 
confusion matrix showing classification of samples (with correctly classified 
samples in bold), (B) sensitivity and specificity of the model for classifying 
samples (not including unclassified samples). NSQ = normal squamous, BE = 
Barrett’s oesophagus, DYS = dysplasia, AC = adenocarcinoma.  
A 
 True pathology classification 
Predicted NSQ BE DYS/AC 
NSQ 7 0 0 
BE 0 7 0 
DYS/AC 0 0 15 
UNKNOWN 3 5 8  
 
B 
Sample pathology Sensitivity Specificity 
NSQ 100 100 
BE 100 100 




A 90% threshold was chosen for this model, aiming to include only samples that 
the model was able to predict with high confidence, but allowing a small margin 
for error on pixel classification. Classification performance of the 90% threshold 
voting model is shown in Table 4-6. Using a 90% threshold gives 100% 
accurate diagnosis for those samples the model is able to classify, but results in 
35.6% of samples being unclassified. This provides further evidence that the 
classification model, where confident in its predictions, is accurate, but leaves a 
high proportion of samples unclassified. This could nonetheless be useful in 
clinical practice as an automated system with ‘knowns’ fully trusted and 
unknowns sent for pathology review.   
 
4.9.2. 2 group classification models 
4.9.2.1. ‘Normal’ versus ‘abnormal’ 
A 2 group model was also evaluated, combining the Barrett’s, dysplasia and 
adenocarcinoma samples: this could be clinically applicable if used simply to 
classify samples as ‘normal’ versus ‘abnormal’, with abnormal samples selected 
for further review. The results of the 2 group model are shown in Table 4-7 and 
Figure 4-9 below.  
The ability of the model to discriminate between normal and abnormal 
pathology is very good, with sensitivity and specificity for classification of 
individual spectra of 93.6% and 99.8% respectively. When translated into whole 




Table 4-7 Performance of the 2 group model NSQ vs BE/DYS/AC. Results for 
individual spectra are shown in A) confusion matrix (with correctly classified 
spectra in bold), and (B) sensitivity and specificity. Threshold voting 
classification of whole samples is shown in C) confusion matrix and D) 
sensitivity and specificity. NSQ = normal squamous, BE = Barrett’s 



















(no. of spectra) 
BE/DYS/AC 
(no. of spectra) 
NSQ 153349 1304 
BE/DYS/AC 10491 572136 
 Tissue pathology 
Performance of 2 
group model 
NSQ BE/DYS/AC 
Sensitivity (%) 93.6 99.8 
Specificity (%) 99.8 93.6 




NSQ 10 0 
BE/DYS/AC 0 35 
 Tissue pathology 
Performance of 2 
group model 
NSQ BE/DYS/AC 
Sensitivity (%) 100 100 
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Table 4-8 Performance of the 2 group model NSQ/BE vs. DYS/AC. Results for 
individual spectra are shown in A) confusion matrix (with correctly classified 
spectra in bold), and (B) sensitivity and specificity. Threshold voting 
classification of whole samples is shown in C) confusion matrix and D) 
sensitivity and specificity. NSQ = normal squamous, BE = Barrett’s 
















 Tissue pathology 
Predicted spectral 
pathology 
NSQ/BE   
(no. of spectra) 
DYS/AC 
(no. of spectra) 
NSQ/BE 295272 48359 
DYS/AC 65176 328473 
 Tissue pathology 
Performance of 2 
group model 
NSQ/BE  DYS/AC 
Sensitivity (%) 81.9 87.2 
Specificity (%) 87.2 81.9 
 Tissue pathology 
Predicted sample 
pathology 
NSQ/BE  DYS/AC 
NSQ/BE 17 1 
DYS/AC 5 22 
 Tissue pathology 
Performance of 2 
group model 
NSQ/BE  DYS/AC 
Sensitivity (%) 77.3 95.7 



















































































































































































































models described above. Deducing which biomolecules contribute to which 
peaks can be done using known spectra from the literature or by measuring 
spectra from pure biomolecules to act as reference standards. At certain 
wavenumbers there may be overlap with a number of possible bond vibrations 
(or a number of possible biomolecules) causing spectral peaks at that position. 
There are also some slight differences in peak wavenumbers quoted in different 
reference sources. Where they exist, reference standards from human 
oesophagus are used as the primary source to inform peak assignment for this 
project. Where human oesophagus reference standards are not available, 
published data from other tissue sources are used, or ‘in house’ reference 
standards. The in house reference standards are a set of pure biomolecules 
measured previously using FTIR by another member of the Biophotonics 
Research Unit (Dr M Isabelle). These reference standards are listed in 
Appendix VIII.  
Given the overlap in quoted wavenumbers for certain biomolecules, there may 
be more than one possible molecular cause for a given spectral appearance, 
and consequently individual peak assignments listed here are tentative. 
Nonetheless, where multiple peaks within a spectrum all point to the presence 
of a particular biomolecule, this is considered strong supportive evidence.  
 
4.10.1. Spectral peak assignment 
The first stage of spectral analysis was to examine the key spectral peaks of the 
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peak was considered to be a marker of cytoplasm. The cytoplasm content of 
normal squamous cells is higher than glandular cells in Barrett’s, which in turn is 
higher than in dysplastic/adenocarcinoma cells: this is consistent with the 
1650cm-1 peak height seen in Figure 4-13.   
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Wang et al., 2003, 
Wang et al., 2007  
Quaroni et al., 2009 
Wang et al. 2007, 
Quaroni et al., 2009 
1117 1117 O-H bend Glycoprotein Stomach Wang et al., 2007 
1157 1154 C-O stretch Glycogen Oesophagus Wang et al., 2007, 
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- Glycoprotein Reference 
standard 
Wang et al., 2007 
1394 1398 C-H bend Protein Oesophagus Wang et al., 2007 
1448-1460 1454 C-H bend Protein Oesophagus Wang et al., 2007 
1514 1520 - Protein: actin IHRS IHRS 




Oesophagus Wang et al., 2007, 
Wang et al., 2003 





Oesophagus Amrania et al., 2012, 
Wang et al., 2007 
1743 1744 C=O stretch Phospholipid Reference 
standards 
Serum 
IHRS, Baker et al., 
2014 
Sheng et al. 2013 
IHRS = In house reference standards; 
 
There are a number of glycogen peaks, most clearly at 995cm-1, 1024cm-1 and 
1157cm-1. In all of these cases the peak is visibly highest in the normal 
squamous group, suggesting higher glycogen content in this tissue than the 
Barrett’s or dysplasia/adenocarcinoma. This replicates the previous findings in 
oesophageal tissue using FTIR (Wang et al. 2003, 2007), and the same finding 
has been made using Raman spectroscopy (Shetty et al. 2006).  
The peak at 1084cm-1 may be caused by glycogen, but may also be due to 
glycoproteins: here the normal squamous peak is slightly higher than the 
Barrett’s peak, which is higher than the dysplasia/adenocarcinoma peak. A 
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possible explanation would be the higher glycogen content causing the higher 
normal squamous peak, with the relatively higher glycoprotein content giving 
the Barrett’s group a higher peak than the dysplasia/adenocarcinoma group.  
Peaks that may be attributable to DNA occur at 1084cm-1, 1236cm-1 and 1650 
cm-1. However, at each of these wavenumbers there are other biomolecules 
that may contribute a spectral peak. In the study by Amrania et al. (2012), the 
1234cm-1 peak was considered to represent DNA and used as a marker of 
nuclear material. The 1236cm-1 peak is visibly highest in the 
dysplasia/adenocarcinoma group, consistent with an increase in nuclear 
material.  
The peak at 1743cm-1 is likely due to phospholipid, and is highest in the 
dysplasia/adenocarcinoma group. 
There are many further small differences between the spectra: these can be 
more readily visualised by subtracting the mean spectrum of one pathology 
group from another. However, caution must be exercised in interpretation of 
these subtraction spectra where the absolute differences in intensity between 
groups are very small, and there is significant variation in intensity within each 
group. Figures 4-14 to 4-16 highlight the differences between the spectra by 
subtracting one group mean from another.  
In Figure 4-14, the normal squamous tissue contains strong peaks at 1022cm-1 
and 1153cm-1 consistent with higher glycogen content. The peak at 1650cm-1 
representing cytoplasm is also much higher in the normal squamous tissue. The 
peak in the Barrett’s tissue at 1377cm-1, along with the shoulder at 1172cm-1, 
could be attributable to glycoproteins. The other main glycoprotein peak is 
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In Figure 4-15, the glycogen peaks are clearly stronger in the normal squamous 
tissue, at 1024 and 1153cm-1, as is the cytoplasm content represented by the 
peak at 1653cm-1. The 1082cm-1 peak is stronger in the normal squamous 
tissue, which is likely due to glycogen content, although glycoproteins may also 
have an effect here.  
The DNA peak at 1234cm-1 is much stronger in the dysplasia/adenocarcinoma 
tissue, consistent with increased nuclear material. The glycoprotein peak at 
1377cm-1 is stronger in the dysplasia/adenocarcinoma group.  
Again, above 1400cm-1 the subtraction spectrum becomes noisy and harder to 
interpret, with many small protein peaks.  
The phospholipid peak at 1741cm-1 is higher in the dysplasia/adenocarcinoma 
group.  
In Figure 4-16, the Barrett’s tissue has stronger signal across the wavenumbers 
1000-1150cm-1. The major peaks are at 1074 and 1113cm-1, which are most 
likely attributable to glycoproteins, but this region may also include contributions 
form glycogen at 1024, 1080 and around 1150cm-1. The other glycoprotein peak 
at 1373cm-1 is stronger in the Barrett’s tissue, as is the peak around 1650cm-1 
representing cytoplasm.  
The major DNA peak at 1236cm-1 is stronger in the dysplasia/adenocarcinoma 
group. The peak at 1338cm-1 is likely due to the amino acid phenylalanine.  
Once again, the wavenumber region above 1400cm-1 is difficult to interpret, with 






























































































































4.10.2. Interpretation of principal component loadings 
Having analysed the differences between the spectra and the biomolecular 
contributions to these differences, the principal component (PC) loadings can 
then be examined to see what spectral differences have been used to 
discriminate between the groups.  
There were 48-50 PCs chosen by ANOVA for each training model: in order to 
focus on those that contribute the most to the group classification, only the 5 
most discriminatory PCs as calculated on F ratio (see Figure 4-4 above) will be 































































































































PC3 shows a strong (negative) glycogen peak at 1026cm-1. The shape of the 
peaks at 1068-1097cm-1 is similar to the normal squamous versus Barrett’s 
subtraction plot: this may be separating glycoproteins (positive) from glycogen 
(negative). The effect of the glycogen peak at 1151cm-1 indents a larger protein 
peak at 1198cm-1 (and creates a smaller peak at 1140cm-1), which merges with 
the strongly positive DNA peak at 1234cm-1. The positive peak at 1743cm-1 
represents phospholipid. The region above 1400cm-1 is largely noise. Taken as 
a whole, PC3 appears to separate Barrett’s/dysplasia/adenocarcinoma 
(positive) from normal squamous (negative).  
PC4 shows positive peaks at 966 and 1223-1240cm-1. The 1223-1240cm-1 peak 
is likely to have a large contribution from the DNA peak at 1234cm-1. The 
966cm-1 peak was not clearly seen in the subtraction spectra, but previous work 
in oesophageal tissue has identified a DNA peak at 970cm-1 (Wang et al. 2007), 
so it is possible this represents a further DNA peak. There is also a strongly 
positive peak at 1070 and 1086cm-1, which could be due to glycoproteins, 
though this shows none of the indentation previously seen with an opposing 
effect from glycogen. There is a small positive peak at 1379cm-1 which may also 
be due to glycoprotein. The strongly negative peaks at 1022 and 1155cm-1 
represent glycogen. Again, therefore, it seems that PC4 separates 
Barrett’s/dysplasia/adenocarcinoma (positive) from normal squamous 
(negative). 
PC7 contains positive peaks at 970, 1070-1088 and 1236cm-1. The 970cm-1 
peak may represent DNA as discussed for PC4, as does the 1236cm-1 peak. 
The 1070-1088cm-1 peak is harder to interpret, since there is no other 
supportive evidence that it points to glycoproteins without a positive peak at 
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1373cm-1. The negative peaks at 1026 and 1153cm-1 represent glycogen, and 
the strongly negative 1651cm-1 represents cytoplasm. Therefore PC7 probably 
separates dysplasia/adenocarcinoma (positive) from Barrett’s/normal squamous 
(negative), although its separation from the Barrett’s group on this basis may be 
weak.  
PC12 again shows positive peaks at 968 and 1230cm-1 suggesting DNA 
content. The 997cm-1 peak may possibly represent glycogen, though the 
absence of other glycogen peaks weakens this explanation. The 1034cm-1 peak 
does not appear in the subtraction spectra and it is not clear which groups this 
peak would separate. There is a further positive peak at 1334cm-1 which most 
likely represents phenylalanine. There is a negative peak at 1394cm-1 
representing proteins, and the higher wavenumbers are again largely noise. 
There is a negative peak at 1741cm-1 which probably represents phospholipid. 
Given the DNA peaks, PC12 probably weakly separates 
dysplasia/adenocarcinoma (positive) from Barrett’s/normal squamous 
(negative), though the negative phospholipid peak goes against this.  
 
4.11. Discussion 
This study has demonstrated the ability of FTIR mapping to discriminate 
between normal squamous, non-dysplastic Barrett’s and dysplasia  
/adenocarcinoma tissue samples. To our knowledge, this is the first study to 
achieve this using tissue from all four major pathology groups in Barrett’s 
oesophagus. We have used a novel method of analysis to combine spectral 
classifications across an FTIR map for whole sample predictions. This is also 
154 
 
the first study to analyse fresh-frozen oesophageal sections using high-
resolution transmission FTIR mapping.  
The key biomolecular differences detected in this study are summarised in 
Table 4-10 above. Glycogen acts as an energy store and is contained in the 
cytoplasm. Normal squamous tissue has more abundant cytoplasm than the 
other tissue types, and the increased metabolic activity of the other tissue types 
would be expected to reduce the concentration of this energy store. Thus our 
finding of greater glycogen signal in normal squamous tissue is consistent with 
tissue biology. This finding has been made previously in studies of oesophageal 
tissue with both FTIR (Wang et al. 2003, 2007) and Raman spectroscopy 
(Shetty et al. 2006).  
Glandular cells have a higher mucin content than normal squamous cells, with 
the highly mucinous goblet cells seen in intestinal metaplasia being one of the 
defining features of Barrett’s oesophagus. Therefore our spectroscopic finding 
of higher glycoprotein signal in Barrett’s samples is consistent with this tissue 
feature, and replicates the previous finding of Wang et al. (Wang et al. 2007). 
One of the key histological features used to identify dysplastic or cancerous 
tissue is that of enlarged nuclei, with a decreased cytoplasm to nuclear ratio. 
Consequently the finding of stronger DNA signal within this group, suggesting 
increased nuclear material, is in keeping with the histological basis for 
discrimination between the groups. This finding has also been reported 
previously in both FTIR and Raman studies of oesophageal tissue (Shetty et al. 
2006; Wang et al. 2007). 
Thus the key biomolecular differences found on spectral analysis are consistent 
with previous findings and correspond to the histological differences between 
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the tissue types. However the stronger phospholipid signal seen at 1743-7cm-1 
in the dysplasia/adenocarcinoma group has not been reported previously in 
studies of oesophageal tissue. FTIR measurements of malignant cells and 
tissues have reported differing results on the signal strength at this 
wavenumber.  A study of oral cancer tissues reported a markedly lower 
phospholipid signal at 1745cm-1 in the malignant versus normal tissues 
(Mackanos and Contag 2010). Wang et al. found a lower overall tissue signal in 
malignant gallbladder tissue at 1740cm-1 (Wang et al. 2010), but noted an 
increased signal at the same wavenumber from malignant tissue plasma 
membrane and individual malignant gallbladder cells. In a further cell study, 
signal at 1740cm-1 was found to be a marker of apoptosis in a human colon 
cancer cell line (Gao et al. 2015). 
These reported results are somewhat contradictory, but it is conceivable that 
Barrett’s dysplastic or cancerous cells could have increased apoptosis, which in 
turn could lead to accumulation of the degradation product lipofuscin. Lipofuscin 
has been posited as a possible marker of dysplasia in work using 
autofluorescence by DaCosta et al. in both oesophagus and colon (DaCosta et 
al. 2005; Kara et al. 2004, 2007).  This hypothesis is rather speculative but may 
be worth investigating with future work.  
These spectral differences have contributed to the principal components 
selected as the most discriminatory between pathology groups, and used to 
develop a classification model. The PC loadings suggested strong 
discrimination between the normal squamous samples and the other tissue 
groups, with weaker features to discriminate between Barrett’s and 
dysplasia/adenocarcinoma groups. This correlates with the findings of the 
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classification models, both for individual spectra and whole samples, which 
produced a very highly accurate classification of normal squamous samples, 
and a moderately good classification of Barrett’s versus dysplasia 
/adenocarcinoma groups.  
The aims of this study were twofold – firstly to investigate the ability of FTIR 
mapping to develop a classification model for oesophageal tissue, and secondly 
to identify key spectral differences to inform work on FTIR measurement and 
classification of oesophageal cells.  
Using the 30% threshold voting system, our 3 group model identified normal 
squamous samples with 100% sensitivity and specificity. The sensitivity for 
detecting dysplasia/adenocarcinoma was 95.6%, with only one out of 23 
samples being misclassified. Applying the 30% threshold improved the 
sensitivity of the dysplasia/adenocarcinoma group at the expense of the 
Barrett’s group, which had a sensitivity of 75%.  
The 3 group model was tested further using LOPOCV, since between patient 
differences can contribute significantly to the spectral differences seen in 
studies with small numbers of patients. Although there was a slight drop in the 
sensitivity of Barrett’s samples, the normal squamous and 
dysplasia/adenocarcinoma groups were minimally affected. This is further 
evidence that our 3 group model is highly promising in this small study.  
As a more simple test to identify all ‘abnormal’ samples, the 2 group and 3 
group models suggest this could be achieved with very high accuracy indeed, 
since both models achieved 100% sensitivity and specificity. Alternatively, a 2 
group model may be used to identify ‘high-risk’ samples in patients with known 
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Barrett’s oesophagus: our model was able to achieve 100% sensitivity with 
specificity 77.3%.  
The ultimate goal of developing a classification model for oesophageal tissue 
would be for use in clinical practice as an automated histopathology tool. Future 
work, including how these results could be translated into clinical practice are 
outlined in the summative discussion.  
The results in this study could have been affected by a number of inaccuracies 
in tissue identification and measurement. Histology classification may be 
inaccurate, as is well-documented, however the use of consensus pathology 
should limit this problem, and care was taken to select homogeneous regions of 
pathology for measurement. Consequently, the tissue regions included here are 
likely to be more homogeneous than most regions chosen at random, and 
therefore may overestimate the ability of the model to classify sample regions.  
Misidentification of regions of the unstained section is possible, and could result 
in inclusion of tissue in the training model that did not represent the appropriate 
pathology, or the inclusion of non-epithelial (e.g. stromal) tissue. This inclusion 
of inappropriate regions in the training model would have impaired its 
performance.  
There was considerable discrepancy in the reporting of the dysplastic samples, 
with 4 out of 5 patient samples being graded differently as either HGD or LGD 
by the two pathologists. Since dysplasia is a spectrum of disease, LGD samples 
may be considered intermediate between non-dysplastic and high-grade 
dysplasia (HGD). It is possible that any classification model based on tissue 
biochemistry would find LGD samples more difficult to separate from Barrett’s 
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oesophagus than HGD, and this could result in a significantly poorer 
classification performance.  
Instrument calibration and background measurements were performed prior to 
every sample measurement, so should be a minimal source of variation. The 
number of spectra recorded per pixel (64) was selected as a balance between 
spectral quality and time taken (both for experimental purposes and for any 
prospect of clinical translation). Using fewer spectral measurements in clinical 
practice could impair the classification ability. This could be explored further 
with experimental work, or alternatively modelled using computer simulated 
degradation of the current dataset.  
Further discussion of future work, and possible steps required to translate our 
findings into clinical practice, are covered in the Summative Discussion 
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5. FTIR ANALYSIS OF OESOPHAGEAL CELLS 
5.1. Preliminary work 
Preliminary work on this study began as a collaboration with a group led by 
Professor Max Diem at Northeastern University in Boston. This group has 
experience in infrared spectroscopy of cells in a variety of organ systems. We 
recruited a small number of patients (10 patients, 8 with Barrett’s oesophagus, 2 
dysplasia) and collected samples which we sent to the Diem group to do initial 
work in measuring oesophageal cells using an infrared spectrometer. We then 
performed cytological classification of a number of these cells to develop a 
training model for pathology classification. These preliminary results have now 
been published (Townsend et al., 2015).  
The project in this thesis was designed as a much larger study with samples 
from normal squamous, Barrett’s oesophagus, dysplasia, adenocarcinoma and 
stomach cells, and more rigorous inclusion criteria for developing a training 
dataset.  
 
5.2. Ethical approval and informed consent 
Ethical approval was obtained for this study and all patients participating in the 
study provided informed consent. The ethical approval and consent processes 
were identical to those mentioned in section 4.1 above, and copies of the 




5.3.  Sample selection 
Developing a robust training dataset for spectral classification requires reliable 
pathology classification of any samples included. Classification of oesophageal 
cells presents some different challenges from histopathology for tissue samples. 
Firstly, oesophageal cytology is performed less commonly than tissue biopsy, 
and expertise in interpretation is correspondingly more limited. Secondly, cells 
of different morphological appearance may be collected from a region with a 
homogeneous tissue pathology e.g. normal squamous cells are frequently seen 
in addition to glandular cells in samples taken from regions of Barrett’s 
metaplasia. It is not known whether these cells would have spectral 
appearances consistent with normal squamous cells taken from healthy 
mucosa, or signal more similar to glandular Barrett’s cells.  
In order to be certain that cells included in the training dataset were 
representative of the correct pathology, a biopsy was taken from the area after 
cell collection, and only those cells whose cytological appearance was 
consistent (on review by 2 cytopathologists) with the contemporaneous 
endoscopy and biopsy results were included. In cases where the cytology and 
histology results did not agree, the cells were not included in the training model.  
For later analysis of whole samples included in the test dataset, the 
classification of the whole sample was based on the endoscopy and biopsy 
result as the gold standard. To remove further the possibility of 
misclassification, patients were only included in the test dataset if they had no 
history of more advanced disease i.e. to be included as a normal control they 
must have no history of Barrett’s oesophagus, and to be included as Barrett’s 
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oesophagus they must have no history of oesophageal 
dysplasia/adenocarcinoma.  
 
5.4. Sample collection 
Samples were collected from patients undergoing scheduled endoscopy, either 
as part of Barrett’s surveillance or indicated for other clinical grounds. In order 
to enrich the sample population for patients with oesophageal adenocarcinoma, 
some samples were also collected from patients undergoing surgery for 
oesophageal cancer. Normal oesophageal squamous cells used as controls 
were collected from patients undergoing endoscopy for symptoms of dysphagia 
or dyspepsia in whom no endoscopic or histological abnormality was identified. 
Samples of stomach cells were taken from the fundus of the stomach in order to 
test the ability to differentiate stomach cells from oesophageal glandular cells.  
Cytology samples were collected at endoscopy using an endoscopic cytology 
brush (Medi-Globe, Achenmule, Germany) passed down the instrument channel 
of an endoscope, under direct vision at endoscopy. The region of interest was 
brushed for around 3-5 seconds. The cytology brush was then withdrawn into its 
sheath, the brush removed from the endoscope, and the brush itself 
immediately cut off the long wire introducer and placed into a specimen pot 
containing formalin (10% neutral buffered formalin, Genta Medical, York, UK) 
(later in the project this was changed to ThinPrep CytoLytTM solution (Hologic 
Inc., Massachusetts, USA), the reasons for this are discussed in section 5.5.2.1 
below). The brush containing the cells was then stored at room temperature 




Figure 5-1 Collection of cell sample at endoscopy 
 
For the samples collected at surgery for oesophageal cancer, the same 
technique was used but without passing the brush through an endoscope. The 
brush was immediately placed in a formalin-filled specimen pot as above. 
After cell collection at endoscopy or surgery, tissue biopsies were taken from 
the region of interest and sent for histology, to allow comparison of the histology 
and cytology findings.  
 
5.5. Cell sample preparation 
5.5.1. Initial protocol 
Since no one in the group currently performs experimental work with cells I set 
up a link with the cytology department at Cheltenham General Hospital to 
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support this project, and enable me to prepare the cell slides with initial 
supervision from a cytology technician.  
The initial protocol used for cell preparation was based on a protocol used by 
the group in Boston with whom we collaborated in the preliminary work.  
To ensure the collected cells were effectively transferred from the cytology 
brush to the formalin solution, the specimen pot was vortexed for approximately 
30 seconds prior to removal of the brush. The brush was then disposed of, and 
the cell suspension transferred to a Sterilin pot (Sterilin Ltd., Newport UK) and 
topped up to approximately 1ml with formalin. The Sterilin pot was then 
centrifuged at 3000 revolutions per minute (rpm) for 5 minutes. The supernatant 
was then discarded, and the cell pellet diluted to 1ml with 0.9% NaCl. This 
solution was then vortexed, and then centrifuged at 3000rpm for a further 5 
minutes. The supernatant was then discarded and the pellet diluted a second 
time to 1ml with 0.9% NaCl. This suspension was vortexed and then centrifuged 
at 3000rpm for a third time for 5 minutes. The supernatant was again discarded, 
and the pellet diluted to 1ml NaCl. This final suspension was vortexed, and then 
6 drops (approximately 0.3ml) were taken by pipette and placed in the Cytospin 
conical funnel (EZ Single Cytofunnel with white filter cards, Thermo Scientific) 
(see Figure 5-2). The Cytofunnels were loaded with a calcium fluoride slide 
(Crystran 1mm x 20mm Raman grade polished window) onto which the cell 
sample would be deposited. Calcium fluoride slides were used as they have 
very few spectral peaks in the biological region of interest. The Cytospin 
(Thermo Scientific) was then run at 1500rpm for 3 minutes: the centrifugal force 
acts on the cell suspension in the conical funnel, which is driven through a 5mm 
hole onto the slide. Excess liquid is absorbed by the filter paper, leaving a 
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deposit of cells on the calcium fluoride slides. The slides were left to air dry for 




Figure 5-2 Cytofunnel (Thermo Scientific). The calcium fluoride slide is loaded 
into the slide holder, which is then closed with the filter paper over the slide. The 
cell suspension is placed into the conical funnel, which is closed with a lid, then 
placed into the Cytospin.   
 
5.5.2. Optimising cell preparation protocol 
A first batch of 10 cytology samples were used to test the above protocol, and 
the slides reviewed with a cytopathologist. Of these, 5 samples were considered 
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to be too thick, with densely clumped cells, and 5 were considered to be good 
samples, with a relatively even distribution of cells.  
Following this, the final dilution stage was changed to dilute the cell pellet to 2ml 
with normal saline rather than 1ml, and place 3-6 drops into the cytospin conical 
funnel depending on whether the sample was judged to be highly cellular or 
appeared blood-stained on visual inspection. A second test batch of 12 samples 
was then prepared. Of these, one slide broke in the cytospin centrifuge, one 
sample had very few cells, one was too heavily bloodstained, and the other 9 
were considered good samples. On discussion with the cytopathologist, it was 
felt that some variability was inevitable, and we decided to continue using this 
protocol for the remainder of the samples.  
Later in the project, a number of further modifications were made to the protocol 
to address problems that became apparent with the slides. Some slides had 
large pieces of non-cellular debris, and an additional step was introduced, after 
the slides were fully dry, to wash them in distilled water.  
It later became apparent that many samples had small numbers of cells, so the 
final dilution stage was adjusted again, such that the final dilution of the cell 
pellet was now 0.5-2.0ml NaCl, depending on sample thickness.  
High numbers of red blood cells continued to be a problem, and on advice from 
a cytopathologist we tried storing samples in ThinPrep CytoLytTM solution 
(Hologic Inc., Massachusetts, USA) rather than formalin. CytoLytTM is a 
methanol based buffered preservative, designed to have a haemolytic effect. An 
experiment to compare the spectral effects of this change is presented in 




5.5.2.1. Comparison of CytoLytTM and formalin fixatives 
We designed an experiment to compare CytoLytTM and formalin as fixatives for 
storing and preserving the cells. Samples were collected from 5 patients 
undergoing endoscopy: for each patient 2 brushings were taken from the same 
region of the oesophagus, with one sample stored in CytoLytTM and the other in 
formalin. The samples were then prepared using an identical protocol, and the 
resulting slides visually compared. In general, the samples stored in CytoLytTM 
had slightly fewer red blood cells, and there was slightly less clumping of cells. 
An example of this is shown in Figure 5-3.  
However there was considerable variation in the quality of the slide preparation, 
which was not systematically attributable to either CytoLytTM or formalin. The 
most striking example of this was in sample 61A and 61B, shown in Figure 5-4. 
These samples were collected from the same region of the oesophagus in the 
same patient, at the same time, and prepared in the same way (the only 
difference being the storage solution). The cell preservation and cell density in 
61A is far greater than in 61B, where there is a small deposition of cells at the 
circumference of the cell spot only. Since this finding was not a consistent 
difference between the two fixatives, it seemed rather to illustrate the variability 
of slide quality using the current technique. Several slides prepared later in the 









Figure 5-3 Comparison of cell slides A) stored in CytoLytTM and B) stored in 
formalin. Cells were collected from the same region of oesophagus in the same 











Figure 5-4 A Comparison of cell slides A) 61A and B) 61B. Cells were collected 
from the same region of oesophagus in the same patient at the same time, and 






Figure 5-4 B Comparison of cell slides A) 61A and B) 61B. Cells were collected 
from the same region of oesophagus in the same patient at the same time, and 
slides prepared using an identical protocol. 
 
Since the CytoLytTM showed a slightly improved appearance over the formalin 




However, it was important to investigate whether this would have any effect on 
the resulting cell spectra. We therefore used PCA to see if any spectral features 
could be identified to discriminate between the samples stored in CytoLytTM and 
those stored in formalin. 25 PCs were selected and the most discriminatory 
identified using ANOVA. The 2 most discriminatory PCs are plotted in Figure 5-
5. 
 
Figure 5-5 PCA plot showing 2 most discriminatory components for comparison 
of cells stored in CytoLytTM or formalin.  
The most discriminatory principal components were PCs 21 and 23, suggestive 
of poor discrimination, and the scatter plot in Figure 5-5 shows a seemingly 
random appearance, with no separation between the two groups. On this basis, 
we concluded that there was a negligible difference in the contribution to the 
spectrum from the two fixative solutions. We therefore decided to switch to 
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CytoLyt™ since it gave a slightly better slide quality, with fewer red blood cells 
and reduced clumping.  
 
5.6. Sample measurement 
5.6.1. Choosing the infrared spectrometer 
The FTIR tissue mapping study was performed using the Agilent FTIR 
microspectrometer in Exeter. However, previous FTIR work in cells had been 
done on a Perkin Elmer Spectrum One FTIR spectrometer at the Biophotonics 
unit in Gloucester, and it was suggested that this system gave a higher quality 
spectral signal than the Agilent system.  
On both systems multiple scans can be measured per pixel, then the mean 
spectrum is stored as the measurement for that pixel. Using more scans per 
pixel improves the signal to noise ratio. Each scan on the Agilent system is of 
lower quality than the Perkin Elmer, but this can be compensated for by its 
ability to collect more scans in a similar time frame. In order to decide which 
system to use for our study, the signals from the two systems were compared.  
One of the slides of oesophageal cells was chosen, and a small region of the 
slide selected for mapping on both systems. Comparable parameters were 
chosen that would be used for mapping samples: PE measurements were 
performed using 2 scans per pixel, 4cm-1 resolution and 6.25µm pixels. For the 
Agilent, 2 measurements were performed for each cell, at 16 and 32 scans per 
pixel, both at 4cm-1 resolution and 5.5µm pixel size.  
The measured region contained 4 cells: the mean spectrum from each cellular 













Figure 5-6 Comparison of mean spectra for cells 1-4 measured on the Perkin 
Elmer (PE) and Agilent infrared spectrometers. 
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For each of the 4 cells, while the overall spectrum is similar for all 3 
measurements, there is more noise in the spectra measured on the Agilent. 
There is very little difference between the spectra measured using 16 versus 32 
scans on the Agilent system. We therefore decided to use the PE system for 
our measurements, since this gave a less noisy signal using only 2 scans per 
pixel.   
 
5.6.2. Final protocol used for sample measurement 
Samples were measured at the Biophotonics unit at Gloucestershire Royal 
Hospital using a Perkin Elmer Spectrum One FTIR spectrometer with a Perkin 
Elmer Spotlight 400 imaging system, containing a 16-element focal plane array 
detector. Infrared absorption maps were obtained in imaging mode, with 
measurements in transmission mode, raster scanning at 6.25μm per pixel, at 
4cm-1 spectral resolution across a wavenumber range of 750-4000cm-1. The 
automated atmospheric correction for CO2 and water vapour was turned on for 
our initial experiments, but this was later switched off as a result of our work to 
optimise sample measurement and data processing (see section 5.7.3 below). 
An initial background reading was taken using 120 scans per pixel from an 
acellular region of the slide. A white light image of the entire cell spot area 
(5mm x 5mm) was captured. This enabled selection of a region of the cell 
sample to be measured. We initially planned to measure a 4mm x 4mm region 
for the Barrett’s, dysplasia and adenocarcinoma samples (anticipating that 
these samples would have fewer cells of the representative pathology than the 
normal squamous samples), however this was later reduced to a 4mm x 2mm 
region to reduce the time taken to measure each sample. Since the total time 
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taken to measure the 4mm x 4mm area (around 8 hours) exceeds the maximum 
measurement time on the Perkin Elmer system without refilling the liquid 
nitrogen dewar to maintain adequate detector cooling, the region was 
subdivided into quadrants or halves for measuring. Maps of infrared absorption 




Figure 5-7 White light image of cells and raw absorbance map created 
 
5.6.2.1. Effect of time delay between plating and measurement 
Both as part of this study, and if this technique were to be applied in clinical 
practice, it may be necessary to store cell slides prior to FTIR measurement. 
We therefore performed an experiment to investigate the stability of the cells 
and the corresponding spectral measurements over time. 
176 
 
A single cell sample (collected, stored and plated as above) was measured 
(using the same protocol each time) at a number of time points: immediately 
after plating (<12 hours), then again after 1 week, 2 weeks, 4 weeks and 8 
weeks.  
Cells on the slide, and some regions of cell debris identified by the binary mask, 
were selected and the spectra compared across the various time points. Some 
examples of the mean spectrum for certain regions at different time points are 
shown in Figure 5-8.  
On visual assessment of the spectra, overall there is very little difference 
between the spectra for a given region measured at different time points, for 
either cells or cell debris. In Cell 1, Cell debris 1 and Cell debris 2, there is 
slightly increased noise in the spectra above around 1450cm-1 in the Week 8 
measurement. This wavenumber region corresponds to the protein region of the 
spectrum and could thus possibly represent protein changes occurring between 
weeks 4 and 8. However a similar appearance is seen in Cell 2 at week 4, but is 
then not seen in the later week 8 measurement. It is possible that this noise is 
simply within the limits of normal variation for a single cell measurement. 
The cells therefore appear stable and give consistent spectral measurements 
up to 4 weeks after plating. Beyond this, it is possible that some protein 
breakdown occurs, increasing the noise in the protein region of the spectrum. 
















Figure 5-8 Mean spectrum of each cell region measured at different time 
points. A) Cell 1, B) Cell 2, C) Cell debris 1, D) Cell debris 2. 
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5.7. Data processing: optimising cell spectra and automated cell 
identification 
The overall aim of data processing was to develop training and test datasets as 
described in general in section 2.4, and specifically for FTIR mapping in section 
4.7 above. The initial data pre-processing steps are similar to those reported for 
FTIR mapping (section 4.6). The automated cell identification process described 
in section 5.7.2 below was developed with Dr Gavin Lloyd from the 
Biophotonics Unit in Gloucestershire Royal Hospital.  
Data measured on the Perkin Elmer system are initially recorded as 
transmittance of infrared and must be converted to tissue absorbance for 
analysis.  
With the relatively smaller signal coming from cells compared to tissue, noise 
effects due to atmospheric water can be significant, and must be corrected for. 
This is described in more detail below. 
A further step to increase the signal to noise ratio is then applied: a Savitzky-
Golay filter. This acts to smooth the data by fitting the curve between a small 
number of datapoints (we used 11 datapoints) to a low order polynomial (we 
used 2nd order).  
An extended multiplicative scattering correction (EMSC) is then applied, which 
has several functions. EMSC normalises the data relative to a reference 
standard spectrum (in our case we used a mean spectrum weighted equally 
across the pathology groups, calculated by taking the mean value of the mean 
spectrum for each pathology group), applies a scattering correction (outlined 
further below), and can be used to identify outlying spectra. Since EMSC 
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correction uses least squares fitting to a reference spectrum, it gives a measure 
of distance for each spectrum in the dataset from the reference spectrum. A 
large distance implies great difference from the reference standard, and this can 
be used as a threshold to exclude anomalous measurements. We used a 
threshold that excluded less than 5% of spectra from the dataset.   
 
5.7.1. Mie scattering correction 
Mie scattering is a recognised problem in infrared spectroscopy of small 
particles such as cells. To correct for this, we developed a correction algorithm 
based on previously published techniques (Bassan et al. 2009, 2010): the 
technique is described in detail in these papers. Firstly, parameters must be 
chosen for the range of size of the particle (in this case diameter of the cell, 
which we estimated to be 10-50µm depending on cell type), and the refractive 
index of the particle (the authors of the paper describing the technique 
estimated a value of 1.3 for biological cells, and used a range of 1.1-1.5, so on 
this basis we used the same values). These parameters are used to plot curves 
that represent the range of possible scattering effect for particles of this size: in 
our model we used 1000 curves. Principal components are then used to 
describe the difference between these curves and the reference spectrum (in 
this case our weighted mean spectrum). In the original paper 7 PCs described 
99.9% of the variance, so we used PCs 1-7 in our study. These PC loadings are 
then used in a least squares fitting algorithm to estimate the scattering 




5.7.2. Automated identification of cells 
Our intention was to develop a system that used mapping to measure large 
areas and then automatically identify cells within the measured region.  In this 
way an automated measurement system could be used for a cell slide without 
having to visually identify and measure each cell individually.  
We used a post-processing algorithm to detect cellular regions and extract the 
spectra from this region, assigning it to a particular cell.  
The algorithm combines spectral information and size criteria to determine 
which regions may be cellular. From the FTIR mapping work, we knew the 
largest protein peak occurred at around 1650cm-1, and that this corresponded 
well to regions of cytoplasm in our study and previous work. Since all cells 
should contain cytoplasm, this seemed a good choice of wavenumber to use to 
identify cells. The algorithm then uses a threshold intensity of the 1650cm-1 
peak to decide whether a spectrum has come from a cellular region or not: if the 
1650cm-1 signal is strong enough, the spectrum is considered to be from a cell. 
Cellular regions are then coloured black, and non-cellular regions white, to 
create a ‘binary mask’ representing the cells on the slide. To exclude 
proteinaceous debris that may also have a strong signal at 1650cm-1, size 
criteria are used to remove contiguous areas detected by the binary mask that 
exceed 400 pixels in total area (125µm x 125µm – 125µm is approximately the 
size of 3-4 large squamous cells). An example of a cell slide and its binary mask 





Figure 5-9 A) White light image of an unstained slide prior to measurement B) 
Binary mask created from infrared map of the same slide, with black regions 
corresponding to cellular areas detected by the automated algorithm. The 




5.7.2.1. Testing the binary mask against point measurement 
The ‘binary mask’ algorithm was used to highlight areas of the map that 
contained cells, and extract spectra from these regions. It is critical that this 
process extracts the spectral information corresponding to the signal measured 
from the correct cell, otherwise our training model would not be composed of 
the correct spectra.  
There are a number of potential sources of error, e.g. if the extracted spectra do 
not correspond exactly with the boundaries of the cell, incorrect labelling such 
that the spectral information from one cell is labelled as another cell/region on 
the slide, or if the binary mask does not accurately identify cellular regions.  
To confirm the binary mask was able to perform these functions accurately, a 
test sample was measured firstly in mapping mode, using the binary algorithm 
to detect cells, then manually taking point measurements of the same cells, and 
comparing the spectra.  
The same settings were used for both point measurement and mapping: 2 
scans per pixel, resolution 4cm-1. A background of 120 scans was collected 
prior to measurement for both mapping and point mode. The pixel size for 
mapping is 6.25µm x 6.25µm, and any pixels detected as part of the cell by the 
binary mask were included; for point measurement an aperture size of 24µm x 
30µm was used, which fitted within the cells without including any edge regions 
or non-cellular areas. For larger cells 2 regions were measured. Figure 5-10 
shows the white light image of the unstained cell slide, and the binary mask 













































































































































































































































































































































Figure 5-11 Comparison of binary mask cell spectra (‘mapping’) with point 
measurement spectra from the same cell. Cell labels correspond to the labels 
on the binary mask in Figure 5-10 above.  
 
All the regions identified using the binary mask appear to contain biological 
spectra. Looking at each cell comparison individually, in every case the same 
peaks are present in both mapping and point measured spectra, strongly 
suggesting the spectra are from the same cell. In examples where there are 
clear differences between the cells e.g. at 1080cm-1 there is a small sharp peak 
in Cell 7 or Cell 15, but in Cell 11 there is a much broader peak across 1020-
1090cm-1, these features are consistently seen in the two modalities for the 
same cell.  
The relative intensities are similar, although not identical: the mean spectrum 
from the mapping measurement is composed of all pixels within the cellular 
region, so will contain more spectra than the point measurements, and 
Wavenumber (cm -1)



























consequently in most cases has a higher signal strength, and a greater 
smoothing effect from averaging a larger number of measurements.  
On this evidence we concluded that the binary mask was successfully 
identifying cellular regions, extracting their spectra, correctly labelling them, and 
equivalent to point measurement of individual cells, and could potentially be 
used for automating cell detection.  
 
5.7.3. Atmospheric water vapour correction 
Water vapour within the measurement chamber can cause artefacts in the 
spectral signal. There are a number of methods for minimising this effect. 
Spectrometer measurement chambers can be continuously purged with 
anhydrous gas to exclude water vapour from the measurement: this requires a 
continuous supply of gas whilst samples are measured and is therefore a 
relatively costly approach, and not appropriate for the current project. 
Alternatively the artefacts from the water vapour can be removed in post-
processing. This involves subtraction from (or addition to) the spectrum to 
counteract the effects of the water spectrum on the measured sample spectrum, 
with the aim of removing all contributions of water vapour. We initially used a 
standard algorithm used by the spectrometer manufacturer, however early 
measurements showed an artefact suggestive of water vapour. 
When inspecting the spectra from the initial cell maps, many spectra showed 
evidence of an artefact that created a rapidly oscillating spectral trace. 
Intriguingly, the artefact was present in only some spectra, but not others, even 
when measured from cells close together on the same slide. An example of this 
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is shown in Figure 5-12, which plots all cellular spectra from a single map. The 





Figure 5-12 A) Binary mask showing cellular regions and B) raw spectra (mean 
spectrum per cellular region) from cell sample C8 bottom right quadrant.  


















































C8 bottom right quadrant










This problem has been recognised previously for FTIR measurement as being 
caused by atmospheric water vapour. The spectral contribution of water vapour 
should be reduced by subtracting the background signal (we measured a blank 
area of the slide prior to each measurement, this is subtracted automatically on 
the Perkin Elmer), however algorithms to correct for any residual water vapour 
artefact have been developed (Bruun et al. 2006). The Perkin Elmer system 
automatically applies an in-built algorithm to the spectra it collects, so the ‘raw’ 
spectra that it presents have already been corrected for water vapour. However 
the presence of this oscillating artefact in our spectra suggested that the 
correction algorithm was not working well for our cell spectra.  
The correction algorithm used by Perkin Elmer is not publically available, and it 
is not possible to see the original spectra before and after applying this 
correction. However, it is possible to switch the automated correction off. We 
therefore compared the effect of the atmospheric correction on spectra by 
measuring the same region with the automated correction on, and measuring 
the spectra again with the correction off.  
In order to compare the difference for individual cells, cells were selected from 
the mapped region to compare the differences between their mean spectra with 


















































































































































Figure 5-13 Comparison of effect of atmospheric correction for individual cells. 
Mean spectra per cell are shown with atmospheric correction on or off.  


































































Looking at the spectra in Figure 5-13, the effect of the atmospheric correction is 
highly variable. In some cases, e.g. Cell 5 and Cell 12, the atmospheric 
correction appears to work well, removing the artefact from the spectrum 
measured with the correction off, and smoothing the spectrum. In some cases, 
e.g. Cell 11 or Cell 18, the correction algorithm has had very little effect. Whilst 
in others, such as Cell 10 or Cell 17, the algorithm appears to have introduced 
an increased artefact, greater than the small artefact that was present in the 
spectrum measured with no atmospheric correction.  
This result suggested that water vapour, and problems with the PE algorithm to 
correct for it, were the cause of the artefact seen in our spectra. We therefore 
designed an experiment to test this, and develop our own algorithm to improve 
it.  
To exclude atmospheric water vapour, the Perkin Elmer system can be 
connected to a cylinder of nitrogen gas, which then flows into the measurement 
chamber continuously to purge the system of air, and any concomitant water 
vapour. The measurement chamber is not completely airtight, but saturation 
with nitrogen gas allows measurement of a ‘pure’ signal with minimal 
contribution from water vapour.  
To demonstrate the effect this has on our cellular spectra, a map was measured 
whilst purging the system with nitrogen using a high flow rate. The spectra from 
individual cells were compared against those measured with the atmospheric 






Figure 5-14 Comparison of measurements using nitrogen purge against those 
measured with normal atmospheric contribution. Each cell was measured with 
atmospheric correction switched on, and again with the correction switched off.  





































































Figure 5-15 Cell measured with nitrogen running at half flow rate.  
 
Figure 5-16 Cell measured 15 minutes after nitrogen purge stopped.  

































































N2 purge (N2 finished)
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The effect of the nitrogen purge can be seen in Figures 5-14 to 5-16. When 
measurements were taken with the nitrogen purge, such as Cell 10 or Cell 17 in 
Figure 5-14, the spectral trace is smooth and free from artefact. Cell 12 (Figure 
5-15) was measured with the flow rate halved, and some very minor artefact is 
seen in the spectrum.  Further measurements were taken after the nitrogen was 
switched off, and Figure 5-16 shows the spectrum of Cell 18 at 15 minutes after 
stopping the nitrogen. Here there is a large artefact and the spectrum is highly 
distorted. This effect is greater than that seen in the ‘normal’ measurements 
because the background (which is automatically subtracted from the spectral 
signal) was measured with a purged system. Therefore, even though the water 
vapour content is likely to be the same across all 3 measurements, the water 
vapour relative to the background is much higher in the measurement 
performed after the nitrogen purge. 
This confirmed that water vapour was the source of the artefact in our earlier 
measurements. To correct for this in future measurements, we developed an 
algorithm to subtract the spectral contribution from water vapour. In order to 
characterise the contribution from water vapour, a background spectrum without 
water vapour is needed for comparison. 
The water vapour is seen in the spectrum from around 1300-2000cm-1, and 
again at around 3500-4000cm-1. There is a large peak around 2350cm-1 due to 
atmospheric carbon dioxide. The nitrogen purge reduces both the water vapour 
and CO2 signal but does not eliminate them.  In this experiment there was no 
further change in signal after 5 minutes of purging the measurement chamber 
with nitrogen, suggesting that this was the greatest level of saturation with 




Figure 5-17 Comparison of original background spectrum with spectra obtained 
after purging the Perkin Elmer measurement chamber with nitrogen gas. 
Spectra are offset for clarity.  
 
This allows a ratio to be calculated of the original background (with water 
vapour) versus the background after nitrogen purge – in effect an ‘atmospheric’ 
spectrum, containing the spectral contribution from the atmosphere. This can 
then be used to subtract from the sample spectrum to reduce the contribution of 
water vapour from our sample spectra (the CO2 peak would also be subtracted 
but this occurs outside the fingerprint wavenumber range used for analysis).  
Figure 5-18 shows the mean spectra from C8 bottom right quadrant after the 
algorithm has been applied (see raw spectra in Figure 5-12 above for 
comparison). The water vapour artefact has been almost completely removed, 
200 
 
and there is very little noise in the spectra. Consequently we decided to 
measure all samples with the PE atmospheric correction switched off, and use 
our own algorithm.  
 
 
Figure 5-18 C8 bottom right quadrant, mean spectra per cell after water vapour 
correction.  
 
5.8. Summary of measured samples 
From previous work within the Biophotonics unit, sample sizes of around 100 
are sufficient to capture a high degree of within-group variation. We therefore 
estimated that a sample size of 100 cells in each pathology group would be 
sufficient to inform a robust training model. To ensure that this captured 
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sufficient between-patient variability, again based on previous work within the 
research group, we estimated that 20 patients would be needed for each 
pathology group.  We therefore required an average of 5 representative cells 
per slide to meet our target of 100 cells in each group. Because of the potential 
for low numbers of dysplastic cells amongst dysplasia/adenocarcinoma 
samples, we aimed to include 25 patients in this group, and 20 in each of the 
other groups.  
Cell brushing samples were only included if the histology from that region was 
certain. Discrepancies were possible because brushing occurs over a larger 
area than the size of a biopsy, and there were a number of possibilities where 
the samples could be discordant. For example, if a brushing was taken from a 
region that appeared dysplastic, with dysplasia on other biopsies in the 
oesophagus, but not seen in the biopsy taken from the region of brushing, the 
sample was excluded. Similarly, if a brushing was taken from a region thought 
to be non-dysplastic Barrett’s, with no dysplasia on the biopsy from the region of 
brushing, but dysplasia was found on other biopsies taken at the same 
endoscopy, the sample was excluded.  
A total of 107 patients were recruited to the study. Of these, 69 patients were 
included in the study, contributing a total of 91 samples. Each patient only 
contributed one type of oesophageal sample, but stomach samples were 
collected almost entirely from patients who also contributed oesophageal 




Table 5-1 Summary of measured data 
 NSQ BE DYS/AC STOMACH TOTAL 
Patients 20 21 26 21 69* 
No. of 
brushings 
21 22 27 21 91 
FTIR maps 22 34 44 22 122 
Total spectra 3,891,600 5,222,400 7,270,400 4,300,800 20,685,200 
Cell regions 
identified 
786 2074 3164 1041 7,065 
Total spectra 
in cell regions 
32,807 63,640 94,876 37,693 229,016 
NSQ normal squamous; BE Barrett’s oesophagus; DYS/AC 
dysplasia/adenocarcinoma. *Stomach samples were taken largely from patients 
who also contributed an oesophageal sample.  
 
5.9. Developing a training dataset 
The prepared cell slides contained a mixture of different cell types, along with 
cellular and non-cellular debris. In order to inform a training dataset accurately, 
we aimed to include only those cells that were representative of the appropriate 
pathology type. We planned to achieve this by staining the slides after FTIR 
measurement, recording microscope images of a representative number of 
stained cells, correlating the position of the photographed cells with their 
corresponding cell number on the binary mask from the FTIR map of that 
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particular sample, then showing the images to 2 cytopathologists for 
classification. This process is illustrated in Figure 5-19.  
 
Figure 5-19A: Developing a training dataset. The whole measured region: 
binary mask (upper image, with each cell numbered) and corresponding stained 
cell slide (lower image). With high cell density, identifying which cell on the slide 
corresponds to the same cell on the binary mask could be very challenging. In 
both images the bar represents 300µm. The highlighted region is enlarged in 




Figure 5-19B Enlarged region of binary mask highlighted in 5-19A, and 
corresponding region of slide. This enabled labelling of the individual cells. The 
correspondence between the stained slide and the binary mask was often 
imperfect. Only cells that could confidently be identified as a particular cell in the 
binary mask were included in the training dataset.   
 
5.9.1. Cell staining 
After infrared measurement samples were stained using a ‘Diff-Quik’ staining 
technique. Staining was performed by dipping the cell slides into Diff-Quik 
fixative reagent (methanol based fixative, Thermo Scientific) for 10 seconds, 
followed by Diff-Quik solution I (an eosinophilic red stain, to identify cytoplasm, 
Thermo Scientific) for 10 seconds, then Diff-Quik solution II (a basophilic blue 
stain, to identify nuclear material, Thermo Scientific) for 10 seconds, then 
rinsing with a buffer solution at pH7.2. The slides were then air dried and 




5.9.2. Photographing cells and correlating with binary mask 
We had initially hoped to be able to photograph cell slides automatically with a 
slide scanner, but unfortunately this was not possible. The CaF2 slides were not 
compatible with the available slide holders in the two slide scanners we tried 
(University College London), which required a slide of standard rectangular 
dimensions and thickness. We attempted mounting a CaF2 slide onto a regular 
slide, which overcame the problem with the slide holders. Unfortunately, 
however, by changing the distance of the slide surface from the lens, one of the 
slide scanners accepted the slide but produced an out of focus image, and the 
other would not process the slide as it recognised that the surface was less than 
a minimum required distance from the lens, and risked scratching the lens. 
As a result, I manually reviewed and photographed cells on the slides. This 
process involved identifying individual cells on the stained slide and correlating 
the position of the cell with the number assigned to it on the binary mask. The 
cell was photographed, and labelled with the number it had been assigned on 
the binary mask – this would then allow us to extract the spectra from the 
correct cell into the training dataset after cytopathology review of the cell 
photograph.  
The process of manually correlating the position of the cell on the slide with the 
binary mask was very time consuming. The binary mask worked variably well in 
identifying every cell – on some slides there were many regions of cellular 
debris which were labelled as cells (see Figure 5-20).  This was more readily 
apparent on the stained slides, and in some cases there was a great deal of 
debris and very few cells indeed. In other cases, structures that appeared 
cellular were not picked out by the binary mask, though this occurred 
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infrequently. There were also a few slides where some cells were ‘missing’ and 
had presumably been washed off the slide by staining.  
 
 
Figure 5-20 Example of cell debris/degenerative cells on the slide. There are 
two squamous cells (labelled), but the other material is cell debris or possibly 
degenerative squamous cells. Such material was often identified by the binary 
mask as being cellular, but was not included in the training dataset. 
 
Whilst doing the photographing it also became apparent that there was, on 
average, a difference between the cellularity of the different pathology groups 
on the slides. The normal squamous samples tended to have much lower cell 
density than Barrett’s samples, and the dysplasia/adenocarcinoma samples 




It was clear from initial review of the slides that there would be far more normal 
squamous cells identified to include in the training model than Barrett’s, 
dysplasia/adenocarcinoma, or stomach cells. Because of the time taken to 
identify and photograph the cells, we decided to include only half of the normal 
squamous samples in the training dataset, since this would be sufficient to 
include more cells than the other groups, and a balanced training dataset is 
required to build an accurate classification model. Therefore 10 normal 
squamous samples, and all of the other samples (22 Barrett’s, 13 dysplasia, 14 
adenocarcinoma, 21 stomach) were reviewed and photographed. For the 
normal squamous samples, a maximum of 30 cells per sample were selected to 
be photographed for review. For the Barrett’s, dysplasia/adenocarcinoma and 
stomach samples, it was clear that mixed cell types were present on the slides, 
with many cells of squamous morphology. Every cell region that was considered 
to possibly be a glandular cell was photographed, along with some examples of 
cells that were clearly of squamous morphology.  
This step in the development of the training model proved to be very 
challenging, as it became apparent that much of what was on the slides was 
unidentifiable debris, or poorly preserved cells. This drastically limited the 
number of cells that could potentially form part of the training model. It also 
became clear that the overwhelming majority of cells on the Barrett’s, dysplasia 
and adenocarcinoma slides appeared squamous in morphology, further 
reducing the number of cells to be included in the training model. This proved to 
be one of the major limiting factors in this study. These problems, and potential 




5.9.3. Cytology review 
Individual cell photographs were then presented to 2 cytopathologists, who 
reviewed each image together (not independently) to achieve a consensus on 
each image (if no consensus was achieved the cell was not included in the 
training model). The pathologists were blinded to the endoscopy and biopsy 
results for the sample from which the cell was taken. 
Cells were classified into one of five labels: ‘squamous’, ‘glandular’ (considered 
to be non-dysplastic Barrett’s if from a Barrett’s sample, or stomach if collected 
from stomach fundus), ‘dysplastic’ (i.e. dysplasia/adenocarcinoma), 
‘degenerative cell’, or ‘cell debris/other’.  
 
5.10. The training dataset 
As mentioned above, the number of cells included in the training dataset was 
greatly reduced by the finding of cellular debris and poor preservation of cells 
on the slides. 
In total 6,008 spectra were included in the training set from 146 cell regions with 
consensus cytopathology (Table 5-2), from 20 patients. The term ‘cell regions’ 
is used because many of the regions contained multiple adjacent cells, which 
formed a single continuous cellular region identified on the binary mask. For 
brevity, the terms ‘cell’ and ‘cell regions’ will be used interchangeably below.  
The numbers of cells and patients in each group except normal squamous were 
far smaller than our desired sample size. This was particularly true for the 
stomach cells, from which only 2 cell regions were classified as glandular 
stomach cells.  
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Clearly this result was very disappointing, and is a major limiting factor on the 
ability of the training dataset to develop a robust classification model.  
 
Table 5-2 Summary of numbers of patients, cells and spectra with consensus 
cytopathology included in training dataset. 




No. of cell 
regions 




8 8 107 4,780 
Barrett’s 
oesophagus 
5 5 15 291 
Dysplasia/ 
adenocarcinoma 
5 5 22 735 
Stomach 2 2 2 202 
TOTAL 20 20 146 6,008 
 
 
5.11. Classification performance of the training dataset 
The disproportionate numbers of cells in each group creates a problem for 
building classification models: if there is a significant imbalance in the number of 
spectra per group, the model will tend to favour placing spectra in the largest 
group. To account for this, rather than using all 107 normal squamous cells, 22 
normal squamous cells (the same number as the largest group, 
dysplasia/adenocarcinoma cells) were randomly chosen to build each 
classification model. Because the choice of which cells were included could 
affect the model performance, 50 iterations were run for each model, randomly 
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choosing 22 normal squamous cells each time. This allows a mean sensitivity 
and specificity to be calculated, along with a standard deviation.  
With only 2 cells in the stomach group we decided not to include this in the 
training model, since it would be impossible to draw any firm conclusions from 
only 2 datapoints.  
One of the Barrett’s samples (C31A) had a markedly different appearance from 
every other sample measured (including all pathologies). In every spectrum of 
the sample there was a strongly negative peak at around 1180cm-1. This could 
not be accounted for by the background spectrum, which was identical to the 
others. It is not clear what caused this unusual appearance in this sample, but 
as a result it was not included in the training set (the sample was still included in 
the test dataset when using whole sample data).  
 
Figure 5-21 Barrett’s sample C31A: all cellular spectra 
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Exclusion of this sample, which contributed 3 cells to the Barrett’s training 
group, left only 12 cells remaining and significantly reduced the number of 
spectra in the Barrett’s group. 
Exclusion of outlying spectra was performed on each iteration of the training 
model. The measure of least squares distance from the reference spectrum 
(weighted mean spectrum) was calculated, and a histogram constructed to plot 
these values. Figure 5-22 shows an example histogram from the 3 group model 
below. The histogram shows a peak at around 0.75, and then 2 smaller peaks 
at around 1.5 and 2. This may represent the distribution of 3 distinct pathology 
groups. Spectra falling outside the range 0-2.5 were removed. This resulted in 
less than 5% of spectra being removed for each iteration.  
 
Figure 5-22 Histogram of least squares distance for each spectrum relative to 
reference spectrum for 3 group model. 
 
EMSC co-efficient






















Following exclusion of the outlying spectra on EMSC, the total number of 
spectra available for analysis in the training dataset is shown in Table 5-3. 
 
Table 5-3 Summary of data included in the training dataset, following exclusion 
of sample C31A from the Barrett’s group, EMSC exclusion of outliers, and 
random selection of 22 normal squamous cells (the exact number of normal 
squamous spectra will vary with each iteration, so the number shown is the first 
iteration chosen as an example).  
 No. of 
patients 




8 22 726 
Barrett’s 
oesophagus 
4 12 76 
Dysplasia/ 
adenocarcinoma 
5 22 678 
TOTAL 17 56 1,480 
 
 
5.11.1. 3 group model 
The aim of this project was to develop a test that could be used either as a 
screening tool to identify Barrett’s oesophagus, or as a method of Barrett’s 
surveillance to detect dysplasia or adenocarcinoma. To achieve this clinical aim, 


































































































































The linear discriminant functions are shown in Figure 5-24. LDA achieves good 
grouping and separation of each of the pathology groups, but there remains a 
cluster of Barrett’s datapoints close to the other two groups. Every one of these 
outlying datapoints was from a single sample, C64B.  
 
Figure 5-24 Scatter plot of all spectra, plotted by linear discriminant (LD) 
function. NSQ = normal squamous, BE = Barrett’s oesophagus, DYS = 
dysplasia, AC = adenocarcinoma. 
 
A classification model was constructed using PCA-fed LDA, and tested using 
LOSOCV. The performance of the classification model is shown in Table 5-4.  
The sensitivity of the model for individual spectra is reasonably good for normal 
squamous cells at 83.6%, but only moderate for the Barrett’s and 
dysplasia/adenocarcinoma cells. The standard deviation was largest for the 
normal squamous cells, as would be expected since the cells chosen were 
LD1

















different for each iteration. The size of the variation in the sensitivity for the 
dysplasia/adenocarcinoma group reflects the overlap with the normal squamous 
cells and hence this varies depending on which cells are included. There was 
very little variation in the Barrett’s result, with a small standard deviation.  
 
Table 5-4 Performance of the training cells 3 group classification model 
Mean values after 50 
iterations 
NSQ 
Mean % (SD) 
BE 
Mean % (SD) 
DYS/AC 
Mean % (SD) 
Individual 
spectra 
Sensitivity 83.6 (5.2) 62.8 (0.8) 69.5 (4.5) 
Specificity 70.8 (3.8) 97.5 (0.9) 87.8 (3.5) 
30% threshold 
vote 
Sensitivity 71.5 (5.3) 83.0 (1.7) 60.7 (7.1) 
Specificity 69.9 (4.9) 96.5 (2.0) 84.8 (3.5) 
Mean spectra 
per cell 
Sensitivity 61.9 (8.3) 78.5 (4.5) 43.0 (10.1) 
Specificity 59.9 (5.3) 94.9 (3.9) 77.9 (7.6) 
SD standard deviation; NSQ normal squamous; BE Barrett’s oesophagus; 
DYS/AC dysplasia/adenocarcinoma. 
 
Classification of whole cells, rather than individual spectra, was attempted using 
a threshold voting system, as introduced for FTIR mapping samples in Chapter 
4, and also using a training model developed using mean spectra per cell. The 
threshold voting system improved the result for Barrett’s cells, but gave a poorer 
performance for the other two groups. This threshold voting tool was designed 
to give a high sensitivity for detecting pathology, but only achieved a detection 
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rate of 60.7% for dysplasia in this model. Analysis of the individual pixel 

















































































































































































































































Figure 5-25 Classification of each cell using voting classification for 3 group 
model. The proportion of pixels classified as each pathology is shown for each 
cell within each pathology group in turn: A) normal squamous, B) Barrett’s 
oesophagus, C) dysplasia/adenocarcinoma samples. Cells misclassified using 
the 30% threshold are marked with an asterisk at the top of the bar. NSQ = 
normal squamous, BE = Barrett’s oesophagus, DYS = dysplasia, AC = 
adenocarcinoma.  
 
For every cell from sample C12, over 50% of the pixels were misclassified, with 
the vast majority of these classified as normal squamous. Most of the cells from 
C12 were therefore classified as normal squamous, and since this sample 
contributed nearly 50% of the cells in the dysplasia/adenocarcinoma group, this 
had a strongly detrimental impact on the model. Possible reasons for this are 

































































































































































The Barrett’s cells classified well in this model, but 2 cells from one sample 
were misclassified. In such a small sample size, this has a big impact on the 
classification performance.  
The model built on mean spectra had an even worse performance than the 
majority voting, with sensitivity for dysplasia/adenocarcinoma 43.0%. Although 
not illustrated graphically, the model developed using mean spectra 
misclassified the same Barrett’s and dysplasia/adenocarcinoma cells as the 
threshold voting based on individual spectra, but also misclassified the four C12 
cells which were correct with threshold voting (and excluded one dysplastic cell 
entirely on EMSC correction). The normal squamous cells are randomly chosen 
and therefore change with each iteration. 
Using mean spectra removes any weighting in the training model towards larger 
cells or clusters of cells, since each region contributes only one mean spectrum 
to the model. One potential cause of error is from pixels that include the edge of 
cells. This is due both to the increased Mie scattering that occurs at an edge, 
and because only part of the light for this pixel has passed through the cell, and 
some of the region contributing to the spectrum will be blank slide. These edge 
pixels may therefore have a lower quality signal than the pixels from the middle 
of a cell. For smaller cells the edge pixels will form a larger proportion of the 
total and the mean spectrum will be more affected by edge pixels. 
One dysplastic sample in particular (C12) contributed heavily to the training 
dataset (10 out of 22 cells), but then performed very poorly in the classification 
model. On subsequent review of this sample, it was noted to be more heavily 
stained than many of the other samples. Since larger, darker nuclei are a 
feature of dysplastic change, heavy staining of the nuclei can potentially lead to 
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‘over-calling’ of cells as dysplastic. This is a possible explanation both for the 
high number of cells this sample contributed, and for its subsequent 
misclassification.  
 
5.11.2. 2 group model 
If cytology were to be used as a screening tool to identify Barrett’s oesophagus 
(with patients then going on to have endoscopy) then discriminating between 
metaplasia and dysplastic change may not be required. Consequently, a two 
group analysis comparing normal squamous with a combined group of Barrett’s, 
dysplasia and adenocarcinoma (BE/DYS/AC) was performed.  
Once again, PCA-fed LDA was used to construct a model. The 3 most 
discriminatory PCs and LD functions are plotted in Figures 5-26 and 5-27. 
These figures show reasonably good grouping of the spectra within each group, 
and LD1 separates between the two groups with a few outlying spectra, and a 
small amount of overlap.  
The model was then tested using LOSOCV: performance of the two group 
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Table 5-5 Performance of the training cells in a two group training model 
Mean values after 50 iterations NSQ 
Mean % (SD) 
BE/DYS/AC 
Mean % (SD) 
Individual 
spectra 
Sensitivity 84.4 (5.8) 72.6 (2.6) 
Specificity 72.6 (2.6) 84.4 (5.8) 
30% threshold 
vote 
Sensitivity 71.6 (7.0) 66.0 (5.0) 
Specificity 66.0 (5.0) 71.6 (7.0) 
Mean spectra 
per cell 
Sensitivity 62.4 (11.5) 58.5 (5.8) 
Specificity 58.5 (5.8) 62.4 (11.5) 
 
Whilst the sensitivity for normal squamous cells is reasonably good at 84.4%, 
for the BE/DYS/AC group it is 72.6%. This figure is slightly better than for 
individual spectra using the 3 group model, but remains too low to be 
considered in clinical practice. Using the threshold vote and mean spectra, the 
detection rate is worse, with sensitivity of 66.0% and 58.5% respectively.  
The threshold voting bar graphs in Figure 5-28 illustrate how certain samples 
are classified incorrectly. These poor results reflect the large contribution of 
sample C12 to the BE/DYS/AC group: as in the 3 group model, nearly every cell 
from this sample has been classified incorrectly. Since the 
dysplasia/adenocarcinoma group is larger than the Barrett’s group, this single 








Figure 5-28 Voting classification of each cell for 2 group model. The proportion 
of pixels classified as each pathology is shown for each cell: A) NSQ B) 
BE/DYS/AC samples. Cells misclassified using the 30% threshold are marked 
with an asterisk at the top of the bar. NSQ = normal squamous, BE = Barrett’s 







































































































































































































































































































































































5.11.3. Spectral analysis: spectral basis for classification 
5.11.3.1. Spectral peak assignment 
As discussed in the spectral analysis for the FTIR mapping chapter (section 
4.10.1 above), assigning biomolecules to spectral peaks is tentative, as there 
are frequently several possible bond vibrations that can cause a peak at a given 
wavenumber, and multiple biomolecules that could explain a given bond 
vibration. Whilst interpreting the cell spectra, these problems are compounded 
by the much smaller numbers of spectra in each pathology group dataset than 
in the tissue work discussed earlier. Nonetheless, attempts to interpret the 
spectral differences are outlined below. The table of peak assignments listed in 
Section 4.10.1 (Table 4-9) is used again as a reference for spectral peak 
labelling.  
As in the FTIR mapping section, inverse second derivative spectra were used to 
identify spectral peaks. The mean spectra for the 3 pathology groups included 
in the analysis are shown in Figure 5-29, along with the second derivative 





Figure 5-29 Mean spectra for all cellular regions included in the training dataset 
for the 3 pathology groups. NSQ normal squamous; BE Barrett’s oesophagus; 
DYS/AC dysplasia/adenocarcinoma.  
  





























































































































































































































































Figure 5-30 Second derivative of the mean spectra shown in Fig. 5-29, A) 
Normal squamous, B) Barrett’s oesophagus, C) Dysplasia/adenocarcinoma, 
with the text colour indicating the likely biomolecule mainly responsible for that 
peak. NSQ normal squamous; BE Barrett’s oesophagus; DYS/AC 
dysplasia/adenocarcinoma. Green = glycogen, blue = glycoprotein, red = DNA, 
Black = amino acid/protein, Purple = mixed contributions/multiple possibilities. 
  
The major glycogen peaks identified in the FTIR mapping study described in 
section 4.10.1 occurred at 995, 1024 and 1153cm-1; of these, the largest was 
the 1024cm-1 peak. The normal squamous inverse second derivative spectrum 
(Figure 5-30A) shows small peaks at 989, 1026 and 1153cm-1, which likely 
correspond to glycogen as in the tissue study. The peak at 1078cm-1 may 
contain contributions from glycogen, glycoproteins and DNA (Quaroni and 




























































































Casson 2009; Wang et al. 2007). Small glycoprotein peaks occur at 1170 and 
1365cm-1: the peak at 1127cm-1 was not identified in the FTIR mapping study, 
but a peak at 1124cm-1 has previously been reported as representing 
glycoprotein in Barrett’s samples by Quaroni and Casson (Quaroni and Casson 
2009). The 1236cm-1 peak corresponds to the DNA peak seen in the FTIR 
mapping study at 1234-6cm-1. Many peaks are likely to correspond to 
protein/amino acid peaks. The 1296 and 1313cm-1 peaks were not seen at this 
location in the mapping study, but a single peak at 1307cm-1 was attributed to 
phenylalanine, as was the 1338cm-1 peak (likely to be the 1340cm-1 peak seen 
here). Similarly, there was a 1394cm-1 protein peak seen in the mapping study, 
whereas there is now a doublet at 1388 and 1400cm-1 in the cell spectra. 
Further protein peaks around 1450cm-1, the amide I and amide II regions, are 
again similar to the mapping study. The small peak at 1739cm-1 may 
correspond to phospholipid, where the peak was seen at 1741-7cm-1 in the 
mapping study.  
The Barrett’s oesophagus inverse second derivative spectrum is shown in 
Figure 5-30B. There are many similarities to the normal squamous spectrum 
and a number of differences.  There is an additional peak at 969cm-1 which 
probably represents DNA, with a higher and broader peak at 1227cm-1 than the 
normal squamous DNA peak at 1234cm-1. The peaks at 987 and 1158 may 
represent glycogen, though they are very small, but the peak at 1024-6cm-1 is 
missing. Instead there are peaks at 1018 and 1037cm-1 that are not seen in the 
normal squamous group or the tissue mapping study. Whilst this may simply 
reflect a different location for glycogen peaks, there is an appreciable difference 
in the raw spectra in Figure 5-29, between wavenumbers 1000-1090. This 
shows a broader, higher intensity peak in the Barrett’s and 
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dysplasia/adenocarcinoma group than the normal squamous cells. Since a 
higher proportion of the Barrett’s/dysplasia/adenocarcinoma samples were 
preserved in formalin, and the formalin spectrum shows a strong peak in this 
region, the possibility of a contribution from the formalin solution has also been 
considered. This is discussed further below, in section 5.11.4.  
Whilst there is a single peak at 1078cm-1 in normal squamous cells, there are 
two peaks at 1067 and 1084cm-1 in the Barrett’s cells. This may follow from the 
different contributions of glycoprotein, glycogen, and DNA in this region.  There 
are similar glycoprotein peaks at 1121, 1172 and 1367cm-1, though with greater 
intensities in the Barrett’s cells. The protein and amino acid peaks in the amide 
I, amide II and amide III regions are all at very similar wavenumbers to those in 
the normal squamous cells, with the exception of the region 1667-1694cm-1. 
The principal amide I peak at 1651cm-1 has greater intensity in the normal 
squamous group, which correlates with the finding in the tissue mapping study.  
The dysplasia/adenocarcinoma inverse second derivative spectrum has many 
similarities to the other groups. It has a DNA peak at 969cm-1 as seen with the 
Barrett’s cells, and the peak around 1234cm-1 is broader, stretching between 
1228-1240cm-1. Peaks at 1018 and 1040cm-1 are seen as in the Barrett’s cells, 
with no glycogen peak at 1026cm-1  as in the normal squamous group and in 
the tissue mapping study.  The only clear glycogen peak is at 1154cm-1. 
Glycoprotein peaks occur at 1126, 1169 and 1367cm-1, similar to the other 2 
groups. The protein peaks in the amide I, amide II and amide III regions are 
similar to the other groups, though the amide I region is perhaps more similar to 
the normal squamous rather than the Barrett’s cells.  
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In summary, there are many similarities in the spectral peaks seen in each of 
the three cell groups to the peaks identified in the tissue mapping section 
earlier. The amide I (1651-3cm-1) and amide II (1546cm-1) peaks are in almost 
exactly the same positions as the tissue mapping (1651-3 and 1547cm-1 
respectively).  A DNA peak was seen at 1234-6cm-1 in the tissue mapping, and 
there is a peak in this region for each of the cell groups, though with some 
variation. There were some minor differences in the peaks attributed to 
glycoprotein – with peaks 1121-7cm-1 (1113-7cm-1 in the tissue work), 1169-
72cm-1 (1171-2cm-1 in tissue), and 1365-7cm-1 (1373-7cm-1 in tissue). The peak 
seen at 1080cm-1 in the tissue study was attributed to mixed contributions of 
glycogen, glycoprotein and DNA: the normal squamous and 
dysplasia/adenocarcinoma groups showed a peak at 1077cm-1, but the Barrett’s 
group had a doublet in this region at 1067 and 1084cm-1. The glycogen peaks 
also show a difference: in the tissue work, glycogen peaks were seen at 995, 
1022-6 and 1153-7cm-1. In the cell spectra, peaks were seen at 987-9, 1026 
and 1153-8cm-1. However, the 1026cm-1 peak was seen only in the normal 
squamous cells, and not in the Barrett’s or dysplasia/adenocarcinoma groups, 
both of which showed a doublet in this region of 1018 and 1037-40cm-1.   
The phospholipid peak seen around 1740-5cm-1 in the tissue mapping study is 
not seen here. It is possible that signal from cell membranes may be removed 
during pre-processing. The pixels at the edge of cells can contribute artefact 
due to scattering effects: if this were consistently recognised by the pre-
processing steps they might therefore be removed.  
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The many similarities between the cell spectra and the earlier tissue study 
support the findings of both studies, and imply that these spectral peak 
positions will be consistent findings in both oesophageal cells and tissue.  
 
5.11.3.2. Principal component loadings analysis 
In order to analyse which spectral differences have contributed to the 
classification model, the most discriminatory principal component (PC) loadings 
were analysed. The 5 most discriminatory PCs are shown in Figure 5-31. 
Many of the key discriminatory peaks seen in the tissue mapping study, and 
identified in the inverse second derivative spectra of the cells, do not feature 
prominently in the PC loadings. The glycogen peak at 1022-6cm-1, which 
occurred only in the normal squamous cells, appears only in PC4. The glycogen 
peak at around 1150cm-1 appears in PC4 (1150cm-1), PC7 (1153cm-1), and may 
be part of a broader peak in PCs 3 (1140-1203cm-1) and 11 (1145-89cm-1). 
However, the other glycogen peak seen around 987-9cm-1 does not appear 
consistently at this position in the PC loadings, and in the absence of the other 
glycogen peaks it is difficult to draw conclusions from the presence of the 
1150cm-1 peak alone. Where it occurs with the 1022cm-1 peak in PC4 (both 
positive), this suggests that high glycogen content is selected for in the positive 
direction. Thus PC4 could potentially be separating out the normal squamous 
cells. This is supported by the negative peaks, which correspond to the doublet 
seen at 1064 and 1089cm-1 in the Barrett’s cells, along with the DNA peak at 
1225cm-1  (the position for the Barrett’s cells) and the peak at 1371cm-1 which 
may represent glycoprotein. Taken together, this implies that PC4 may be 































































































































































































































































































































Figure 5-31 Most discriminatory PC loadings in descending order of 
discrimination. A) PC4, B) PC7, C) PC3, D) PC9, E) PC11. 
 
The discriminatory role of the other PCs is less clear. Whilst certain peaks 
feature frequently (e.g. 1367-75cm-1 may be glycoprotein), in the absence of 
further peaks representing the same biomolecule to support this assertion, 
conclusions are limited. The major DNA peak which was a strong discriminator 
in the tissue work (1234-6cm-1) does not appear frequently in these PC 
loadings. There is a large peak at 1238cm-1 in PC11 which may represent DNA 
(this peak is seen at 1234cm-1 in the normal squamous cells inverse second 
derivative spectra, and a broader peak is seen at this location for the 
dysplasia/adenocarcinoma group), and the 1225cm-1 peak in PC4 may 
represent DNA in the Barrett’s cells as mentioned above.   






































































































The protein peaks in the range 1400-1700cm-1 generally do not occur at 
consistent positions and are therefore difficult to interpret.  
The peak at 1036-9cm-1 occurs in 3 of the PC loadings (PCs 7, 9 and 11). The 
biomolecular origin for this peak is not entirely clear, as discussed above, and if 
artefact, this may represent a significant source of variance in the data, and is a 
major potential source of error.  
Whilst there are a number of spectral peaks seen in the PC loadings that 
correspond to peaks identified in the inverse second derivative spectra, many of 
these peaks do not feature strongly, and there are other peaks present that do 
not correspond well with the key discriminatory peaks seen in the tissue work. 
This suggests that the spectral basis of classification for the cells may not have 
included certain key biochemical differences between the pathology groups, 
which could contribute to a poor classification performance. Simultaneously, the 
PC loadings may include artefact/non-pathological differences between the 
groups, which could give a falsely elevated performance amongst the training 
cells, but would likely reduce the performance if applied to new test data. These 
factors may be a result of the small sample size and hence sample differences 
may be more significant source of variation than any true biochemical 
differences resulting from pathology.  
 
5.11.4. Revisiting the spectral contribution of CytoLyt™ vs. formalin  
The spectral analysis revealed that there were some differences between the 
groups in the wavenumber region 1000-1100cm-1, that did not correspond with 
the findings in the earlier tissue mapping study. One particular unexpected 
235 
 
finding was the broad peak seen in the Barrett’s and dysplasia/adenocarcinoma 
group that was not present in the normal squamous cells (see Figure 5-32). 
 
 
Figure 5-32 Region of unexpected difference between the pathology groups 
 
Since this was not seen previously, we considered possible causes for this 
difference other than cell pathology. One other difference between the groups 
was that many more of the NSQ samples were preserved in CytoLyt™ (rather 
than formalin) compared to the Barrett’s and dysplasia/adenocarcinoma 
samples (1 out of the 4 Barrett’s samples and none of the 5 
dysplasia/adenocarcinoma patients’ samples were stored in CytoLyt™, versus 4 
out of 8 normal squamous samples). Although principal component analysis 






































had failed to find a consistent difference between cells prepared using the two 
different fixatives, we nonetheless revisited the possibility that this could be the 
cause of a spectral difference. 
  
 
Figure 5-33 Mean spectra from earlier experiment comparing Cytolyt™ and 
formalin  
The initial experiment comparing the fixative solutions compared 10 samples, 5 
stored in formalin, 5 in CytoLyt™. The mean spectra of the two groups showed 
a difference in this same region between 1000-1100cm-1 (see Figure 5-33), 
though this was initially attributed to baseline differences seen from 900-
1200cm-1. Reassessing this with the experience gained from the training cells 
analysis, it appeared that the difference seen in the training cell groups 
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collected in formalin (Barrett’s/dysplasia/adenocarcinoma), i.e. a broad peak 
starting around 1000cm-1 and extending to 1080cm-1, was also present in the 
formalin group in the initial experiment.  
To explore this further, we went on to examine the mean spectra for cells in the 
training dataset collected in formalin versus CytoLyt™. Since half of the normal 
squamous cell samples in the training dataset were collected in each fixative, 
we divided the normal squamous cells into ‘formalin’ and ‘CytoLyt™’ groups for 
comparison. The mean spectra are plotted in Figure 5-34.  
 
 
Figure 5-34 Comparison of mean spectra for all normal squamous cells in the 
training dataset, based on fixative solution used. 
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Once again, there is a difference in the same region, with the cells stored in 
formalin showing a broad peak around 1000-1080cm-1 that is not present in the 
cells stored in CytoLyt™.  
Given this consistent difference in the spectra in this region, the raw fixative 
solutions were measured to see if such a difference due to the solutions was 
plausible. A drop of solution was placed on a clean calcium fluoride slide and 
spectral measurements taken, using the same instrumentation and settings as 
the cell measurements. The spectra from the raw solutions are shown in Figure 
5-35. 
Looking at the spectra from the raw fixative solutions, the formalin solution has 
its strongest signal across the wavenumbers 934-1090cm-1, with various peaks 
in this range. The CytoLyt™ does not have strong signal in this region, but 
shows large peaks at 1424 and 1572cm-1. It is difficult to predict how this would 
translate into the measured spectrum of a cell containing a small amount of this 
solution, since there would be many other compounds present that could 
influence the spectrum. The region of strongest signal in the formalin solution 
does not correspond perfectly with that seen in the cells stored in formalin, and 
the strongest features in the CytoLyt™ solution are not clearly seen in the cells 
stored in CytoLyt™. However, given the consistent finding that cells stored in 
formalin have a stronger signal in the range 1000-1080cm-1, and this 
wavenumber region occurs in the region of strongest signal for formalin 
solution, it certainly seems possible that this is a potential cause for the 









Figure 5-35 Mean spectra of raw solutions A) Formalin and B) CytoLyt™. 








































































































A training model developed using cells only stored in one type of fixative 
(preferably CytoLyt™) would therefore be desirable. Given the moderate 
classification performance of our training dataset, with the major limitation being 
sample size in each group, subgroup analysis of our dataset to include only 
cells stored in one type of fixative is not appropriate, as firm conclusions cannot 
be drawn.  
 
5.12. Whole sample classification 
The aim of this study was to develop a classification model using 
cytopathologically identified cells, which could then be applied to whole cell 
samples. As discussed above, the performance of the training cell model was 
only moderately good, and spectral analysis suggested that certain features 
were not included in the model, and differences due to artefact may have been 
included e.g. difference due to formalin preservative. In addition, the variability 
of the plating had resulted in large numbers of samples having no identifiable 
cells of the ‘correct’ pathology. Given these limitations, conclusions from the 
application of the training model to the whole sample test set may be limited. 
Nonetheless we proceeded to complete the analysis, not least because the 
process of developing the software algorithms is an important next step in the 
process.  
The number of samples and spectra included in the test dataset (after the same 
pre-processing steps as those applied to the training dataset) are shown in 
Table 5-6. Cells that were included in the training dataset were excluded from 




Table 5-6 Total number of samples included in the test dataset 
 No. of 
patients 
No. of FTIR 
maps 
No. of cell 
regions 




18 19 722 27,662 
Barrett’s 
oesophagus 
21 33 1,891 48,322 
Dysplasia/ 
adenocarcinoma 
25 42 2,620 54,418 
Stomach 21 21 969 33,032 
TOTAL 66* 115 6,202 163,434 
*Some patients contributed to both stomach and one other pathology group 
The stomach samples were included in the test dataset, even though they did 
not form part of the training set, simply as an exploratory experiment to see how 
they would classify amongst the other three groups. Without a training group, 
they cannot be classified ‘correctly’ as there is no ‘stomach’ group, but it is of 
interest to see whether they are spectrally more similar to the other non-
pathological group (normal squamous) or the other glandular groups 
(Barrett’s/dysplasia/adenocarcinoma).  
The Barrett’s and dysplasia/adenocarcinoma groups have greater numbers of 
samples: because of the anticipated difficulty in identifying representative cells 
in these pathology groups, certain samples had more than one region 
measured to increase the number of cells that could contribute to the training 
set. These different regions on the same slide will be considered as separate 





Figure 5-36 Steps involved in assigning pathology labels to every cell A) 
unstained slide, B) binary mask identifies cell regions, C) training model applied 
to cells to assign pathology label. The bar in each image represents 300µm. 
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This greater number of samples partly accounts for the greater number of cell 
regions identified in the Barrett’s and dysplasia/adenocarcinoma groups, but 
this is also due to the greater cell density (on average) on these slides 
compared to the normal squamous and stomach samples.  
The training model was applied to every cell region identified in the test dataset. 
A threshold vote system was used as described earlier, using the same 
threshold of 30% for classification. For most samples, not every cell was 
classified into the same pathology, so a similar threshold vote was used to 
classify the whole sample based on the classification of its constituent cells. In 
this first iteration, a simple majority system was used, whereby over 50% of the 
cells had to be classified as a certain pathology for the sample to be classified 
as such. A visual representation of this sequence, from the unstained cells to 
the pathology labelled binary mask, is shown in Figure 5-36. 
The results from application of the training model to this test dataset are shown 
in Table 5-7.  
Overall, the detection of normal squamous and dysplasia/adenocarcinoma 
samples was reasonably good, with a sensitivity of 79.0% and 83.3% 
respectively. The detection of Barrett’s was very poor, however, with only 31.3% 
of samples classified correctly. The confusion matrix shows that none of the 
normal squamous or dysplasia/adenocarcinoma samples was misclassified as 
Barrett’s. The most likely cause for these results is that the training model 
contained far fewer Barrett’s spectra than the other groups. The training model 
is therefore skewed away from classifying spectra into the Barrett’s group, and 
the Barrett’s group can also more readily be affected by a small number of 
outlying spectra.  
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Table 5-7 Classification performance of the training model applied to the whole 
samples as a test dataset. A voting threshold was used for classifying each 
individual cell on a slide (30% threshold) and for classifying the sample overall 
(50% threshold). A) Confusion matrix, B) Sensitivity and specificity.  NSQ 
normal squamous; BE Barrett’s oesophagus; DYS/AC dysplasia/ 
adenocarcinoma. 
A 
 True pathology classification  
Predicted NSQ BE DYS/AC STOMACH 
NSQ 15 7 7 7 
BE 0 10 0 0 
DYS/AC 4 15 35 14 
UNKNOWN 0 1 0 0 
TOTALS 19 33 42 21 
 
B 
 NSQ BE DYS/AC 
Sensitivity 79.0 31.3 83.3 
Specificity 77.9 100 54.2 
 
The same argument probably explains the absence of stomach samples 
classified as Barrett’s. Two-thirds of the stomach samples were classified as 
dysplasia/adenocarcinoma, with the remainder as normal squamous. This 
suggests that the stomach samples are closer to the glandular cells than the 
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normal squamous samples, but only limited conclusions can be drawn in the 
absence of a stomach training dataset.  
Only one sample was classified as ‘unknown’, having failed to reach the 50% 
threshold for classification. Thus for every other sample, over 50% of the cells 
were classified as a single pathology. This level of homogeneity was not 
expected given the absence on cytopathology review of clearly glandular or 
dysplastic cells: many of the Barrett’s and dysplasia/adenocarcinoma samples 
contained large numbers of squamous cells and cellular debris. For many of 
these samples, we might therefore expect the majority of cells to be classified 
as squamous. However this was the case in only 16.7% of the 
dysplasia/adenocarcinoma samples, and 21.2% of the Barrett’s samples.  
There are a number of possible explanations for this. The simplest explanation 
would be that there are systematic spectral differences amongst cells in the 
training model that are used for classification, other than true biochemical 
differences between the pathology groups. This is possible due to the fact that 
all samples are included in the test set (there is no ‘leave-one-out’ validation), 
so although the cells used to develop the training model are excluded, spectra 
from patients included in the training set are also included in the test dataset. 
Thus patient or sample specific differences could contribute to the result. 
Nonetheless, since only a minority of the patients were included in the training 
set (e.g. 5 out of 25 patients in the dysplasia/adenocarcinoma group), such 
differences cannot explain the result alone.  
One possibility is the presence of unidentified dysplastic cells on the slides, 
although this is unlikely to occur in great numbers. Another possibility is that the 
biochemical content of the cellular debris is similar to the content of whole cells, 
246 
 
and hence, although such debris may not be useful for classification of cells 
using conventional cytopathology, the biochemical information is useful for 
spectral classification. If the cellular debris is simply the result of plasmolysis or 
fragmentation due to the preparation of the slides, this debris would logically be 
biochemically representative of the underlying cell pathology.  
 A further possibility is that biochemical changes precedes a morphological 
change in cell appearance. If a region of dysplasia or adenocarcinoma 
underwent a field change (probably reflecting genetic change) that preceded 
phenotypic change in the cells, there may be a detectable biochemical 
difference in cells that appear squamous.  
To test this idea further, we attempted to develop a training model using only 
cells that had been classified as appearing squamous on cytopathology, but 
assigning the cells’ pathology to the underlying pathology from which it was 
taken.  
 
5.13. ‘All squamous’ training model 
As described above, we aimed to test whether cells that appeared squamous, 
but had been taken from a region of e.g. Barrett’s, showed biochemical changes 
that could be used to identify the underlying pathology.  
During the development of the training dataset, many cells that were identified 
on samples taken from regions of Barrett’s or dysplastic histology were 
classified as appearing squamous on cytology review. We used these cells to 
build a training model: a summary of the data included (after identical pre-
processing steps to the initial training dataset) is shown in Table 5-8.  
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Table 5-8 Summary of data included in the ‘all squamous’ training model 
 No. of patients No. of cell 
regions 
No. of spectra for 
analysis 
Normal Squamous 8 107 4,714 
Barrett’s 
oesophagus 
13 148 4,847 
Dysplasia/ 
adenocarcinoma 
11 69 2,061 
TOTAL 32 324 11,622 
 
With a total of 324 cells and 11,622 spectra in this training set, it is significantly 
larger than the initial training dataset, which contained 56 cells (the number of 
spectra changed with each iteration since 22 normal squamous cells were 
chosen at random).  
The training model was developed using the same methods as described 
earlier, with PCA-fed linear discriminant analysis, followed by LOSOCV. Figure 
5-37 shows the spectra plotted according to the most discriminatory PCs (A) 









Figure 5-37 Individual spectra plotted according to A) most discriminatory 
principal components (PCs) and B) linear discriminant (LD) functions, for the ‘all 
squamous’ training model.  
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The PC scatter plot shows marked heterogeneity of the dysplasia/ 
adenocarcinoma group, with the points separated over a wide distance by PC1. 
The normal squamous spectra are much more closely grouped, and the 
Barrett’s spectra show some heterogeneity across PC1, but much less than the 
dysplasia/adenocarcinoma group. It is possible that this reflects the greater 
heterogeneity within the dysplasia/adenocarcinoma group: this group shows the 
greatest variation in genetic and histological appearance, and this may be 
reflected here. Further, the cells in this group could potentially be a mixed 
population, with some ‘normal’ squamous cells, whilst others may be abnormal 
cells showing biochemical changes that precede morphological change.  
The results of the ‘all squamous’ training dataset after LOSOCV are shown in 
Table 5-9.  
The ability to discriminate between the groups is far better than would be 
expected if the cells from the three different groups (which all appear to be 
squamous) were biochemically identical. The classification performance is very 
good for normal squamous spectra, moderate for Barrett’s and poor for 
dysplasia/adenocarcinoma. The poorer performance of the dysplasia/ 
adenocarcinoma group may result from the heterogeneity implied by the PC 
scatter plot above. The smaller number of spectra in this group may also 
contribute to the reduced sensitivity. 
The classification of the normal squamous spectra is similar to, but slightly 
better than, the original training dataset (which had sensitivity 83.6%, specificity 
70.6%). This may result from the larger number of spectra in the ‘all squamous’ 
training dataset.  
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Table 5-9 Classification performance of the ‘all squamous’ training model 
applied to individual spectra: A) Confusion matrix, B) Sensitivity and specificity. 
NSQ normal squamous; BE Barrett’s oesophagus; DYS/AC dysplasia/ 
adenocarcinoma  
A) 
 True pathology classification 
Predicted NSQ BE DYS/AC 
NSQ 4170 516 128 
BE 408 3177 966 
DYS/AC 136 1154 967 
TOTALS 4714 4847 2061 
 
B) 
 NSQ BE DYS/AC 
Sensitivity 88.5 65.6 46.9 
Specificity 90.7 79.7 86.5 
 
Whilst the classification performance overall is too poor to be clinically useful, 
this does suggest that many of the cells which were classified as squamous by 
the cytopathologists could have biochemical changes that mark them as 
different from normal squamous cells. Many of the caveats expressed regarding 
the results from the original training cells dataset still hold however, and 
although this dataset is larger, with a total of 32 patients, this remains a small 





The overall aim of this project was to use FTIR to detect Barrett’s oesophagus 
and neoplastic change (dysplasia/adenocarcinoma) in endoscopically collected 
cell samples. In this study, classification of normal squamous cell samples was 
performed with sensitivity 79.0%, sensitivity for detecting Barrett’s oesophagus 
was 31.3% and for detection of dysplasia/adenocarcinoma it was 83.3%.  
This was based on the application of a training model with the ability to classify 
individual spectra from the training dataset with sensitivity (after cross-
validation) 83.6% for normal squamous cells, 62.8% for Barrett’s oesophagus, 
and 69.5% for dysplasia/adenocarcinoma.  
To our knowledge, there were no studies applying infrared spectroscopy to 
oesophageal cell classification prior to commencement of this work. Previous 
work using IR to classify cell pathology with similar methodology (‘spectral 
cytopathology’, SCP), has shown the ability to classify squamous cell samples 
from the cervix, urinary tract and head and neck (Bird et al. 2008; Gajjar et al. 
2014; Papamarkakis et al. 2010; Schubert et al. 2010), although this work 
focussed on proof of concept and spectral differences, and did not publish 
equivalent figures for sensitivity and specificity.  
The classification model developed using the training dataset contained small 
numbers of cell regions in all groups (in the case of the normal squamous group 
this was deliberately reduced to balance the group size), but this was 
particularly true for the Barrett’s group with only 12 cells. Not only did this have 
the smallest number of cells, but these tended to be small, isolated cells (rather 
than a cluster of cells of the same type), and thus contained very few total 
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spectra (76 in this group, versus 678 in the dysplasia group, and 726 in the 
normal squamous). This is a very small number upon which to build a 
spectroscopic training dataset, and this makes the Barrett’s dataset prone to 
strong influence from differences due to individual samples or patients rather 
than true biochemical differences due to pathology.  
Analysis of the inverse second derivative spectra indicated that the key 
discriminatory peaks seen in the FTIR tissue mapping study, and reported by 
other studies of FTIR in oesophageal tissue (see Section 4.10.1), were also 
present in the cells. However, only a few of these features were picked out by 
principal component analysis, suggesting other differences between the groups 
were used in the classification model. This is likely to be a major contributing 
factor in the relatively poor performance of the model when LOSOCV is applied 
to the training dataset. We might expect this problem to be greatest in the 
Barrett’s group since it is the smallest, and this may partially explain the lowest 
sensitivity in this group.  
Small sample size not only skews the training model towards patient and 
sample differences, but can also allow a single sample to heavily affect the 
result. In the case of the dysplasia/adenocarcinoma group, 10 out of 22 training 
cells were drawn from one sample (and it was noted that this sample stained 
darker than many others, and this could potentially contribute to ‘over-calling’ 
the dark-stained nuclei as dysplastic). The majority of cells from this sample 
were classified as normal by the training model, and this accounted for all but 
one of the misclassifications in this group, significantly reducing the sensitivity of 
the model.  
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If the Barrett’s group in the training dataset has been affected by patient or 
sample differences, this is a potential explanation for the poor performance of 
the 2 group model. If based on pathological differences, one would expect the 
similarities between glandular and dysplastic cells to improve the classification 
versus normal squamous, as seen in the tissue mapping study. However, if 
sample differences are introduced to the model which are not based on 
pathological differences also found in the dysplastic cells, this is likely to impair 
the performance, as seen in our results.  
Given the difficulty in identifying cells of representative pathology on the slides, 
the application of the training dataset to test samples in which there could 
potentially be no representative cells of that pathology seems destined to fail. 
The fact that the training model achieved a reasonably good classification of the 
dysplasia/adenocarcinoma samples therefore needs to be explained, and a 
number of possibilities have been discussed above.  
Consistent patient/sample differences due to artefact are not sufficient to 
explain the classification performance of the dysplasia/adenocarcinoma group 
given the small proportion of patients contributing to the training model. Whilst 
misclassification of a few cells is possible, this would not have resulted on the 
homogeneity seen in the classification of these samples, which required over 
50% of cells to be classified as dysplastic to be assigned that pathology label.  
This suggests that other material on the slide – either cell debris, or cells that 
appear to have squamous morphology – is contributing to the spectral 
classification.  
To assess whether cells that appeared squamous (and were classified as such 
at cytopathology review), showed a difference between the pathology groups 
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we developed a training model based solely on these cells. The Barrett’s, and 
particularly the dysplasia/adenocarcinoma groups, appeared very 
heterogeneous on PC analysis, which suggests this may contain a mixed 
population of cells. The ability to discriminate between the squamous cells 
drawn from the different pathology groups was varied, but considerably better 
than would be expected if no biochemical difference existed between the 
groups. This introduces the possibility that cells may exhibit a ‘field change’, 
reflecting underlying genetic change, that has led to the histological change 
observed in that region, but precedes a phenotypic change in appearance in 
some cells. It is plausible that this cell group may be the most superficial cells, 
which are also those that are most readily collected by brushing.  
Interestingly, a similar finding was reported in the largest study of SCP in 
cervical samples to date: Gajjar et al. (Gajjar et al. 2014) found that SCP 
correlated poorly with conventional cytology, but showed better correlation with 
contemporaneous histology from the same region. This paper cites poor 
cytology sensitivity and specificity as the reason for this, but an analogous 
explanation of field change that has not occurred in every cell (and again, 
particularly in the superficial cells), is another possibility.  
This project began as a collaborative project with the group from Northeastern 
University, to whom we gave a small number of samples for analysis; this work 
has recently been published (Townsend et al. 2015).  
Based on a total of 10 samples, the authors developed 2 group classification 
models comparing (in turn) normal squamous, Barrett’s and dysplastic cells, 
using a random selection of 400 spectra in each group to balance the group 
size. They report a sensitivity to detect Barrett’s versus normal squamous of 
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95.5%, normal squamous versus dysplasia 93.4%, and Barrett’s versus 
dysplasia 88.7%. However spectra from the same patients were included in 
both test and training datasets, and since these results are drawn from a very 
small number of patients it is possible that ‘between patient’ differences (as 
opposed to ‘between pathology’ differences) contributed to this result. Also, 
since both the analysis by Townsend et al. and the present study rest on very 
small numbers of patients, there is potentially a wide margin of error in both 
studies. Of note however, the cell preparation protocol in this study did not 
seem to encounter the same level of difficulty that our study found in identifying 
representative cell samples: this study included 145 Barrett’s cells and 14 
dysplastic cells from a total of 10 samples. This study used a different staining 
protocol from ours (Papanicolau staining as opposed to ‘Diff-Quik’), and used 
xylene and a cover slip to prevent degradation after staining – these factors 
may have improved cell staining and preservation and aided cell identification.  
Further, the discriminatory spectral features seen in the work by Townsend et 
al. are similar to the findings seen in the inverse second derivative spectra in 
our study (it should be noted that Townsend et al. used second derivative 
spectra as the basis for their classification model), and also correlate with the 
findings from our tissue mapping study and previous FTIR work in the 
oesophagus. For example, the amide I peak at around 1650cm-1 is strongest in 
the normal squamous group, the DNA peak at 1235cm-1 strongest in the 
dysplastic cells, and the glycogen peak at 1020cm-1 is strongest in the normal 
squamous cells and almost absent in the dysplasia group. This strengthens the 
findings in their study, and lends further weight to an argument for an underlying 
biochemical difference between the pathology groups, as seen in our analysis 
of the inverse second derivative spectra.  
256 
 
A further finding in the study by Townsend et al. was that cells which appeared 
squamous classified according to the underlying tissue histology. This supports 
our finding that squamous cells from the different groups show spectral 
differences which may be used for classification, and the findings of Gajjar et al. 
This consistent finding therefore supports the theory that genetic and 
biochemical change may precede morphological change in some cells.  
However, others using an alternative approach have argued that cytological 
changes precede histological changes. Reid et al. used flow cytometry in the 
oesophagus and identified some patients with IM only on biopsy who had 
cytological abnormalities which suggested dysplasia (Reid et al. 1987). They 
argued that cytology could therefore be used as an early predictor of dysplastic 
change prior to histological evidence of dysplasia. A very similar finding was 
made by Borovicka et al. (Borovicka et al. 2009): in a large study using digital 
cytometry, they identified a small subgroup of patients with more advanced 
cytology than histology. Of this subgroup, 21% progressed to more advanced 
histological disease on follow up.  
These arguments may be two sides of the same coin: an explanation for both 
effects would be that genetic change occurs and spreads throughout a cell 
population in a given tissue region, and cells then variably express the new 
phenotype. Early in the process, a small population of cells may be detected 
with dysplastic features that precede histological change. Once histological 
change occurs, there may remain a population of cells that have not yet 
undergone phenotypic change.  
As has been mentioned, the small number of patients, cells and spectra in the 
training dataset, and especially the Barrett’s group, has been a major limitation 
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of this study. The factors which contributed to the small sample size, along with 
other limitations of the study, are outlined in section 5.15 below. Potential 
further work based on these findings and their future application to clinical 
practice are discussed in the Summative Discussion (Chapter 10).  
 
5.15. Limitations of the present study 
There are numerous limitations to this study or areas which could be improved 
in future work. A crucial element of this study was the development of a reliable 
training dataset based on representative cells of known pathology. The 
development of this dataset was the key area of weakness of the study: many 
steps were involved in transferring cells from the patient to the calcium fluoride 
slide for subsequent measurement, staining and cytology review, and many of 
these steps could be improved. Since this study began, a paper has been 
published that summarises the optimal steps in preparing cells for infrared 
spectroscopy (Baker et al. 2014), which is referenced below and would be 
helpful in guiding further work. 
The number of cells collected at endoscopic brushing appeared to vary 
enormously based on the apparent density of cell pellets at slide preparation. 
The brush used was the same in every patient, but the technique of performing 
the brushing was not perfectly standardised. Further, the initial plating 
experiment seemed to show more samples were affected by heavy 
bloodstaining than had insufficient cellularity. We therefore attempted to brush 
less vigorously to reduce the bloodstaining. However in retrospect, these early 
samples were mostly dysplasia/adenocarcinoma samples which in general had 
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much higher cellularity and a greater tendency to bleed, and the less vigorous 
brushing probably contributed to the reduced cellularity of some later samples.  
A further problem with collection was the high presence of cells that appeared 
squamous in samples taken from regions with glandular histology, as has been 
discussed. It is possible that this was exacerbated by lighter brushing, which is 
more likely to sample only the most superficial cells, which may include 
squamous cells that originated more proximally in the oesophagus that have 
sloughed off and been deposited more distally over a glandular region.  
Differences attributable to the choice of fixative (CytoLyt™ versus formalin) 
used to store the cells have been discussed above. For future work, in terms of 
spectral contributions the most important factor would be to use only one 
fixative throughout, although CytoLyt™ is probably better since it limits the 
artefact in the carbohydrate region between 1000-1080cm-1, and would also be 
preferred on the basis of reducing cell clumping and the presence of red blood 
cells.  
A more general problem with fixative is ensuring maximal cell survival, and 
particularly in preserving the glandular cells, since any differential preservation 
would contribute to the paucity of glandular cells.  
Prior to plating, some groups advocate washing cells in Hank’s Balanced Salt 
Solution (HBSS), rather than NaCl as we used, as HBSS removes phosphate 
ions before cytospinning (Baker et al. 2014). The presence of excess phosphate 
ions could lead to overestimation of phosphate (and associated peaks, such as 
those frequently assigned to DNA due to phosphate content) on spectroscopy.  
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A further source of error in plating could have been the centrifugation speed. 
We used 1500rpm for 3 minutes in accordance with current standard protocol in 
our cytology department (this equates to approximately 2,100g). However, 
Baker et al. advise using a lower force of 800g for 5 minutes, and warn against 
the problem of small cells ‘bouncing off’ the slide, in which case they 
recommend a protocol of 400g for 5 minutes, followed by 800g for 5 minutes. It 
seems very likely that this contributed to the very low number of (smaller) 
glandular cells seen on our slides.  
Other methodological steps that may have contributed to the difficulties in 
identifying cells were the staining and photographing of cells. Townsend et al. 
(2015) used a different staining technique (Papanicolau) that may have been 
superior to our ‘Diff-quick’ technique. They also used xylene and a cover slip to 
prevent degradation between cell staining and review. It seems likely that a 
small number of cells washed off the slides during staining, contributing further 
to cell loss.  
Photographing the cells for review introduced subjectivity, and the possibility of 
missing cells. Although I have received some training in cytology assessment I 
have very limited experience compared to a cytopathologist or cytology 
technician. Attempting to compensate for this by photographing any cell that 
appeared to be even possibly glandular may not have been sufficient. The other 
great difficulty with photographing the cells was correlating positions with the 
binary mask. Although for some samples this was relatively straightforward, in 
samples with heavy cell density, or where cells had washed off in staining, this 
was very challenging.  
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As described for histology in the tissue mapping sections, cytopathology review 
is a potential source of error. In this study it was performed by two 
cytopathologists together, not independently. Further cytopathologists are not 
used to reviewing single cells in isolation, but more usually look at a whole 
sample for assessment. Presentation of cells in isolation could mean the 
decision is affected by variable staining between slides, which might be 
accounted for by taking the slide as a whole.  
Comparison with cervical cytology can give some indication of the performance 
accuracy of conventional cytology review. Cervical cytology is performed in high 
volume by highly trained and experienced cytotechnologists, however one 
systematic review found sensitivity ranging from 30-87% (Nanda et al. 2000). In 
one large study in England, of 3,759 slides reported as normal, only 45% were 
subsequently deemed to be normal on a second review, and 23% were found to 
have moderate dyskaryosis or worse (Castanon et al. 2012). Since cervical 
cytopathology is performed in much higher volume than oesophageal 
cytopathology, it might be expected that the accuracy of oesophageal 
cytopathology is less good.  
In summary, many factors contributed to the low numbers of glandular cells 
available for the training dataset. This may not be a problem unique to this 
study: low numbers of Barrett’s cells per sample were also a problem in BEST2, 
as the authors of this study report that some of the weakness in sensitivity was 
due to Barrett’s patients not having any glandular cells in the sample (Ross-
Innes et al. 2015). 
The other potential source of error in this study comes from data processing.  
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Pre-processing steps could remove useful spectra and diminish true variation 
between groups. Alternatively, the inclusion of anomalous spectra (particularly 
‘edge’ pixels) could also impair classification. Mie scattering correction runs the 
risk of ‘overfitting’, using curves that can fit any dataset, and therefore the 
process has a minimal effect. 
The major processing step in this study was the binary mask used to process 
maps and identify cells. This used a combination of spectral information (the 
1650cm-1 peak) and size criteria to identify cells. The use of size criteria in the 
binary mask is affected by cell clumping, and may exclude large numbers of 
cells if clumped together.  
The spectral information is non-specific, and will identify any protein signal that 
gives a large amide I peak in this region. It can also miss cells with a relatively 
weaker signal at 1650cm-1 if they have strong signal elsewhere in the spectrum. 
Other spectral markers could be used, either alone or in combination, to more 
accurately identify cells. One approach could use a DNA marker (e.g. the 
1234cm-1 peak) to identify cell nuclei, in combination with associated cell 
cytoplasm (represented by the 1650cm-1 peak). This could be used in 
combination with size criteria to quantify the amount of nuclear material present.  
There is much potential to refine the binary mask with a combination of further 
spectral information and size criteria to give a highly accurate cell identification 
tool. 
Alternative approaches could have been used to overcome some of the 
problems with small numbers of cells and identifying individual cell types. If a 
simpler approach using measurement of cell pellets had been used, this would 
have ensured large numbers of cells were measured and a stronger infrared 
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signal. However this would have introduced difficulties with multiple cell types 
being present in each measurement.  
Alternatively, cultured cell lines could have been used to provide homogeneous 
cells from which to measure each group (i.e. squamous cells, glandular cells 
and dysplastic/cancerous cells). This would have provided a measure of the 
intra-group variation and a reliable cell population from which to identify the 
differences between groups. Knowledge of these differences could then have 




SECTION C: TOWARDS CLINICAL TRANSLATION OF RAMAN 
SPECTROSCOPY FOR DIAGNOSIS OF BARRETT’S-ASSOCIATED 
NEOPLASIA 
CHAPTER 6: INTRODUCTION AND OBJECTIVES 
6. Introduction 
Endoscopic surveillance for Barrett’s oesophagus depends on accurate 
identification of dysplasia and adenocarcinoma to achieve the goal of early 
detection and allow timely intervention. These neoplastic changes are currently 
identified using endoscopy and biopsy. Current guidelines recognise that areas 
of neoplasia may be missed at conventional white-light endoscopy, and 
consequently in addition to biopsy of any visible lesions, a random biopsy 
protocol is recommended, taking quadrantic biopsies every 2cm in the columnar 
segment (Watson et al. 2005). Nonetheless, since this only samples a tiny 
fraction of the Barrett’s mucosa, areas of neoplasia may be missed. Many 
advanced endoscopic imaging technologies have been developed to improve 
detection of dysplasia, with wide ranging reported sensitivity and specificity. Of 
these the most widely used is narrow-band imaging, but none has 
demonstrated sufficient superiority over white-light endoscopy to become 
universally used in clinical practice. Consequently, there remains a clinical need 
for improved detection tools in Barrett’s associated neoplasia.   
Once biopsies have been taken for Barrett’s surveillance, they must be 
processed and analysed by a pathologist. Inter-observer variability in reporting 
Barrett’s dysplasia is well recognised and discussed above. This is therefore a 
further potential source of error for patients undergoing Barrett’s surveillance, 
with potentially significant treatment consequences. A tool that could provide a 
more standardised classification, based on an objective measure such as tissue 
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biochemistry, is therefore highly desirable. If such a tool could be applied in 
vivo, this would allow real-time classification of pathology.  
In recent years there have been major advances in endoscopic treatments for 
HGD and early cancer, allowing patients to avoid radical surgery in the form of 
oesophagectomy, with its associated morbidity and risk of mortality. This not 
only reduces the risks for patients who would previously have undergone 
oesophagectomy, but offers the possibility of curative treatment for many more 
patients who would not have been considered fit enough to survive major 
surgery. Whilst the modes of delivery vary between therapies, in order to deliver 
these treatments accurately and achieve oncological eradication, regions of 
dysplasia or early cancer must be delineated with precision. Consequently this 
shift in the treatment paradigm towards endotherapy presents a pressing need 
for real-time endoscopic identification of neoplasia in the oesophagus.  
Raman spectroscopy is an optical spectroscopy technique that has shown 
considerable promise as a diagnostic tool based on its analysis of tissue 
biochemistry. Raman spectroscopy has a number of characteristics that make it 
an attractive candidate for real-time endoscopic imaging in the oesophagus: it 
provides rapid, objective, non-invasive tissue diagnosis. By providing a 
qualitative and quantitative measure of the biochemical changes occurring in 
the sample, such as proteins, nucleic acids and glycogen content, disease can 
be detected at an early stage. It may be possible to identify the first steps of 
neoplasia occurring even before the changes in tissue architecture that can be 
classified at histology.  
Previous work with Raman microspectrometers has demonstrated the ability to 
discriminate distinct pathologies using ex vivo oesophageal tissue specimens, 
including Barrett’s metaplasia, LGD, HGD and adenocarcinoma (Kendall et al. 
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2003; Shetty et al. 2006). Recent evaluation of a custom-built fibre-optic Raman 
probe (designed to function with a conventional medical endoscope) has shown 
the ability to identify HGD and early cancer in a clinically applicable timeframe 
with sensitivity 86% and specificity 88% (Almond et al. 2013). These results 
were based on the reuse of a single in-house manufactured probe, and further 
work is required in order to translate these highly promising ex vivo results to a 
larger scale in vivo study. A key step in developing the probe for clinical use is 
to demonstrate consistency and reliable performance between multiple probes 
of the same design.   
Previous work investigating the biochemical basis of the differences detected by 
Raman and used to classify pathology has been performed using point 
spectroscopy, or maps with low (~100µm) spatial resolution (Almond et al. 
2013; Bergholt et al. 2014; Hutchings et al. 2010; Kendall 2002; Shetty et al. 
2006). This work has tentatively concluded that normal squamous tissue 
contains a higher glycogen content than metaplastic/neoplastic tissue, and 
metaplastic/neoplastic tissue a higher protein and nucleic acid content. Recent 
advances in Raman mapping instrumentation and computing power have 
enabled large datasets to be acquired using high quality Raman mapping with 
microspectrometers capable of high resolution (1.1µm). Application of these 
techniques in the oesophagus could investigate further the biochemical basis of 
Raman in discriminating between pathology groups in the oesophagus. 
Previous development of the Raman probe in our group has been done with an 
excitation wavelength of 830nm, however other groups have used 785nm. 
Whilst the Raman signal should be independent of excitation wavelength, the 
wavelength will affect the signal strength and the fluorescence background, and 
thus optimising this parameter would enhance performance of a Raman probe. 
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This issue is not limited to the probe: Raman mapping work has been reported 
at a range of excitation wavelengths. The ability to combine data from different 
spectrometers, such as applying a training dataset from one Raman system to a 
test dataset measured on another, is a key requirement if Raman spectroscopy 
is to be used in clinical practice more widely, but there is difficulty in comparing 
results between spectrometers when measured at different excitation 
wavelength. Whilst some have attempted to address this problem for simple 
organic compounds with a calibration protocol (Bocklitz et al. 2015), this is likely 
to be more challenging for complex biological samples. If a certain excitation 
wavelength were known to be optimal for oesophageal tissue then this could be 
used as standard, more readily allowing comparisons of data collected on 
different Raman systems.   
For mapping applications, this issue is not limited to wavelength but also 
modality: both infrared and Raman spectroscopy may be used. Infrared and 
Raman spectroscopy have a number of differences (summarised in Table 2-3 in 
the literature review), and each has its own strengths and weaknesses.  There 
may be a number of reasons for choosing one modality over another, but where 
the ultimate goal is identification of pathology, the sensitivity and specificity of 
classification are clearly of great importance. Quantifying the difference 
between modalities with regard to classification accuracy would therefore be 







1. Translate Raman probes from ex vivo tissue measurements to first in 
vivo measurements. 
a. Evaluate 5 prototype fibre-optic Raman probes built to a novel 
design, prior to larger-scale manufacture for in vivo use.  
b. Optimise parameters for in vivo data acquisition. 
c. Initial safety and feasibility testing of probe in first patients in vivo. 
2. Explore the molecular basis of Raman spectral differences that underpin 
the classification of pathology, using Raman mapping at high resolution 
with a new generation micro-spectrometer with long acquisition times. 
3. Compare classification performance of Raman maps measured using 
785nm, 830nm and FTIR maps of the same region of tissue (the work 
presented above in the FTIR mapping section formed the FTIR 
component of this comparison). 
 
6.2. Sample collection 
Samples for all 3 arms of this study were collected using the same ethical 
approval, consent form and methodology. All tissue samples were then used as 
a tissue bank from which to select samples for each individual arm of the 
project.  
A summary of all tissue samples included in the study, with outcome of double 





6.2.1. Ethical approval and informed consent 
All patients participating in the study provided informed consent. Each patient 
received a standardised information leaflet explaining the study (Appendix V). 
Patients had time to read the leaflet prior to a face-to-face discussion with the 
researcher, which offered an opportunity to ask any questions about the study. 
If happy to proceed, patients then provided their consent to participate, and 
signed a standardised consent form (Appendix IV).  No samples were taken 
from patients unless they had provided informed consent.  
Ethical approval for the study was obtained from the Gloucestershire Local 
Research Ethics Committee (Appendix VI).  
 
6.2.2. Sample collection 
Samples were collected from patients undergoing scheduled endoscopy, either 
as part of Barrett’s surveillance or indicated for other clinical grounds. In order 
to enrich the sample population for patients with oesophageal adenocarcinoma, 
some samples were also collected from patients undergoing surgery for 
oesophageal cancer.  
Tissue samples were collected at endoscopy using endoscopic tissue forceps 
(Olympus Medical, Tokyo, Japan) passed down the instrument channel of an 
endoscope, under direct vision at endoscopy, or at endoscopic resection using 
diathermy.  
The sample was then placed into a Cryovial (Thermo Scientific) and 
immediately snap frozen in liquid nitrogen, before storage at -80°C. 
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For the samples collected at surgery for oesophageal cancer, once the 
oesophagus was removed from the patient it was opened longitudinally, washed 
in distilled water, and samples were collected using a scalpel. Samples were 
placed in Cryovials and snap frozen as above. 
 
6.2.3. Sample preparation and measurement 
Sample preparation, histology consensus reporting, and selection of regions for 
mapping were the same for all mapping measurements, and using identical 





CHAPTER 7: EVALUATION OF RAMAN PROBES 
7. Evaluation of Raman probes 
7.1. Probe design 
The Raman probes evaluated in this project were designed by the Raman for 
Early Cancer Diagnosis (RECaD) consortium (Gloucestershire Royal Hospital, 
University of Exeter, University of Bristol) and built by the Interface Analysis 
Centre at the University of Bristol, and PA Consulting, Cambridge. An earlier 
probe design has been described in detail in a previous publication (Day et al. 
2009). A schematic of this earlier probe design is shown in section 2.2.2.2 in 
Figure 2-5. The current probe design has undergone a number of modifications, 
but is conceptually analogous to the schematic in Figure 7-1. The exact internal 
layout of the probe is awaiting patent and therefore not illustrated here. A photo 
of a packaged probe is shown in Figure 7-2.  
 
 
Figure 7-1 Mock up of probe design using coloured 3D printer. Green is the 
probe template/scaffold and the coloured components are the optics. Each 
tubular lens and ferrule is 1mm in diameter and the total probe has a diameter 





Figure 7-2 Packaged Raman probe with one pound coin for size reference. 
 
Laser light enters the probe via the excitation fibre, where it is collimated by a 
Gradient Index (GRIN) lens, and filtered to remove Raman signal and elastic 
scattering generated within the fibre optic excitation fibre. The light then travels 
through a filter which only allows light of specific excitation wavelength (830nm) 
to pass through, and onto a GRIN lens to be focussed onto tissue. The mean 
collection depth in tissue is 150μm, with the aim of allowing contact with tissue 
and analysing the epithelium. Raman scattered light from the tissue is collected 
by the GRIN lens and collimated. The light then passes to a filter which 
removes elastically scattered light and allows inelastically scattered light to pass 
through. The light is then focussed onto the collection fibre by another GRIN 
lens for return to the spectrometer.  
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The housing of the probe is 3D printed from a polymer, to allow accurate, 
reproducible and low cost manufacture. The internal surface of the probe is gold 
coated which reduces background signal from the polymer housing, and makes 
assembly easier as it provides contrast to see the small component parts.  
The Raman probe is connected to a laser source and spectrometer as shown 
below in Figure 7-3.  The excitation fibre of the probe is connected to a 
monochromatic laser at 830nm wavelength. The collection fibre carries light 
from the probe to a Renishaw System 100 spectrometer (Renishaw plc., 
Wotton-under-Edge, Gloucestershire). Light is then filtered and collimated, then 




Figure 7-3 Schematic of laser, Raman probe and spectrometer, showing 
internal layout of the spectrometer. Reproduced from Almond et al. 2011. 
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7.2. Prototype Raman probe testing  
Unfortunately, due to problems identified on the initial probe evaluation it was 
not possible to perform the programme of experimental work originally intended. 
The experimental plans are outlined below, and the problems discovered during 
initial testing are discussed in section 7.2.1. The full list of planned experiments 
is outlined in more detail in Appendix IX.  
The initial phase of the evaluation aimed to test reproducibility of the probe 
using measurements of known reference standards using multiple probes, 
spectrometers and operators. The effect of the incident angle of light was to be 
evaluated. Probe stability over time was to be assessed. The depth of 
measurement was to be accurately determined using reference standards 
placed at varying depths.  
Once these assessments were complete using measurements of reference 
standards, tissue measurement would begin. Reproducibility of probe 
measurement on tissue, along with the effects of repeated measurement on 
tissue, would then be assessed. Other effects which may be present during 
endoscopic measurements in vivo would then be tested, including the effects of 
saline, water and anti-foam lavage on measurement, and the presence of 
endoscopic white light and narrow band imaging.  
Once the reproducibility testing was complete, assessment of the diagnostic 
performance of the probes would begin, with ex vivo tissue measurement. 
Oesophagectomy specimens would be collected in theatre, and measurements 
made on fresh tissue. After opening the specimen and cleaning with saline, a 
grid would be placed on the tissue surface to ensure consistency between 
spectral measurement and biopsy position. At each position on the grid spectral 
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measurements would be taken using a range of acquisition times (0.1s, 0.5s, 
1.0s) followed by a biopsy from the same point. This would enable correlation of 
the histopathology report for a given tissue sample with its tissue spectrum, and 
development of a training set of data that could then be used to build a 
classification model to predict histology from the Raman spectrum.  
In addition to measurements on fresh ex vivo tissue samples (which would 
necessarily be from patients undergoing oesophagectomy for either 
adenocarcinoma or less commonly squamous cell carcinoma), snap frozen 
tissue from biopsies and endoscopic resections would be used to provide more 
samples of Barrett’s oesophagus and dysplasia as opposed to cancer.  These 
tissue samples would be fully defrosted prior to spectral measurement.  The 
number of measurements and biopsies would depend on the size of the tissue 
section.  
In addition to developing a classification model, use of measurements across 
the oesophagus with the grid could also be used to gain an estimate of how 
many biopsies/probe measurements would be required per unit area to give a 
certain sensitivity for detecting pathology. This would be useful in planning how 
the probe would be used in vivo, and determining the number of measurements 
required for surveillance if the probe was to be used as a single modality (in 
addition to white light endoscopy). 
Once the reproducibility and stability of the probes had been determined we 
aimed to apply for ethical approval to perform initial safety and feasibility testing 




7.2.1. Initial probe testing and loss of power output 
The initial batch of 5 prototype probes was assembled by collaborators from the 
University of Bristol and PA Consulting in Cambridge. On the day of assembly, 
each probe was tested by passing the laser light (830nm) through the probe for 
several seconds and measuring the laser output. Each of the probes were 
found to give a high laser output (approximately 100mW). Following an 
uneventful transport to Bristol the probes were then tested in Bristol two weeks 
later. Immediately after the laser was turned on there was a high laser output, 
however this began to drop off after 2-3 seconds, and then rapidly declined in 
about 10-15 seconds to a low level (<10mW). This was not expected and 
suggested that there was serious problem with the transmission of the laser 
beam through the probe. 
 
7.2.2. Inspecting the probe components 
The fibre-optics were checked and found to be intact, transmitting high laser 
output. After disassembling the probe it was discovered that both of the gradient 










Figure 7-4 A) Gradient Index (GRIN) lens at laser entry point, B) GRIN lens 




The pattern of the residue on the laser input side shows greatest residue 
density around the spot of laser input, then a somewhat haphazard distribution 
around the surface elsewhere. The pattern of residue density on the laser 
output lens (at which point the laser should be a collimated beam) shows an 
even distribution closely corresponding to the size of the laser beam, with a 
reduction in density of the residue with increasing distance from the laser beam.  
The pattern appears to correspond to a vaporised deposition. This fits with the 
observed pattern of loss of power, with the hypothesized mechanism as follows: 
as the lenses heat up (100mW laser will cause heating) this could cause 
vaporisation of a substance within the probe casing which then deposits onto 
the hot GRIN lens. As the lens darkens so it will absorb more energy and heat 
up faster, causing further vaporisation and deposition on the lens. This 
deposition will reduce the laser power output from the probe.   
 
7.2.3. Spectral analysis of residue on the lenses 
A number of possible substances were considered as candidates that could 
have been deposited onto the lens: the gold used to coat the inside of the probe 
casing, the polymer used as substrate for 3D printing the probe casing, Epoxy 
resin used as part of the casing, or the glues used to hold the components in 
place. Raman spectra were measured from each of these substances, and 
compared against the spectra from the deposits on the GRIN lenses. 
The Raman spectra from the GRIN lenses were measured, and slides were 
prepared of the various resins used, to allow spectral comparison. The resins 
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were vaporized onto glass cover slips (Loctite UV adhesive, Norland UV 
adhesive, 2 part epoxy resin, and the polymer used as 3D printing substrate). 
The Raman spectrum from gold was not tested: since it has no molecular 
bonds, pure gold does not have a Raman signal. Raman spectra were then 
measured from each of the resins in turn, using a Raman microspectrometer. 
The spectra from these measured resins, plus the spectra from the deposition 
on the GRIN lens, are shown in Figure 7-5.  
 
 
Figure 7-5 Raman spectra of lens residue and probe substrate materials 
 
The residue deposited on the GRIN lenses showed major peaks at around 
200cm-1 and 250cm-1. Corresponding low wavenumber peaks were not seen in 
any of the resins tested, suggesting the major component of the residue was 
not any of these resins. The GRIN spectra also showed a very small peak at 
1000cm-1 (corresponding to phenylalanine), and small peaks around 1250-
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1300cm-1, which were also present in the Norland UV adhesive. There is a large 
peak in the Norland UV adhesive at around 2900cm-1, with a very small peak in 
the GRIN lens spectrum at the same wavenumber. This peak is also present in 
the 2 part epoxy spectrum.  
Whilst it is possible that some of the resins (particularly the Norland UV 
adhesive) may have contributed to the deposit on the lens, the Raman spectra 
do not closely correspond with any of these substrates. Large signals at low 
wave numbers are often seen with metal oxide compounds, but given the 
chemical properties of gold, it seems unlikely that gold oxide is the chief source 
of the deposit. 
The most plausible source of the deposit seemed to be a combination of the 
housing polymer with the gold coating, but the Raman analysis of the spectra 
have not confirmed this.  
 
7.3. Discussion 
The deposits which formed on the GRIN lenses reduced laser output power and 
hence prevented the planned programme of experimental work from being 
completed. The most likely source of the deposits was the polymer used in 3D 
printing and the gold coating used in manufacturing to coat the interior surface 
of the 3D printed probe body. Clearly this caused a significant problem and 
must be addressed in future iterations of probe design. In order to ensure that 
future designs do not encounter this problem, future work is planned by our 
collaborators at the University of Bristol to build up a model probe sequentially, 
starting with the 3D printed body, a fibre optic cable, and a GRIN lens, then 
gradually add in one component at a time. Sequential testing in this way should 
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identify any other sources of vapour deposition that could potentially coat the 
GRIN lens and lead to the same problem in future.  
Further funding has now been secured to support this development work and 
manufacture new probes. Once successful probes are built, the package of 
planned experimental work could then be undertaken to assess the 
reproducibility and stability of the probes, then proceeding to evaluate their 
diagnostic capability.  
A reproducible, stable, and diagnostically sensitive and specific probe would 
have great clinical value. Success in optimising the Raman probe for in vivo use 
would provide the necessary evidence to inform a clinical trial in patients to 
evaluate the Raman probe. The planned clinical trial could then provide 
supporting evidence to implement this technology widely to allow patients to 
benefit.  
Potential applications and clinical implications of this technology are discussed 





CHAPTER 8: RAMAN MAPPING TO EXPLORE THE MOLECULAR 
BASIS OF RAMAN CLASSIFICATION 
8. Raman mapping to explore the basis of Raman classification 
8.1. Instrumentation 
Raman maps were measured using a new prototype Renishaw 802 micro-
spectrometer at the Biophotonics Research Unit in Gloucestershire Royal 
Hospital. This instrument is still in development and is not yet generally 
available. 
The principles of measuring Raman spectra are outlined earlier in the thesis. 
Raman mapping is performed by moving the sample on a motorised stage 
under the laser beam. Renishaw’s StreamlineTM technique uses a linear laser 
beam, which passes across the sample as the stage moves, creating a series of 
parallel spectra on the detector. For a given point, the spectrum moves across 
the detector as the stage moves, and signal is collected on the detector 
continuously as the laser line raster scans across the sample (see Figure 8-1). 
The 802 system uses excitation wavelength 785nm, and uses a Leica long 
working distance 50x objective lens to focus the laser beam.  
Prior to sample measurement the instrument must be calibrated. The 802 
performs an automated calibration procedure known as ‘Performance 
Qualification’ to optimise the system alignment and make wavenumber 




Figure 8-1 Schematic diagram of a Raman microspectrometer using a 
StreamlineTM laser beam to raster scan across a sample to create a Raman 
map.   (Reproduced from http://www.renishaw.com/en/streamline-generate-
chemical-images-rapidly--9449) 
 
Calibration is essential to ensure the CCD detector records consistent 
wavenumber positions to provide reproducible readings and allow comparison 
of spectra measured at different times.  
Silicon is used to calibrate the Raman shift wavenumber value as it has a single 
sharp peak at 520.4cm-1 which can be used as a reference. If a peak shift has 
occurred in the system and the recorded wavenumber for this peak is incorrect, 
a wavenumber offset can be applied to calibrate the system accordingly, 
bringing the measured value back to 520.4cm-1.  
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Neon-Argon emission lamps are used as they provide an accurate source for a 
number of atomic emission lines across the absolute wavenumber range 10000 
to 12100cm-1. The 802 has an in-built neon-argon lamp, and calibration aims to 
fit the measured spectra to the absolute peaks with the minimum error through 
optimising system alignment.  
A polymer measurement is also recorded to ensure peaks are measured across 
the entire spectral range.  
 
8.2. Sample selection and measurement 
The samples used for this study were selected on the basis of single pathology 
review, prior to review by a second pathologist. The tissue classification used 
was therefore based on a single opinion only (unlike the other tissue mapping 
studies in this project). A small number of the samples were classified differently 
by the second pathologist – this issue is considered further in the discussion. 
The tissue section on calcium fluoride was defrosted prior to measurement. For 
this study, high quality spectra with relatively long acquisition times from regions 
of homogeneous pathology were required. These regions were identified as 
described above for FTIR mapping, and the region of interest was identified on 
the unstained tissue section using the microscope. Raman maps were collected 
using 1.1µm step size, and an acquisition time of 60s. To ensure homogeneous 
pathology and to reduce the length of time taken to measure each map, the 
majority of maps were measured across an area of 50 x 50 pixels, therefore 
giving a total area of 55µm x 55µm, and a measurement time per map of 
around 2 hours. In some cases where more time was available, larger areas 
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were measured to acquire more data, followed by an extra pre-processing step 
to exclude any spectra measured outside the region of consensus pathology. 
 
8.3. Data pre-processing 
In-house software programs written in Matlab® R2014b (Mathworks, USA) were 
developed for pre-processing of Raman map data.  
For larger maps run over large areas to maximise data acquisition, some of the 
measured areas were outside the region of consensus pathology. To ensure 
only the spectra within the region of interest were included, these maps were 
loaded into a software program that allowed visualisation of the map, and 
selection of pixels (i.e. spectra) for inclusion. An example of this is shown in 
Figures 8-2A and 8-2B. 
Once the dataset included only spectra from regions with correctly identified 
tissue pathology, the wavenumber range is firstly truncated to 450-1800cm-1 to 
include only the fingerprint region of the Raman spectrum useful for biological 
samples. Spectral filtering is then performed to identify spectra that do not 
represent a true tissue measurement: this may be because of saturation of the 
detector due to high tissue fluorescence, low signal strength due to low laser 
power or some other system problem, or because a cosmic ray has been 
recorded at that pixel. This is done by calculating the mean and standard 
deviation (SD) of the dataset and applying thresholds based around these to 
exclude extreme outliers. For this analysis an intensity threshold of 5 SDs was 
used to identify areas of saturation (high intensity) or negligible signal (low 
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intensity), and gradient changes between adjacent wavenumbers of >15SDs to 
identify cosmic rays. These pixels were then removed from further analysis.  
 
 
Figure 8-2A Selection of regions of interest within RaMP (in-house software) 
program. Adjusted intensity map to highlight glandular areas within a region of 





Figure 8-2B Selection of regions of interest within RaMP (in-house software) 
program. Grey areas show selected pixels to be included in data analysis (with 
darker grey areas corresponding to the gland lumen showing pixels not to be 
included). See Figure 8-2A for image without selected regions highlighted. 
An EMSC correction algorithm was then applied which normalised the dataset 
to correct for variation in baseline signal intensity, removed the oxygen peak 
seen in all spectra at 1550-1570cm-1 (and interpolates to fill in the resulting gap 
in the spectrum) and corrects for background Raman signal generated within 


























Correcting for the objective was of particular importance in this project because 
there was a high background signal associated with the Leica x50 objective. As 
part of the development of the prototype instrument the objective lens was 
changed early on in the project because the first objective lens spectrum had a 
sharp peak in the key wavenumber region around 1400cm-1. The second 
objective was, however, only a slight improvement. The spectra from the two 
objective lenses are shown in Figure 8-3 above.  
This will have a large effect on the resulting spectrum measured from tissue, 
which will essentially be superimposed on the objective lens spectrum. The 
presence of a high Raman signal in the objective lens at a particular 
wavenumber may limit the ability to detect spectral features in a tissue signal at 
the same wavenumber. An objective lens that gives minimal Raman signal is 
therefore highly desirable.  
Figure 8-4 shows a comparison of a number of objective lenses on another 
instrument: it is clear from these spectra that the Raman signal varies 
enormously with the objective lens.  
In the examples in Figure 8-4, the x50 and x80 lenses have a very low Raman 
signal. The x5 lens has a small Raman signal, and the x2.5 lens has a large 




Figure 8-4 Raman spectra of a number of different objective lenses measured 
using same acquisition time on the same instrument. The Raman signal varies 
markedly between the lenses: this will affect the measured spectrum for any 
tissue sample. The x50 and x80 magnification show very little Raman signal.  
 
8.4. Data analysis  
The data analysis techniques used for FTIR mapping analysis (PCA, LDA and 
LOSOCV, described above in Section 4.7) were used here to develop 
classification models and explore differences between the pathology groups.  
 
8.5. Summary of measurements 
A total of 812,779 spectra were measured from 84 Raman maps, across 40 
tissue samples, collected from 32 patients (some patients contributed tissue of 
Wavenumber (cm-1)

























more than one pathology type, for example if an area of normal squamous 
tissue and an area of adenocarcinoma were collected from the same patient). 
The number of maps recorded and spectra measured for each pathology are 
shown in Table 8-1 below. 
 
Table 8-1 Summary of 802 Raman mapping measurements 
 No. of tissue 
samples 











10 23 310,545 186,088 
Barrett’s 
oesophagus 
11 19 150,465 74,799 
Dysplasia 10 23 139,255 101,322 
Adenocarcinoma 9 19 212,514 170,323 
TOTAL 40 84 812,779 532,532 
 
After selecting regions of interest and excluding tissue areas that did not 
correspond to the correct pathology type, excluding cosmic rays, saturated 
spectra due to background fluorescence or spectra with low signal, a total of 
280,247 spectra were excluded leaving 532,532 spectra for analysis. Mean 































































































examine spectral differences between the groups that contributed to 
classification.  PCA-fed LDA was used to develop the model, which was then 
tested using LOSOCV. The performance of the 4 group classification model is 
shown in Table 8-2. 
 
Table 8-2 Performance of the 4 group model: (A) confusion matrix showing 
classification of individual spectra (with correctly classified spectra in bold), and 
(B) sensitivity and specificity of the model for classifying individual spectra. NSQ 






















NSQ 133,257 2,613 4,975 6,890 
BE 16,703 28,556 51,702 82,361 
DYS 24,937 28,731 27,433 35602 
AC 11,191 14,899 17,212 45,470 
TOTALS 186,088 74,799 101,322 170,323 
 Tissue pathology 
Performance 
of 4 group 
model 
NSQ BE DYS AC 
Sensitivity (%) 71.6 38.2 27.1 26.7 
Specificity (%) 95.8 67.1 79.3 88.0 
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The performance of the 4 group classification model was very poor. The model 
was able to classify normal squamous samples with reasonable accuracy, but 
classification of Barrett’s, dysplasia and adenocarcinoma spectra was very 
poor. The dysplasia and adenocarcinoma sensitivity was only fractionally better 
than random assignment (which would be 25% in a 4 group model with equal 
numbers of spectra).  
To analyse how the principal components (PC) were separating the data, the 
key PC plots for each pathology group were examined (Figure 8-6). 
Examination of the PC plots showed that each individual pathology separated 
into two groups on PC1 i.e. the principal component that described the greatest 
difference between spectra.  
Given the separation of the pathologies into two groups, it seemed likely that 
this was caused by the use of two different objective lenses, and the failure to 
correct for this adequately with the objective correction algorithm. This would 
very seriously impair the classification ability. The dataset was then examined 
excluding those samples measured using the first objective. This resulted in the 
exclusion of 8 Raman maps (2 normal squamous, 4 Barrett’s, 1 dysplasia and 1 
adenocarcinoma) and 222,923 spectra (this relatively larger number of spectra 
given the number of samples reflects the fact that many of the earlier samples 
were very large maps, measured when there were fewer tissue samples and 
hence more time available for measurement). There were therefore 76 Raman 








































The classification model was re-run after exclusion of data measured on the first 
objective lens, and the performance is shown in Table 8-3, with the PC plots in 
Figure 8-7. 
Table 8-3 Performance of the 4 group model after exclusion of first objective 
data: (A) confusion matrix showing classification of individual spectra (with 
correctly classified spectra in bold), and (B) sensitivity and specificity of the 
model for classifying individual spectra. NSQ = normal squamous, BE = 























NSQ 102,879 1,046 3,307 3,247 
BE 3,639 20,620 11,728 15,350 
DYS 16,350 6,616 27,017 9,343 
AC 8,365 7,826 10,510 61,766 
TOTALS 131,233 36,108 52,562 89,706 
 Tissue pathology 
Performance 
of 4 group 
model 
NSQ BE DYS AC 
Sensitivity (%) 78.4 57.1 51.4 68.9 

























































This showed a marked improvement but nonetheless the classification 
performance remained poor, suggesting that limited biochemical data would be 
learned from studying the differences between the groups. 
The PCs in Figure 8-7 showed that there was no longer a clear separation of 
each pathology into two groups, but there was still considerable heterogeneity. 
The dysplasia and adenocarcinoma groups particularly demonstrated 
separation of some spectra from the main group. This suggested that certain 
sample measurements were systematically different from others within a 
pathology group, due to inaccuracies with either region selection or the 
instrument.  
To exclude such differences, the maps were examined and excluded if the 
spectra from the map formed two separate groups on PC analysis, or appeared 
very heterogeneous, suggesting either two different tissue types due to 
inaccurate region selection that may not have corresponded to consensus 
pathology, or a change in the instrument during measurement.  This decision 
process introduced an element of subjectivity, and ‘over-exclusion’ of outliers 
risks falsely elevating classification performance. However, this step was 
primarily to explore whether the performance could be improved sufficiently to 
justify further spectral analysis, given the poor performance of the classifier 
demonstrated thus far, rather than to test spectral classification.  
This resulted in the exclusion of 9 further samples (3 normal squamous, 4 
dysplasia, 2 adenocarcinoma), and 131,973 spectra, leaving a total of 177,636 
spectra and 67 samples. Performance of the 4 group model after these further 
exclusions is shown in Table 8-4. 
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Table 8-4 Performance of the 4 group model after further exclusions: (A) 
confusion matrix showing classification of individual spectra (with correctly 
classified spectra in bold), and (B) sensitivity and specificity of the model for 
classifying individual spectra. NSQ = normal squamous, BE = Barrett’s 





After the further exclusion process described above, the classification 
performance showed a minor improvement but remained poor overall. The 
model was able to classify the normal squamous spectra with good sensitivity 
and very high specificity, and the adenocarcinoma classification was also 
reasonably good.  
Given the persistently poor performance of the 4 group model in discriminating 
between Barrett’s, dysplasia and adenocarcinoma, a simpler analysis was 
















NSQ 38,195 1,039 215 1,106 
BE 772 18,923 9,087 9,938 
DYS 659 7,004 24,875 2,691 
AC 4,325 9,142 8,786 40,879 
TOTALS 43,951 36,108 42,963 54,614 
 Tissue pathology 
Performance 
of 4 group 
model 
NSQ BE DYS AC 
Sensitivity (%) 86.9 52.4 57.9 74.9 
Specificity (%) 98.2 86.0 92.3 81.9 
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performed to see if the classifier was able to detect differences in a 2 group 
model: Barrett’s versus the dysplasia/adenocarcinoma combined group. The 
results are shown in Table 8-5. 
Table 8-5 Performance of the 2 group model after further exclusions: (A) 
confusion matrix showing classification of individual spectra (with correctly 
classified spectra in bold), and (B) sensitivity and specificity of the model for 
classifying individual spectra. NSQ = normal squamous, BE = Barrett’s 









The performance of the 2 group model remained poor. The strong background 
signal from the objective lens was a concern, so we aimed to test whether this 
was impairing the classification performance. The 2 group analysis was 
repeated, excluding those wavenumbers in the region most affected by the 
objective. The strongest peak from the objective lens was in the region 1250-
1400cm-1, and there was a strong effect in the wavenumber region above 
1700cm-1, so the truncated dataset excluded these wavenumbers.  




(no. of spectra) 
DYS/AC 
(no. of spectra) 
BE 22,878 27,995 
DYS/AC 13,230 69,582 
TOTALS 36,108 97,577 
 Tissue pathology 






Sensitivity (%) 63.4 71.3 
Specificity (%) 71.3 63.4 
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Table 8-6 Performance of the 2 group model using truncated wavenumber 
range: (A) confusion matrix showing classification of individual spectra (with 
correctly classified spectra in bold), and (B) sensitivity and specificity of the 
model for classifying individual spectra. NSQ = normal squamous, BE = 









This result was almost identical to the 2 group analysis using the full 
wavenumber range, implying that this wavenumber range from 1250-1400cm-1, 
and above 1700cm-1, did not contribute any spectral information to the 
classification model. 
 
8.7. Spectral analysis 
The 4 group models discriminated normal squamous spectra reasonably 
accurately, however the poor performance of the 2 group model suggested 




(no. of spectra) 
DYS/AC 
(no. of spectra) 
BE 22,788 27,922 
DYS/AC 13,320 69,665 
TOTALS 36,108 97,577 
 Tissue pathology 






Sensitivity (%) 63.1 71.4 
Specificity (%) 71.4 63.1 
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there was limited useful spectral information with which to distinguish between 
the Barrett’s and dysplasia/adenocarcinoma groups. 
The result from the truncated dataset suggests that, in the region most affected 
by the objective signal, any spectral differences between tissue types are 
obscured.  
It is therefore only possible to perform a limited spectral analysis, both in terms 
of wavenumber range, and the effect of the objective in obscuring small peaks 
throughout the spectrum due to shot noise (this is explained further in the 
Discussion below, section 8.8). Assigning biochemical constituents to spectral 
peaks is usually done tentatively: in the context of these limitations even greater 
caution must be advised in interpreting peaks in this dataset. Consequently we 
will focus only on the larger spectral differences in the subtraction spectra and 
avoid the wavenumber range which has been shown to contain no useful 
discriminatory information.  
Looking at the differences in the subtraction spectra between normal squamous 
and the other pathology groups (Figure 8-8), the normal squamous group 
shows strongly positive peaks at 483 and 934cm-1 – these peaks are also 
sufficiently large that the difference in the normal squamous group can be seen 
clearly in the mean spectra in Figure 8-5 earlier in this chapter. Both of these 
peaks have been consistently reported in previous Raman studies in the 
oesophagus as representing glycogen, and present in greater amounts in 
normal squamous tissue (please refer to Table 8-7 below for further references 
of peak assignments reported in the oesophagus) (Almond et al. 2013; 
Hutchings et al. 2010; Shetty et al. 2006). There are a number of other glycogen 
peaks reported in the literature: glycogen peaks reported in multiple studies 
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include those at 852-5cm-1 and 1086-8cm-1. Figure 8-8 shows positive peaks at 
850-861cm-1, and a small peak at 1081cm-1 – it is possible these correspond to 
glycogen. This finding of increased glycogen content in normal squamous tissue 
is therefore consistent with both the reported literature, and the findings from 
the FTIR mapping section in Chapter 4. 
  
 
Figure 8-8 Subtraction spectra comparing normal squamous (NSQ) mean 
spectrum versus combined mean spectrum for Barrett’s (BE), dysplasia (DYS) 
and adenocarcinoma groups. 
The main amide I peak around 1650cm-1 splits to form two peaks at 1648cm-1 
(positive) and 1663cm-1 (negative). This peak represents proteins, and therefore 




The major negative peaks represent higher content in the combined 
Barrett’s/dysplasia/adenocarcinoma group, and occur at 716, 1003, 1254, 1441-
50 and 1581cm-1. DNA peaks have previously been reported at 719-20cm-1 and 
1576-9cm-1 and it is possible that the increased DNA content of these tissues is 
reflected here. The 1003cm-1 (phenylalanine) and 1441-50cm-1 peaks are likely 
to represent increased protein content. The 1254cm-1 peak occurs at the 
beginning of the large peak in the objective spectrum and is likely to be artefact. 
 
 
Figure 8-9 Subtraction spectra comparing Barrett’s mean spectrum versus 
combined dysplasia and adenocarcinoma mean spectrum. 
 
The differences in the subtraction spectra of the Barrett’s versus the combined 
dysplasia/adenocarcinoma group (Figure 8-9) are small compared to those 
306 
 
seen in Figure 8-8 (the ‘arbitrary units’ in both figures are the same scale). 
Although the first major positive peak at 484cm-1 may represent glycogen, this 
is not borne out in the presence of other positive glycogen peaks (e.g. 855, 934, 
1082cm-1) elsewhere in the spectrum. Similarly, there does not appear to be a 
consistent pattern amongst the most commonly reported DNA peaks at 781-5, 
852-5, 1334, 1576-9cm-1. The positive peaks at 1003cm-1 and 1439cm-1 may 
reflect protein content, but the amide I peak around 1650cm-1 is predominantly 
negative, so again interpretation is difficult. In summary, this analysis is 
consistent with the inability of the classification model to identify useful spectral 
information with which to classify these pathology groups. 
 
Table 8-7 Raman peak assignments in oesophageal tissue 
Wavenumber (cm-1) Biomolecule Reference 
470 Glycogen Hutchings et al., 2010 
481-90 Glycogen Shetty et al., 2006, Almond et al., 
2013 
719-20 DNA Shetty et al., 2006 
748-55 DNA Shetty et al., 2006 
750 Lactic acid Shetty et al., 2006 
781-5 DNA Shetty et al., 2006, Hutchings et al., 
2010, Almond et al., 2013 
820 Protein Shetty et al., 2006 
852-5 Glycogen 
Protein 
Shetty et al., 2006, Hutchings et al., 
2010 
Hutchings et al., 2010 
884 Protein Shetty et al., 2006 
885 DNA Almond et al., 2013 
918 Lactic acid Shetty et al., 2006 
933-7 Glycogen Shetty et al., 2006, Almond et al., 
2013 




944 Glycogen Hutchings et al., 2010 
1001-4 Phenylalanine (Bergholt et al. 2014) 
(Stone et al. 2004) 
Hutchings et al., 2010 




Hutchings et al., 2010 
Hutchings et al., 2010 
1048 Glycogen Shetty et al., 2006 
1078 Lipids Bergholt et al., 2014 
1086-8 Glycogen Hutchings et al., 2010, Almond et al., 
2013 
1128 Glycogen Almond et al., 2013 
1135 Glycogen Hutchings et al., 2010 
1223 Protein Shetty et al., 2006 
1261 Protein Hutchings et al., 2010 
1278 Protein Shetty et al., 2006 
1265 Protein (amide III) Bergholt et al., 2014 
1302 Lipid Bergholt et al., 2014 
1312 Protein Hutchings et al., 2010 
1333-8 Glycogen Shetty et al., 2006, Hutchings et al., 
2010 
1334-5 DNA Almond et al., 2013, Bergholt et al., 
2014 
1360 Nucleic acid Almond et al., 2013 
1453 Protein Hutchings et al., 2010 
1467 Glycogen Hutchings et al., 2010 
1511 Nucleic acid Almond et al., 2013 
1576-9 DNA Bergholt et al., 2014, Hutchings et 
al., 2010 
1618 Porphyrins Bergholt et al., 2014 




Shetty et al., 2006 
Shetty et al., 2006 







The aim of this study was to use high quality Raman mapping measurements 
with a long acquisition time to investigate spectral differences between 4 
pathology groups in the oesophagus: normal squamous, Barrett’s oesophagus, 
dysplasia and adenocarcinoma.  
Discrimination of spectra from normal squamous tissue was performed with 
reasonable accuracy, and a sensitivity of 86.9% and specificity 98.2%. The 
largest spectral differences contributing to this classification were strong 
glycogen peaks at 483 and 936cm-1, consistent with previously reported work in 
the oesophagus, and the findings from the FTIR mapping study in Chapter 4 
(Almond et al. 2013; Bergholt et al. 2014; Hutchings et al. 2010; Shetty et al. 
2006). Tentative peak assignment suggested increased DNA and protein 
content in the Barrett’s/dysplasia/adenocarcinoma tissue compared to normal 
squamous, and this again is consistent with previous findings.  
The discrimination of the Barrett’s, dysplasia and adenocarcinoma groups was 
very poor. The paucity of useful spectral differences for classification was 
confirmed by the absence of consistent biochemical differences on subtraction 
analysis.  
The diagnostic classification performance in this study was worse than reported 
previously for Raman in the oesophagus, both in earlier work by our group and 
that reported by others (Almond et al. 2013; Bergholt et al. 2014; Hutchings et 
al. 2010; Kendall et al. 2003). Since this result was rather worse than previous 
studies using similar, or shorter, acquisition times, we had to consider what had 
changed within the new prototype system that could cause such a poor result. 
The most obvious difference was the Leica objective lens, which had a very 
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strong background Raman signal. The previous studies had used either an 
Olympus objective lens or a probe with a custom made lens to focus the laser 
beam.   
The truncated 2 group model results imply that the objective lens is seriously 
limiting the classification performance in the wavenumber range where the 
largest peak is seen, between 1250-1400cm-1, with this region contributing 
effectively no spectral information to the classification. It is likely that this region 
contains some key discriminatory spectral peaks: earlier work in the 
oesophagus has reported a protein peak at 1265cm-1 (Bergholt et al. 2014), a 
lipid peak at 1302cm-1 (Bergholt et al. 2014), a further glycogen peak at 1333-
8cm-1 (Hutchings et al. 2010; Shetty et al. 2006), nucleic acid peaks at 1335cm-1 
(Bergholt et al. 2014) and 1360cm-1 (Almond et al. 2013).    
However, whilst the loss of spectral information in this region will impair 
classification, there are many peaks in other wavenumber regions that could 
potentially discriminate (as discussed in the spectral analysis section). We must 
therefore look for other reasons why our model failed to achieve good 
classification between Barrett’s and dysplasia/adenocarcinoma tissue.  
Although the largest peak in the objective lens spectrum is at 1250-1400cm-1, 
there is high signal throughout the fingerprint range, with a number of other 
small peaks. Inaccuracies in the algorithm correcting for the objective may 
reduce the effect of spectral differences as a result.  
A further problem associated with a high background Raman signal due to the 
objective lens is an increase in noise. Even with perfect correction for the 
objective lens signal, with a high signal you have an increase in shot noise 
which impairs the signal to noise ratio. Shot noise results from the quantum 
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nature of Raman scattering, and the random probability of scattering occurring 
for a given incident photon at a certain wavelength. The shot noise varies with 
the square root of the total number of counts, so as the total count increases, 
shot noise increases, but it becomes a smaller fraction of the signal.  
Since the shot noise is proportional to the square root of the total number of 
counts, with a large background signal from the objective, this gives a large shot 
noise relative to the size of the measured tissue signal. Therefore even 
correcting for the objective lens still leaves a spectrum with a relatively high shot 
noise. The random variation in spectra due to noise can therefore overwhelm 
the true variation between the groups and seriously impair classification 
performance. As a result of this work other members of the Biophotonics group 
have developed a simulated model to demonstrate the effects of shot noise with 
a strong lens objective signal. This simulation is included in Appendix X.  
There are a number of other factors that may have contributed to the poor 
performance of the classification model in this study. In this study, single 
pathologist reporting was used to classify pathology. Subsequent review by a 
second pathologist showed a number of discrepancies: the overall agreement 
for samples included in this study was 81.7% (see Appendix VII). If differences 
between LGD and HGD are ignored (since for this study we amalgamated these 
groups) and it is also assumed that ‘malignant: type unsure’ represents 
adenocarcinoma, then the agreement rises to 90%. The inclusion of non-
corcordant samples may be a significant source of inaccuracy. If a reliable 
classification model could be constructed without these samples, it would be 




The failure of the correction algorithm to account for the change in objective 
lens resulted in the exclusion of a significant proportion of the total samples and 
measured spectra.  
Further exclusions attempting to remove data that included multiple pathology 
groups or instrument problems led to a further reduction in the size of the 
dataset.  
This was primarily stimulated by a concern about the functioning of the 
prototype Raman microspectrometer. On a number of occasions there had 
been repeated problems with the automated calibration procedure. No maps 
were run when the calibration failed, however given the problems with 
calibration we were concerned that the laser could have been running at low 
power or with suboptimal system alignment when the automated process 
reported the calibration had ‘passed’. There were a number of occasions where 
the system crashed during measurement and the map had to be repeated. 
Whilst none of the maps in which there was a known system failure were 
included, it is possible that a more subtle change in system alignment could 
have occurred without it being obvious in the resulting map, and the map would 
have been included.  
These problems are related to the fact that this was a prototype system, and 
development is ongoing. We have worked closely with the manufacturers during 
this project to feed back the problems we have encountered, many of which 
have now been improved. The choice of objective lens has also been discussed 
at some length, and on the basis of this work the manufacturers plan to change 
the lens for future prototypes.  
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Other factors which could have limited the performance of the model could have 
been related to the sample biochemistry or to mislabelling of pathology group 
for spectra within the training model. The inclusion of the same patient in 
multiple pathology groups (e.g. where normal squamous or Barrett’s samples 
were taken from those regions in a patient who also (at a separate location) had 
an adenocarcinoma), could present difficulty. If patient differences (as opposed 
to pathology differences) were being used by the classifier to discriminate, this 
would have impaired the performance of the model.  
Alternatively, if there was genuine biochemical field change in these regions 
(i.e. the tissue adjacent to the tumour appeared histologically as Barrett’s but 
contained genetic and biochemical changes consistent with adenocarcinoma), 
this would have led to misclassification.  
As with the FTIR classification, LOSOCV was used to test the model, but 
multiple samples from the same patient were in the training set. Using a leave 
one patient out cross validation may further degrade the classification model if 
between-patient differences were being used as a basis of classification. This 
was not pursued further here since the primary aim was not to test classification 
ability, and the classification performance had been relatively poor anyway.  





CHAPTER 9: COMPARISON OF RAMAN MAPPING AT 785NM, 
830NM AND FTIR MAPPING 
9. Comparison of Raman mapping at 785nm, 830nm and FTIR mapping 
9.1. Study design 
This project aimed to compare classification performance of spectroscopic 
mapping using different spectroscopic modalities (infrared and Raman) and 
different excitation wavelengths for Raman (785nm and 830nm) on the same 
tissue section. As a related project, contiguous tissue sections to those 
measured here were taken for measurement using CARS, to allow a further arm 
of comparison with another Raman modality, as part of a project by another 
PhD student at Exeter (Kelly Curtis). 
The FTIR mapping data are presented in Chapter 4 above. In order to allow 
comparison, immediately after FTIR measurement (<24 hours) the same tissue 
region was then measured using Raman, first at 830nm then at 785nm. The 
FTIR methods and analysis are presented above, and the Raman methods and 
analysis are detailed below, with the FTIR data used here for comparative 
purposes. The CARS results are not included in this thesis.  
 
9.2. Instrumentation 
Raman maps were measured using a Renishaw InVia micro-spectrometer in 
the Department of Physics at Exeter University. This instrument is an older 
version of the 802 system described in Chapter 8 above. The InVia 
spectrometer uses the same StreamlineTM technique to raster scan across 
samples and create a Raman map (see Figure 8-1 in Chapter 8).  
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The InVia system has an in-built Neon-Argon lamp and uses this to optimise 
system alignment as described for the 802.  Other calibration steps are not 
automated, and performed by the user each day prior to measurement.  
Silicon calibration is performed manually, with measurement of a silicon 
standard followed by manual entry of the required wavenumber offset. 
A measurement of a standard sample of green glass was then performed. 
Green glass has a smooth fluorescent spectral signal with few Raman peaks 
across a broad wavenumber range. This can be used to correct for variations in 
spectrometer detector sensitivity by applying an energy transfer function 
correction.  
Cyclohexane was also measured as it has Raman peaks at 801, 1027, 1264 
and 1441cm-1, and drift in these peaks over time (e.g. due to changes in laser 
wavelength) can be monitored.  
 
9.3. Sample measurement 
The samples were first measured on FTIR, then Raman at 830nm then 785nm, 
with the order of measurement chosen to minimise the risk of thermal tissue 
damage with sequential measurements. 
For Raman measurement the region selection had already been performed for 
FTIR. The white light image taken on the FTIR microscope was used to identify 
this area once the sample was mounted on the Raman system, and allow 
measurement of the same region of tissue with Raman.  
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The regions measured using FTIR were 128 x 128 pixels using 1.1µm pixel 
size, i.e. 140.8µm x 140.8µm. Since the closest step size on the InVia Raman 
system was 1.4µm, the maps were collected over 101 x 101 pixels, giving a 
total area of 141.4µm x 141.4µm. This is a very small difference in size between 
the maps, and likely to be smaller than the margin of error in identifying and 
measuring the exact same region of tissue on both systems.  
Measurements at both excitation wavelengths were performed using a grating 
of 300l/m, with collected wavenumbers centred at 2350cm-1, giving a 
wavenumber range 406.25-3738.55cm-1. Inclusion of the high wavenumber 
range was selected because this would be helpful in informing the CARS 
measurements on the contiguous tissue sections as part of a separate PhD 
project.  
An acquisition time of 30s per spectrum was used. For a laser line measuring 
70µm, using a step size of 1.4µm and therefore 50 pixels, this gives an 
acquisition time 30/50 = 0.6s per pixel. This was chosen because it roughly 
equates to the target acquisition time for the Raman probe, of around 0.5s 
(previous work has shown good discrimination at 1s for an earlier prototype). It 
was also felt to be the shortest realistic time to get quality discrimination, and 
therefore comparable on that basis to the FTIR maps, though the time taken per 






9.4. Data pre-processing 
An in-house software programme written in Matlab® R2014b (Mathworks, USA) 
was used to identify cosmic rays and saturated spectra. Each Raman map was 
loaded into the software programme and the wavenumber range was truncated 
to 450-1800cm-1, to leave only the ‘fingerprint’ region. Cosmic rays were 
removed by applying a median filter – this analyses a region of 3x3 pixels and 
replaces the central pixel with the median spectrum of the group, thus ensuring 
each pixel is unaffected by extreme outliers such as a cosmic ray. The map was 
inspected to look for large regions of saturation where the median filter would 
not work in removing outliers, and such areas were manually selected for 
removal.  
The spectra were then normalised and an objective correction applied. The 
objective correction was again important as the Leica objective lens on the 
InVia system also has a strong contribution to the signal. The objective lens 
spectra measured at 785nm and 830nm are shown in Figure 9-1.  
Measured at 785nm, the objective lens spectrum has a significant peak at 700-
900cm-1, and a very large, sharp peak from 1100-1500cm-1. Measured using 
830nm, the objective lens has a high intensity signal at wavenumbers below 
1000cm-1, with a very large peak from 700-900cm-1, then the signal rapidly falls 








re 9-1 Objective spectrum mea
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9.5. Data analysis 
The same data analysis techniques used for FTIR mapping analysis (PCA, LDA 
and LOSOCV, described above in Section 4.7) were employed for the Raman 
data to develop classification models and explore differences between the 
pathology groups. As with the FTIR, 50 PCs were calculated, with ANOVA 
threshold 0.99 used for inclusion in the training model.  
 
9.6. Summary of measurements 
Each of the tissue sample regions measured using FTIR was measured using 
785nm and 830nm, i.e. 22 tissue samples from 19 patients (some patients 
contributed tissue of more than one pathology type, for example if an area of 
normal squamous tissue and an area of adenocarcinoma were collected from 
the same patient). 141.4µm x 141.4µm regions were measured to match the 
FTIR regions, with 2 maps measured per sample (for the normal squamous 
tissue samples one ‘extra’ map was measured for 3 samples, and one map 
crashed during measurement). At 785nm a total of 459,045 spectra were 
measured from 45 maps (one map from one of the dysplasia samples crashed 
during measurement); at 830nm a total of 469,246 spectra were measured from 
46 maps. The number of maps recorded and spectra measured for each 




Table 9-1 Summary of InVia Raman mapping measurements at 785nm 










5 12 122,412 118,775 
Barrett’s 
oesophagus 
6 12 122,412 118,173 
Dysplasia  5 9 91,809 88,944 
Adenoca. 6 12 122,412 114,590 
TOTAL 22 45 459,045 440,482 
 
Table 9-2 Summary of InVia Raman mapping measurements at 830nm 
 No. of tissue 
samples 








5 12 122,412 118,943 
Barrett’s 
oesophagus 
6 12 122,412 117,743 
Dysplasia  5 10 102,010 98,521 
Adenoca. 6 12 122,412 114,339 
TOTAL 22 46 469,246 449,546 
 
 
9.7. Spectral analysis and classification models 
The mean spectrum for each pathology group measured at 785nm and 830nm 
is shown in Figure 9-2. The mean spectra have been normalised but not 































The 785nm mean spectra show strong peaks from 700-800cm-1 and 1200-
1400cm-1 as seen in the objective spectrum above. However it appears the 
spectral peaks are shifted relative to one another, with a similar spectral shape 
but major peaks occurring at markedly different wavenumbers. 
The 830nm mean spectra show a very strong effect from the objective – with a 
high peak around 600-800cm-1, then a marked drop in the baseline intensity as 
the wavenumber increases. There also appears to be a more subtle peak shift 
with respect to the normal squamous samples.  
The appearances of the mean spectra were concerning: firstly, it suggested that 
the objective lens contribution may again be a problem as the mean spectra at 
both wavenumbers exhibited a strong effect from the objective spectrum, and 
secondly, the presence of a peak shift suggested a calibration problem, with 
potential to be a major source of variation in the data, which would affect 
classification performance.  
To identify which of the individual samples showed evidence of peak shift, the 
sample mean plots for each pathology group were examined individually 
(shown in Figures 9-3 to 9-6). The 1002cm-1 peak represents phenylalanine and 
is likely to be relatively constant across the pathology groups (Dingari et al. 
2012; Stone et al. 2004). This peak can be used as a reference standard within 
each sample, and the position of the peak used to identify peak shift if it 






































































Looking at the mean spectra it was clear that certain samples showed a peak 
shift, suggesting problems with the instrument calibration. In the 785nm group, 
all samples were shifted with a phenylalanine peak around 989cm-1. The 
Barrett’s samples were also shifted, with peak positions between 966-994cm-1. 
In the dysplasia group, 2 maps from one sample (D1 area 1 and area 2) were 
significantly shifted at 971-5cm-1, but the others grouped between 1004-
1008cm-1. The peak position for every sample in the adenocarcinoma group 
was 1004cm-1. 
At 830nm, one of the normal squamous samples showed phenylalanine peak 
shift to 988cm-1 in all 3 Raman maps (N2 area 1, 2 and 3), with the other normal 
squamous samples all at 1005cm-1. One Barrett’s sample (B2 area 1) was 
shifted to 997cm-1, with the other peaks all found between 1004-1008cm-1. The 
dysplasia samples varied between 1000-1008cm-1, and the adenocarcinoma 
peak positions were from 1000-1005cm-1.  
This variability in peak positions had the potential to undermine the basis of 
spectral classification. Further, the fact that the variation was different across 
the groups (particularly for the 785nm data), introduced the possibility of 
artificial differences in the spectra between the groups. Nonetheless, a ‘first-
look’ 3 group classification model was constructed including all the samples, 
with the results in Table 9-3.  
This shows a good classification performance at 785nm, but a poor 
performance at 830nm. It is quite possible that the sizeable peak shift in many 
of the samples at 785nm was improving the classification – this would happen if 
the PCs used this artificial source of variation between the groups to help 
classify the spectra. At 830nm, the small degree of peak shift in each of the 
327 
 
pathology groups was likely sufficient to impair classification performance, but 
not systematically different between the groups in a way that would artificially 
improve separation.  
 
Table 9-3 3 group classification model for all spectra measured at 785nm and 
830nm (FTIR results shown for comparison). 
3 group classification model comparing 785nm, 830nm and FTIR data 
  NSQ  BE  DYS/AC  
785  Sensitivity  97.4 85.5 89.3 
Specificity  94.8 93.1 98.7 
830  Sensitivity  77.2 47.8 60.2 
Specificity  95.6 76.1 66.4 
IR  Sensitivity  93.6 76.8 84.6 
Specificity  99.9 88.5 85.8 
 
Whatever its effect on performance, the peak shift would be affecting the 
classification model, and hence ought to be corrected if true biological 
differences were to form the basis of our classification.  
In order to correct for the peak shift a number of approaches were taken. The 
calibration performed at the time using the silicon peak ought to have corrected 
for any instrument error. The silicon peak value after the wavenumber 
correction had been applied was recorded for every calibration: if the instrument 
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had not been correctly calibrated these values should show the error in the 
silicon peak. This value could then be applied across all the wavenumbers to 
correct the peak shift across the entire spectrum.  
The silicon peak values recorded prior to measurement of the samples showing 
peak shift (and certain selected ‘unshifted’ samples for comparison) are plotted 
in Figure 9-7. 
Figure 9-7 shows that the variation in silicon peak value was at most 2cm-1 
away from the calibration value of 520.4cm-1. This did not correlate with the 
magnitude of the variation seen in some of the samples, where the 
wavenumber shift reached in excess of 30cm-1. This was not an expected 
result, and we contacted the spectrometer manufacturer for advice. After 
servicing the instrument they discovered that the calibration process was 
malfunctioning: when a wavenumber correction was applied to the silicon peak, 
this correction was then applied by the instrument to the next point 
measurement. The next point measurement was the test to see if it had been 
applied correctly (and the calibration value recorded for each map), and this 
value was therefore correctly calibrated. However this correction was not then 
applied to the subsequent map as it should have been. Therefore the calibration 
values we recorded did not reflect the state of the instrument for data 
acquisition. This was clearly a disappointing finding, and we then had to explore 



























































































































































































































































































































































































The classification performance of the model after shift correction only (with no 
objective lens correction) is shown in Table 9-4. 
This result is better than using the objective lens correction for each pathology 
group measured at 785nm, and an overall improvement for the 830nm data. 
Overall however the classification performance is reasonably good for normal 
squamous tissue, but poor for Barrett’s and dysplasia/adenocarcinoma 
measured at either wavelength. 
However, given the difficulties in arriving at this result with the necessary 
correction algorithms, it is difficult to draw direct comparisons between the 3 
modalities as originally intended. 
Similarly, spectral peak analysis in this context would not be able to draw any 
firm conclusions given that all the peaks have been shifted. 
Table 9-5 Threshold voting classification using 30% threshold after shift 
correction (but not objective lens correction). (A) 785nm dataset confusion 
matrix (B) 785nm dataset classification performance (C) 830nm dataset 
confusion matrix (D) 830nm classification performance. NSQ normal squamous; 
BE Barrett’s oesophagus; DYS/AC dysplasia/adenocarcinoma 
A 
 True pathology classification 
Predicted NSQ BE DYS/AC 
NSQ 9 0 0 
BE 0 7 2 










 True pathology classification 
Predicted NSQ BE DYS/AC 
NSQ 9 0 0 
BE 1 6 3 







To complete the comparison against the FTIR mapping data, these results were 
then used to construct threshold voting classification of whole samples as 
explained for FTIR. The results are shown in Table 9-5 above.  
 Tissue pathology 
Performance of 
30% voting model 
NSQ BE DYS/AC 
Sensitivity (%) 81.8 63.4 90.5 
Specificity (%) 100 93.8 72.7 
 Tissue pathology 
Performance of 
30% voting model 
NSQ BE DYS/AC 
Sensitivity (%) 81.8 54.5 86.4 
Specificity (%) 100 87.9 72.7 
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These results suggest reasonably good classification of normal squamous and 
dysplasia/adenocarcinoma groups for both the 785nm and 830nm datasets, 
although conclusions are limited as discussed above.  A summary of these 
results and comparison against FTIR is shown in Table 9-6 below.  
 
Table 9-6 Comparison of 785nm, 830nm and FTIR mapping for 3 group sample 
classification model using shift corrected (but not objective lens corrected) data 
and 30% threshold voting. 
Comparison of 785nm, 830nm, and FTIR whole sample classification 
  NSQ  BE  DYS/AC  
785  Sensitivity  81.8 63.4 90.5 
Specificity  100 93.8 72.7 
830  Sensitivity  81.8 54.5 86.4 
Specificity  100 87.9 72.7 
IR  Sensitivity  100 75.0 95.7 




This study aimed to compare the classification performance of Raman mapping 
at two different excitation wavenumbers: 785nm and 830nm, and enable 
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comparison with results from mapping the same region using FTIR. The ability 
of the model to discriminate individual spectra for normal squamous tissue was 
reasonably good, with sensitivity at 785nm 80.8%, and 78.7% at 830nm. 
However the classification of Barrett’s (sensitivity 72.5% and 60.2% for 785 and 
830nm respectively) and particularly dysplasia/adenocarcinoma (sensitivity 
68.0% and 54.8% for 785 and 830nm respectively) was poor.  
Whole sample classification using a 30% voting threshold improved the ability to 
detect dysplasia/adenocarcinoma, with 785nm sensitivity 90.5% and 830nm 
sensitivity 86.4%. At both wavelengths, no ‘abnormal’ (i.e. Barrett’s or dysplasia 
or adenocarcinoma) sample was classified as normal. However the 
classification of Barrett’s using this system remained poor, with 36.6% of 785nm 
samples and 45.4% of 830nm samples misclassified as dysplasia 
/adenocarcinoma. 
Our results are consistently better at 785nm than 830nm for all pathology 
groups. Previous work has shown that 785 and 830nm are the most suitable 
wavelengths for use in oesophagus (Kendall 2002). The use of a shorter 
wavelength will give higher tissue signal but a higher autofluorescence 
background, with a longer wavelength giving a reduced background signal but a 
weaker tissue signal. Several groups have used Raman in the oesophagus at 
either 785nm or 830nm, but no comparison of classification has been performed 
previously.  Our results tentatively suggest that 785nm may give slightly better 
results, however any firm conclusions are severely limited by both the peak shift 
problem and the strong objective signal seen in this study.  
Phenylalanine is a recognised peak that has previously been used as a 
reference standard (Stone et al. 2008). In the event that the phenylalanine peak 
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position varied due to genuine differences in tissue biochemistry, then the 
correction algorithm would have been inappropriate, and a source of error. 
Whilst the correction algorithm aligned all the phenylalanine peaks successfully, 
if the underlying calibration problem had caused any stretch as well as shift, this 
would not have been corrected by the algorithm.  
The problems caused by a strong objective lens signal are discussed in Section 
8.8 above. The objective lens signal has a high intensity and large peaks for 
both wavelengths: at 785nm, the objective lens has a large peak at 1100-
1500cm-1, with a smaller peak at 700-900cm-1, whereas at 830nm the lower end 
of the spectrum has a much higher signal intensity, but wavenumbers above 
1200cm-1 are relatively unaffected. One would expect therefore that the 785nm 
wavelength may be more suitable for detecting spectral differences in the 
spectral range up to 1100cm-1, whereas 830nm may perform better for 
wavenumbers above 1200cm-1. It was not possible to perform this analysis with 
the peak shift preventing spectral analysis in this study, but this would make an 
interesting analysis as part of future work.   
The objective lens correction algorithm was not appropriate for peak shifted 
data, and consequently the final analysis of the dataset used peak adjusted 
data, but without an objective lens correction. The objective lens correction 
makes adjustments for the varying contribution of the objective lens in samples 
with a different overall signal intensity, which may be due to tissue fluorescence, 
or may be affected by other physical properties of the tissue such as thickness. 
If the correction algorithm is not applied then these physical differences will 
cause a difference in the amount of signal from the objective lens, and this 
introduces a further potential source of error.  
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Many of the same limitations that applied to the FTIR data such as the small 
sample size, or the difficulties of histology correlation, are true for this dataset, 
However, the FTIR data demonstrates a level of performance that can be 
achieved using exactly the same regions. One of the aims of the study was to 
compare Raman and FTIR for mapping applications, however the problems 
encountered in the Raman measurements do not provide a fair comparison of 
optimal measurement parameters. 
In comparing between the modalities, it is also possible that the order of 
measurement may have affected the result. IR is least likely of the modalities to 
cause photodamage and consequently was measured first, but if there had 
been tissue damage this could have contributed to the poor performance in the 
Raman data. If 830nm excitation damaged the tissue, then the 785nm data may 
have been affected, and this could potentially have impaired the result of its 
classification model.  Given that the performance was better for the 785nm 
data, however, this seems unlikely.  
Proposals for future work as a result of these findings, along with considerations 
for implementing Raman mapping in clinical practice, are discussed in the 




SECTION D: SUMMATIVE DISCUSSION 
CHAPTER 10: SUMMATIVE DISCUSSION AND CONCLUSIONS 
10. Summative Discussion and Conclusions 
The role of Barrett’s oesophagus as the first step in progression towards 
oesophageal adenocarcinoma has now been recognised for over 50 years. The 
metaplasia-dysplasia-adenocarcinoma sequence is well characterised, and in 
this time a wealth of research has informed our understanding of this condition. 
Developments in endoscopic therapy have provided many tools for advanced 
endoscopic imaging to aid diagnosis, and revolutionised treatment options, but 
early diagnosis remains the key to a good outcome. Large-scale surveillance 
programmes are in place in many countries for patients known to have Barrett’s 
oesophagus: however, such programmes consume a great deal of healthcare 
resources, and diagnose fewer than 10% of new cases of oesophageal 
adenocarcinoma.  
Improving Barrett’s surveillance, along with population screening, are thus 
major goals of current Barrett’s research. The current project used emerging 
techniques in vibrational spectroscopy to address this problem, with 3 key 
themes underpinning the various aspects of the project: 
i. Development of an automated histopathology tool to reduce the workload 
of Barrett’s surveillance. 
ii. Improving detection of dysplasia in Barrett’s surveillance. 




 Conclusions from this study, progress towards each of these goals, and future 
work required to take these findings further, are discussed in turn below. 
10.1. Development of an automated histopathology tool 
This was investigated with both Fourier Transform Infrared (FTIR) and Raman 
mapping, as described in chapters 4, 8 and 9. The acceptable accuracy of such 
a tool for translation into clinical practice depends on the exact role required. 
Our initial aim was to develop a model that could be used for all biopsies taken 
in the context of a possible diagnosis of Barrett’s oesophagus and associated 
neoplasia. Given the significance of a diagnosis of dysplasia or 
adenocarcinoma and implications for therapy, it is unlikely that an automated 
histology result would be considered sufficient diagnostic evidence alone, at 
least during the introduction of this new technology. Since all diagnoses of 
dysplasia require dual reporting, the most appropriate position of this 
technology would be to act as a ‘first pathologist’ for dysplasia and 
adenocarcinoma samples. Ideally therefore, accurate classification into 3 
groups (normal squamous, Barrett’s and dysplasia/adenocarcinoma) is 
required, to confirm the presence of Barrett’s and the need for surveillance, and 
then identify ‘high risk’ samples for further review: this was the aim of our 3 
group analysis for each modality.  
The results with FTIR mapping were promising. Normal squamous samples 
were identified with 100% sensitivity and specificity by the 3 group model. The 
sensitivity for dysplasia/adenocarcinoma was 95.6% (with specificity 86.4%), 
and 75% for the Barrett’s group (with specificity 96.7%). The weaker sensitivity 
of the Barrett’s group was partly a result of the threshold voting system chosen 
to improve sensitivity for dysplasia/adenocarcinoma. In clinical practice this may 
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be an acceptable trade off, since the samples labelled as ‘dysplastic’ would all 
have undergone pathology review in our proposed model and should therefore 
be re-classified correctly. Unnecessary pathology review is a less severe 
consequence than a missed diagnosis of dysplasia.  
A simpler use would be to screen out all the normal samples and review all 
samples identified as ‘abnormal’ by the model. The 100% sensitivity and 
specificity for this analysis suggests this can be performed with high accuracy; 
this role may also be more clinically acceptable as a first step in introducing this 
new technology.  
A different 2 group model could be used to identify ‘high-risk’ samples in 
patients with known Barrett’s oesophagus: a model well-suited to processing 
samples taken at surveillance endoscopy. As mentioned earlier, a screening 
test requires high sensitivity at the expense of low specificity: our 2 group model 
detected 100% of dysplastic samples with specificity 77.3%. Whilst this false 
positive rate of 22.7% would mean a relatively high rate of unnecessary 
pathology review, overall this could dramatically reduce the workload of 
pathology for Barrett’s surveillance. 
If FTIR mapping were to be translated into clinical practice, the major limitations 
at present are measurement time and cost. Our measurements took 12 minutes 
per sample but only sampled a tiny fraction of the total area of each tissue 
section. If used in clinical practice either a random sampling method could be 
used to cover the whole section, or an automated method for selecting the 
epithelium would be needed, such as combination with other optical 
approaches, to ensure an acceptable measurement time. One possible solution 
has been explored in a variety of cancer models using a combination of 
343 
 
fluorescence spectroscopy with Raman (Kong et al. 2013, 2014). Fluorescence 
spectroscopy is rapid and highly sensitive but poorly specific: using 
fluorescence to identify potential areas of disease for subsequent Raman 
interrogation greatly reduces the time taken.  
The current cost of a research FTIR microscope and spectrometer makes this 
impractical for every pathology unit. However if only a limited number of 
wavenumbers were required to achieve accurate classification, a modified 
instrument could be developed which would radically reduce cost and 
measurement time. Alternatively a more versatile FTIR device which could be 
used for many other applications may justify a greater cost.  
There were a number of limitations to the Raman mapping work investigated in 
chapters 6 and 7 that contributed to poor classification performance. Chapter 7 
aimed to compare Raman wavelengths, and provide a comparison against FTIR 
mapping, however limited conclusions may be drawn. 
For future research applications with biological samples (and if used in clinical 
practice), one possible remedy for the calibration problems we experienced 
would be to institute a post measurement check that confirmed the position of 
phenylalanine peak to within a small margin of error e.g. 998-1006cm-1.  
Aside from classification performance, there are several other differences 
between FTIR and Raman which may affect their use in clinical practice for 
mapping applications. Chief among these is the time taken for measurement: 
the FTIR maps took around 12 minutes, whereas the Raman maps took 
approximately 2 hours. Even if comparable mapping performance were 
demonstrated, this would likely be a very strong factor in choosing FTIR over 
Raman if used as a tool for screening pathology samples.  
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A further factor that may influence choice of modality in clinical practice is the 
cost – this study was performed using CaF2 slides which are necessary for 
Raman and IR in transmission mode, but IR in reflectance mode may be 
performed more cheaply using e.g. MirrIR slides, which are approximately one 
tenth the cost of CaF2 slides.  
Although fresh frozen samples were used in this study, techniques for using 
FTIR on paraffin embedded tissue have been described: this could potentially 
be a big advantage to reduce the costs and ease tissue processing.  
 
10.2. Improving detection of dysplasia in Barrett’s surveillance 
Vibrational spectroscopy has the potential to identify dysplastic change at an 
early stage in the disease process. Neoplastic changes begin with altered gene 
expression, followed by altered protein content and metabolic effects, then cell 
atypia or abnormal tissue architecture and then macroscopic abnormalities. It 
follows that a device capable of detecting the abnormal biochemical changes 
that occur at a gene/protein/metabolic level could potentially identify neoplastic 
transformation before cytological or histological changes become apparent. The 
results in Chapter 5 from FTIR analysis of the ‘squamous’ cells taken from 
diseased tissue regions are consistent with the argument that variable 
phenotypic expression follows genetic and biochemical change.  
This is a major strength of the Raman/FTIR approach and could allow earlier 
detection than conventional cytology/histology for ex vivo samples, or other 
advanced endoscopic systems in vivo. However, in the theoretical situation that 
an ideal diagnostic tool is manufactured and detects changes prior to 
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histological abnormality, this creates a very challenging situation for testing, 
since using a gold standard of histology will inevitably be limited.  
A combined approach analysing DNA, Raman/FTIR and histology may help to 
explore this further. This could be performed using multiple contiguous tissue 
sections from the same samples, with one section stained and examined by a 
histopathologist, one section measured using Raman/FTIR, and another used 
for DNA analysis. The DNA analysis could be done using single gland 
microdissection with whole genome PCR, or investigating specific genomic 
markers.  
Another approach could be to examine the ‘outliers’, where there is 
disagreement between Raman/FTIR and histology, and follow up these patients 
to assess whether the disagreement is due to an ‘incorrect’ prediction from 
Raman/FTIR, or whether it is in fact predictive of pathology that is only 
identifiable at a later stage using conventional histology.  
Several strands of this research project explored potential methods to improve 
the detection of dysplasia over current surveillance techniques of random 
biopsy and histology. Our attempts to test a novel endoscopic Raman probe are 
described in Chapter 7.  Unfortunately we were not able to carry out the 
proposed package of experimental work due to the vaporised deposits on the 
GRIN lenses. The immediate next steps in this project are outlined in chapter 7.  
One aim of the comparative Raman mapping study was to inform further probe 
work with regard to the optimal Raman wavelength. On this evidence 785nm 
has performed slightly better, but as stated earlier this conclusion is very 
tentative due to the limitations of this study (discussed in Chapter 9).  
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Since this study began, significant progress has been made by other groups in 
developing an endoscopic Raman probe for use in the oesophagus: most 
notably, a group from Singapore (Bergholt et al. 2014) have published in vivo 
work showing highly promising results. They used a confocal Raman probe 
(using 785nm) in patients with Barrett’s oesophagus, measuring spectra from 
373 patients with acquisition times 0.1-0.5s (Bergholt et al. 2014). They report 
areas under receiver-operator curves (ROC) for dichotomous discrimination as 
follows: 0.88 for CLO vs. non-dysplastic BO and HGD, 0.84 for non-dysplastic 
BO vs. CLO and HGD, and 0.90 for HGD vs. non-dysplastic BO and CLO. 
A successful endoscopic Raman probe could provide accurate real-time 
diagnosis at endoscopy. This would allow targeted biopsy to ensure areas of 
high-grade dysplasia or focal neoplasia were not missed, and facilitate 
treatment to prevent the progression to oesophageal cancer. It would also 
enable accurate assessment of the margins of disease in vivo, which would 
ensure completeness of treatment, preventing metastatic spread and 
minimising the likelihood of radical surgery in the form of oesophagectomy. 
Mapping studies also have the potential to improve detection of dysplasia if the 
techniques could be more sensitive than histology. The study exploring the 
molecular basis of Raman classification (Chapter 8) aimed to identify key 
biochemical markers used to discriminate between pathology groups. The 
results were very limited due to the unexpectedly high signal from the objective 
lens: this has led to a change in the prototype spectrometer and a lens with a 
smaller Raman signal will be used.  If sensitive biomarkers can be identified, 




10.3. Development of a non-endoscopic screening tool for Barrett’s 
oesophagus 
Spectral cytopathology (SCP) was investigated as a means of identifying 
Barrett’s oesophagus and associated neoplasia, for potential use in conjunction 
with a non-endoscopic cell collection device (Chapter 5).  
In this study, a reasonably good classification performance was seen for normal 
squamous samples (sensitivity 79.0%), and dysplasia/adenocarcinoma (83.3%), 
but the identification of Barrett’s samples was very poor (sensitivity 31.3%). 
The development of the training dataset was a complex multi-step process with 
a number of limitations discussed in Chapter 5. However, this result suggests 
that SCP may be a useful technique for analysing oesophageal cells. There is 
much potential for optimising the cell preparation process which could 
potentially greatly enhance the results. Many of these problems related to the 
small number of glandular cells on the slides, and there were many steps that 
could be improved, as discussed in Chapter 5.  
The results also showed the intriguing possibility that some cells which appear 
squamous with conventional cytology might show similar biochemical 
(spectroscopic) changes to those that appear glandular or dysplastic. This 
would make the technique more robust and less sensitive to difficulties in 
plating the glandular cells.  
Development of an automated cell detection algorithm (the binary mask) was a 
key component of the study. Further improvement of the binary mask by 
incorporating a combination of cell size criteria and multiple biochemical peaks 
could improve this processing step and ensure only cells are detected.  
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One of the major obstacles to future work in this area is obtaining a reliable gold 
standard against which to test the training model. The poor sensitivity and 
specificity in comparable fields (e.g. cervical cytology) suggests that this may 
limit the usefulness of cytology as a gold standard. Comparing against histology 
(as in the whole sample test dataset) may be more accurate, although this faces 
similar limitations  
The relatively poor sensitivity and specificity of cytology causes problems for 
testing, but supports an argument for developing spectral cytopathology since 
this an area in which diagnostic performance could readily be improved. This 
technology could potentially be applied in a range of different pathologies and 
organ systems. 
The use of spectral cytopathology in combination with a non-endoscopic 
collection device could also improve detection of dysplasia: such a device 
potentially samples the entire length of the oesophagus, and could achieve 
early detection of dysplasia as described in section 10.2 above.  
Whilst this study used samples collected at endoscopy in order to enable 
histological and endoscopic validation, there may be further challenges using a 
non-endoscopic cell collection device that collects from the stomach and entire 
oesophagus. The issue of differentiating pathological glandular cells from 
stomach cells was not resolved in the present study due to the small numbers 
of glandular stomach cells. The effectiveness of spectroscopy in discriminating 
between these groups remains to be seen. 
Another major obstacle to clinical implementation is the time needed for sample 
measurement. In the present study over 20 million spectra were measured 
using a mapping technique, but only a few thousand were then used in the 
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training dataset. If a faster automated cell detection process could be used prior 
to infrared measurement, this would avoid measuring large regions that do not 
contain cells, and focus solely on collecting useful spectra.  
Since the present study began, the first trial data (BEST2) from use of the 
Cytosponge™ has been published (Ross-Innes et al. 2015). Cases were 
patients attending for planned endoscopy for Barrett’s surveillance, and controls 
were patients undergoing endoscopy for dyspepsia and/or reflux symptoms. 
Patients were invited to swallow the Cytosponge™ prior to endoscopy, with 
endoscopy and biopsy acting as the gold standard for comparison (Barrett’s 
was defined as circumferential Barrett’s ≥1cm or maximal length ≥3cm, with 
intestinal metaplasia on any biopsy). Cytosponge™ samples were processed 
into paraffin blocks and sections immunostained for TFF3, then scored by a 
researcher and an expert histopathologist. A total of 1042 patients swallowed 
the Cytosponge™, with overall sensitivity for detecting Barrett’s 79.9%, with this 
figure increasing to 87.2% in those with ≥3cm of circumferential Barrett’s, and a 
specificity of 92.4%. This is comparable to the sensitivity seen in our study for 
normal squamous (79.9%) or dysplasia/adenocarcinoma (83.3%). The BEST2 
study did not attempt to discriminate dysplasia, but there are plans for future 
work to incorporate risk stratification using DNA analysis for p53 mutations.   
Identification of Barrett’s/dysplasia in combination is sufficient if used solely as a 
screening tool to identify those who require endoscopy. However, reliable 
detection of dysplasia could potentially replace endoscopic surveillance. The 
results of our study suggest that this may be achievable with SCP. However, 
this is a multistep technique which requires further optimisation and validation, 
which could lead to trials of SCP in combination with a non-endoscopic 
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collection device such as Cytosponge™. The ability of Cytosponge™ to detect 
dysplastic Barrett’s with p53 risk stratification is not yet known. SCP has the 
advantages of being automated (whereas immunohistochemistry requires 
interpretation by a cytopathologist), and, if slide cost were reduced by using 
transflection mode with MirrIR slides, potentially cheap. However the 
immunohistochemical and genetic approach may be quicker and more 
straightforward.  Future developments in this field will determine whether either 








Appendix I: UICC/AJCC Tumour-Node-Metastasis (TNM) staging system 
for oesophageal cancer (7th edition). 
T Status 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis High grade dysplasia 
T1 Tumour invades lamina propria, muscularis mucosae or submucosa 
T1a Tumour invades lamina propria or muscularis mucosae 
T1b Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades adventitia 
T4 Tumour invades adjacent strutures 
T4a Resectable tumour invading the pleura, pericardium or diaphragm. 
T4b Unresectable tumour invading other adjacent structures such as the 
aorta, vertebral body or trachea. 
N Status 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-2 regional lymph nodes 
N2 Metastasis in 3-6 regional lymph nodes 
N3 Metastasis in 7 or more regional lymph nodes 
M Status 
Mx Distant metastases cannot be assessed 
M0 No distant metastasis 
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M1 Distant metastasis 
Histological grading 
G1 Well differentiated 
G2 Moderately differentiated 
G3 Poorly differentiated 
G4 Undifferentiated 




Appendix II: Guidelines for surveillance of Barrett’s oesophagus 
Grade of 
dysplasia 
ACG ASGE AGA BSG SFED 
      
Non-dysplastic 
BO 
2 OGDs in first year, 





OGD every 3-5 years 
OGD every 3-5 
years. 
BO<3cm (with IM), 
OGD every 3-5 years. 
BO≥3cm, OGD every 
2-3 years. 
BO<3cm, OGD 
every 5 years. BO3-
6cm, OGD every 3 
years. BO>6cm, 
OGD every 2 years. 
LGD Repeat OGD within 6 
months; if no HGD, 
then every 1 year 
Repeat OGD within 6 
months; if no HGD, then 
every 1 year 
OGD every 6-12 
months 
Repeat OGD within 3 
months; if no HGD, 
then every 6 months 
Repeat OGD. If 
LGD confirmed, 
OGD 6 months, 1 
year, then yearly. 
HGD  Repeat OGD within 3 
months, then every 3 
months or consider 
endoscopic  therapy. 
Consider repeat OGD 
within 3 months or 
endoscopic therapy 
OGD every 3 










ACG, American College of Gastroenterology; ASGE, American Society for Gastrointestinal Endoscopy; AGA, American 
Gastroenterological Association; BSG, British Society of Gastroenterology; SFED, French Society of Digestive Endoscopy; BO, Barrett’s 
oesophagus; OGD, oesophago-gastroduodenoscopy; LGD, low-grade dysplasia; HGD high-grade dysplasia. Adapted from de Jonge et 
al., 2013.   
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Appendix III: Comparison of advanced endoscopic imaging techniques 
Modality type Modality Tissue Information Advantages Disadvantages Development 
stage 
Wide field imaging 
techniques 
High Resolution Endoscopy 
(HRE) 







Low cost, improved lesion 
detection 




Digital chromoendoscopy (e.g. 




Avoids messy dyes, rapid Operator dependent Commercially 
available 
Autofluorescence Imaging (AFI) Field change within 
tissue 
Sensitive identification of 
neoplasia and inflammation 
High false positive rate Commercially 
available 
Multimodal (HRE/AFI/NBI) Glandular 
architecture/ 
vascularity 
Improved detection rate and 
fewer false positives 












Optical Coherence Tomography Tissue structure Defines histology Insufficient accuracy at 
present 
In vivo feasibility 






Elastic Scattering Spectroscopy Cellular structure Objective, relatively lower cost 
than other spectroscopy 
techniques 
High signal interference 
limits accuracy 
In vivo feasibility 
Raman Spectroscopy Biochemical Objective, defines histology Weak signal, complex 
data interpretation 





Appendix IV: Consent form for specimen collection 
Gloucestershire Hospitals 
 
NHS Foundation Trust 
Biophotonics Research 
Cranfield Health 
Gloucestershire Royal Hospital 
Great Western Road 
Gloucester 
GL1 3NN 
Tel 0300 4225470 





Version 4 – January 2014 
 
Early Diagnosis of Oesophageal Malignancy  
 
Lead Researchers: Prof H Barr, Dr N Stone, Dr C Kendall 
 
Please initial each box 
1. I confirm that I have read and understand the information sheet, dated January 2014
(version 4), for the above study and have had the opportunity to ask questions.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time,
without giving any reason, without my medical care or legal rights being affected. In the
event that I wish to withdraw from this study, data collection will cease immediately and
I can request that all data collected is confidentially destroyed. 
 
3. I understand that Dr N Stone, Dr C Kendall from the Biophotonics Research Group, may
access sections of my medical notes, where it is relevant to my taking part in research. I
give permission for these individuals to have access to my records. 
 
4. I agree to take part in this study.  
 
5. I understand that you may take additional samples during the course of my care to help
you develop new diagnostic tests. These samples may be made available for research
after all the procedures required for my clinical management have been completed. I give
my consent.  
 
 
.............................……..   .....................  ...................……………  
Name of Patient   Date   Signature 
 
.............................……..   .....................   ...................……………  
Name of person taking consent Date   Signature 
(if different from researcher) 
 
..................... ........……..   .....................   ...................……………  
Name of Researcher   Date   Signature 
 
 
1 copy for patient, 1 for researcher, 1 for hospital notes 
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Appendix V: Patient information leaflet 
Gloucestershire Hospitals 
 
NHS Foundation Trust 
Biophotonics Research 
Cranfield Health 
Gloucestershire Royal Hospital 
Great Western Road 
Gloucester 
GL1 3NN 
Tel 0300 4225470 
Fax 0300 4225485 
c.kendall@medical-research-centre.com 
 
Early Diagnosis of Oesophageal Malignancy  
 
Lead Researchers: Prof H Barr, Dr N Stone, Dr C Kendall 
 
You are invited to take part in a research study being carried out at the Gloucestershire Royal
Hospital. Before you decide whether you would like to participate it is important for you to
understand why the research is being done, and what it will involve. Please take time to read the
following information carefully and discuss it with others if you wish. Please ask us if there is
anything unclear or if you would like further information. Please take time to decide whether or
not you wish to take part. Thank you for reading this information. 
 
What is the purpose of the study? 
The staff of Gloucestershire Royal Hospital and scientists at Cranfield University are working
together to find new ways of providing advanced clinical support for the local community. An
area where we feel we can make major advances is in improving our ability to detect
oesophageal disease, pre-cancer and cancer. 
 
Why have I been chosen? 
We will be collecting samples from many people under surveillance for Barrett's oesophagus.
Therefore this request does not mean that your diagnosis is unsure. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to participate you will be
given this information sheet to keep and will be asked to sign a consent form. If you decide to
take part you are still free to withdraw at any time and without giving a reason. Your care,
treatment or method of assessment will not be altered in any way by your decision to donate or
otherwise.  
 
What will happen to me if I take part? 
Your doctor has explained to you that he/she will be removing some oesophagus tissue during
the course of your care. Specialist staff within the hospital will examine this tissue and your care
guided by what they find. If you are willing to allow us, we can use a small number of additional
samples to help us develop new diagnostic tests. No additional procedures will be undertaken as
a result of your consent. In addition there is no need for any lifestyle restrictions to participate in






NHS Foundation Trust 
Biophotonics Research 
Cranfield Health 
Gloucestershire Royal Hospital 
Great Western Road 
Gloucester 
GL1 3NN 
Tel 0300 4225470 
Fax 0300 4225485 
c.kendall@medical-research-centre.com 
 
What is being tested in this study? 
We are developing new techniques using light for the early detection of disease. Using advanced
rapid tests we hope to be able to easily detect this disease earlier without the need for long
uncomfortable procedures. Before these investigations can be carried out on patients, it is
necessary to assess its suitability with human tissue in the laboratory. The Biophotonics
Research Group based at the Gloucestershire Royal Hospital has over five years experience of
working in this field. 
 
What are the possible disadvantages and risks of taking part? 
No additional procedures to your routine care will be undertaken as part of this study, therefore
there are no associated additional risks. 
 
What are the possible benefits of taking part? 
No additional procedures to your routine care will be undertaken as part of this study, therefore
there is no immediate clinical benefit to yourself. However, the information collected from this
study may help us develop new techniques to improve the treatment of patients with Barrett’s
oesophagus. 
 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be kept strictly
confidential. If you consent to taking part in this study you will give permission for Dr N Stone
& Dr C Kendall, from the Biophotonics Research Group to have access to your medical notes,
where it is relevant to your taking part in research.  
 
What will happen to the results of the research study? 
We hope that the results will be published in scientific and medical journals. You will not be
identified in any way in such a publication. 
 
Who is funding and organising the research? 
The research is funded by the NIHR, The Royal Society & Institute of Physics and Engineering
in Medicine. It is being carried out by Cranfield Postgraduate Medical School, a link between the
Gloucestershire Hospitals NHS Foundation Trust and Cranfield University. 
 
Who has reviewed the study? 
The Gloucestershire Local Research Ethics Committee has reviewed the study. 
 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical Research and
You’. This leaflet gives more information on medical research. A copy can be obtained from 
CERES, PO Box 1365, London N16 0BW. 
 
Thank you for your help and co-operation. If you have any questions please contact 

















Appendix VII: Double pathology review of all tissue samples included 
(i) Samples included in the FTIR mapping/comparative Raman mapping 
studies (Chapters 4 and 9). 
SAMPLE  PATHOLOGIST 1 PATHOLOGIST 2 
N1 NORMAL SQUAMOUS NORMAL SQUAMOUS 
N2 NORMAL SQUAMOUS NORMAL SQUAMOUS 
N3 NORMAL SQUAMOUS NORMAL SQUAMOUS 
N4 NORMAL SQUAMOUS NORMAL SQUAMOUS 
N5 NORMAL SQUAMOUS NORMAL SQUAMOUS 
B1 BARRETT'S BARRETT'S 
B2 BARRETT'S BARRETT'S 
B3 BARRETT'S BARRETT'S 
B4 BARRETT'S BARRETT'S 
B5 BARRETT'S BARRETT'S 
B6 BARRETT'S BARRETT'S 
D1 HGD LGD 
D2 HGD LGD 
D3 HGD HGD 
D4 HGD LGD 
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D5 HGD LGD 
A1 ADENOCA. ADENOCA. 
A2 ADENOCA. ADENOCA. 
A3 ADENOCA. ADENOCA. 
A4 ADENOCA. ADENOCA. 
A5 ADENOCA. ADENOCA. 
A6 ADENOCA. ADENOCA. 
 
(ii) Samples included in the Raman mapping to explore the basis of 
molecular classification (Chapter 8). 
SAMPLE  PATHOLOGIST 1 PATHOLOGIST 2 
1 BARRETT'S BARRETT'S 
2 ADENOCA. MALIGNANT (UNSURE TYPE) 
3 BARRETT'S BARRETT'S 
4 BARRETT'S BARRETT'S 
5 BARRETT'S BARRETT'S 
7b ADENOCA. ADENOCA. 
8a BARRETT'S BARRETT'S 
9 HGD INDEFINITE FOR DYSPLASIA 
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12c NORMAL SQUAMOUS NORMAL SQUAMOUS 
12d ADENOCA. ADENOCA. 
14a ADENOCA. ADENOCA. 
16d BARRETT'S BARRETT'S 
17 BARRETT'S BARRETT'S 
18 BARRETT'S BARRETT'S 
21 LGD BARRETT'S 
22a1 ADENOCA. ADENOCA. 
23 LGD BARRETT'S 
24X BARRETT'S BARRETT'S 
24Yb NORMAL SQUAMOUS NORMAL SQUAMOUS 
25 HGD LGD 
28 NORMAL SQUAMOUS NORMAL SQUAMOUS 
30a BARRETT'S BARRETT'S 
30b BARRETT'S BARRETT'S 
32a HGD HGD 
32b BARRETT'S BARRETT'S 
33a NORMAL SQUAMOUS NORMAL SQUAMOUS 
34a BARRETT'S BARRETT'S 
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35b BARRETT'S BARRETT'S 
35c HGD HGD 
35d HGD LGD 
36a ADENOCA. MALIGNANT (UNSURE TYPE) 
37a NORMAL SQUAMOUS NORMAL SQUAMOUS 
37b LGD LGD 
38c NORMAL SQUAMOUS NORMAL SQUAMOUS 
39 HGD LGD 
40 ADENOCA. ADENOCA. 
41b ADENOCA. LGD 
41c NORMAL SQUAMOUS NORMAL SQUAMOUS 
43a NORMAL SQUAMOUS NORMAL SQUAMOUS 
43b BARRETT'S BARRETT'S 
43c ADENOCA. ADENOCA. 
45a NORMAL SQUAMOUS NORMAL SQUAMOUS 
45b BARRETT'S BARRETT'S 
45c ADENOCA. ADENOCA. 
46a NORMAL SQUAMOUS NORMAL SQUAMOUS 
46b ADENOCA. LGD 
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47 LGD LGD 
48a LGD LGD 
48b LGD BARRETT'S 
49a NORMAL SQUAMOUS NORMAL SQUAMOUS 
49b ADENOCA. ADENOCA. 
50a NORMAL SQUAMOUS NORMAL SQUAMOUS 
50c ADENOCA. ADENOCA. 
53b ADENOCA. ADENOCA. 
54a ADENOCA. ADENOCA. 
55a ADENOCA. MALIGNANT (UNSURE TYPE) 
56a ADENOCA. ADENOCA. 
56c NORMAL SQUAMOUS NORMAL SQUAMOUS 
57 HGD HGD 





Appendix VIII: In-house reference spectra 
 
 





Appendix IX: Experimental plans  
1. Evaluation of ‘reproducibility’ of probe measurements 
a. Use polytetrafluoroethylene (PTFE) standard – measure 5 spectra 
with 3 acquisition times: 0.1s, 1s, 10s. 
i. Measure using different probes (5 ‘new’ probes and 
compare with  ‘old’ prototype probe) 
ii. Measure using different spectrometers (2) 
iii. Measurements by multiple operators (3) 
b. Green glass – repeat as above for different probes and 
spectrometers 
c. Air background – repeat as above for different probes and 
spectrometers 
2. Repeat for PTFE with 1 acquisition time (1s) for different incident angles 
(e.g. 15, 30, 45, 60, 75, 90 degrees). 
3. Evaluation of probe stability (repeat for each of 5 probes) 
a. Temporal variation – measure PTFE standard with 1s acquisition 
at 2 minute intervals after switching probe on up to 60 minutes. 
b. Effect of switching laser ‘on’ and ‘off’ after it has warmed up – 
measure PTFE standard with 1s acquisition after laser switched 
off for 1 minute x20. 
4. Evaluate depth of measurement 
a. Sequential measurements of standard e.g. silicon with increasing 
layers of PTFE tape (approx. 50 microns thick per layer). 
b. As above but using intra-lipid with varying depth instead of PTFE. 
5. Reproducibility in tissue measurements (for 3 covered probes only) 
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a. Using a tissue sample, measure defined points using a grid – 
repeat as above for different probes (3)/spectrometers (2)/multiple 
operators (3). 
6. Other variables which may affect probe measurement 
a. Effects on tissue of repeated measurement – measure a defined 
point using grid, same probe, same spectrometer, same operator, 
1s acquisitions x150. 
b. Effect of saline/water/antifoam lavage on fresh tissue 
measurement – 1s acquisitions x5 with each. 
c. Effect of endoscopic white light/narrow band imaging – x5 1s 
acquisitions in presence of (i) no ambient light (ii) endoscopic 
white light (iii) narrow band imaging. 
7. Evaluation of diagnostic capability 
a. Ex vivo oesophagectomy measurements 
i. Open specimen and wash in distilled water. Secure grid on 
oesophagectomy specimen, measure spectra at each 
position (0.1s, 0.5s, 1s acquisition times) then take biopsy 
from same grid position.  
ii. Unopened oesophagus specimen – passing probe down 
endoscope with large lumen instrument channel. Measure 
a spectrum followed immediately by biopsy at each site 
(can use probe to indent tissue after measurement to 
identify site for biopsy), repeat 10 sites per specimen. 
b. Endoscopic resection specimens 
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i. Defrost specimen and mount on CaF2 slide. 0.1s, 0.5s and 







Appendix X: Objective lens signal simulation 
This related work was performed by other members of the Biophotonics team in 
response to the results measured on the 802 system, presented in Chapter 8. 
The aim was to use a simulated 2 group dataset and an objective lens with 
comparable intensity to the measured signal, and model what effect varying the 
intensity of the objective lens background signal had on the classification ability. 

















They applied the objective lens signal at varying thresholds to the simulated 
dataset, then developed a classification model using PCA-fed LDA. The mean 
spectral signals and associated PCA scatter plots for two values (10% and 70% 




Figure XI-IIA Effect of objective lens signal applied at 10% of full intensity on 





Figure XI-IIB Effect of objective lens signal applied at 70% of full intensity on 
dataset mean spectra and classification ability on PCA scatter plot.  
In Figure XI-IIA, the effect of an objective lens spectrum with 10% of the 
intensity is seen as a small amount of ‘noise’ in the signal of the mean 
spectrum, but PCA can achieve very clear separation of the 2 groups. However 
at 70% of the intensity (Figure XI-IIB), there is a large increase in the noise in 
the spectrum, and a complete loss of ability to discriminate on PC score. Figure 
XI-III shows how the ability of PCA to discriminate varies for objective lens 




Figure XI-III Effect of objective lens signal intensity (‘Proportion objective’) on 
the ability of PCA to discriminate (‘Performance’) between 2 groups in simulated 
model.  
As the objective intensity increases from 60-75%, the background shot noise 
overwhelms the differences between the spectra of the two groups. Over 
multiple iterations, where the classification performance was over 95% accurate 
with no objective signal present, the discrimination was no better than random 












Appendix XI: Prizes, awards, presentations and publications during MD  
AWARDS 
• Gloucestershire Hospitals NHS Trust Innovation Award 2015: 
Biophotonics Research Team. 
• Stefan & Anna Galeski/Rex & Jean Lawrie Travelling Fellowship, Sri 
Lanka, March-April 2014. 
• University of Exeter Medical School Annual Research Event, 2nd Prize, 
May 2014. 
• BMJ Cancer Team of the Year, Runner up, May 2014. 
• British Society of Gastroenterology Poster Prize, June 2014. 
• Doyle Travel Award, Heartburn Cancer Awareness and Support, 
September 2014. 
• Harry Morton Anglo-Canadian Travel Fellowship, Royal College of 
Surgeons Of England/Royal College of Physicians and Surgeons of 
Canada, October 2014. 




• Diem M, Miljković M, Bird B, Mazur AI, Schubert JM, Townsend D, Laver 
N, Almond M, Old O. Cancer screening via infrared spectral 
cytopathology (SCP): results for the upper respiratory and digestive 
tracts. Analyst 2015. 
• Old O, Moayyedi P, Love S, Roberts C, Hapeshi J, Foy C, Stokes C, 
Briggs A, Jankowski J, Barr H. 'Barrett's Oesophagus Surveillance 
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versus endoscopy at need Study (BOSS): protocol and analysis plan for 
a multicentre randomised controlled trial.' J Med Screen 2015 22(3):158-
64 
• Old O, Almond M, Barr H. ‘Barrett’s – how should we manage it?’ 
Frontline Gastroenterol 2015;6:108-116  
• D Townsend, M Miljkovic, B Bird, K Lenau, O Old, M Almond, C Kendall, 
G Lloyd, N Shepherd, H Barr, N Stone, M Diem. Infrared 
microspectroscopy for cyto-pathological classification of esophageal 
cells. Analyst 2015 140(7):2215-23 
• Old OJ, Hardy T, Kulkarni S, Slim F, Emerson L, Bulbulia R, Whyman M, 
Poskitt K. 'Incidental non-inguinal hernias in totally extra-peritoneal 
(TEP) hernia repair. Ann R Coll Surg Engl. 2015 Mar;97(2):120-4  
• Almond LM, Old O, Barr H. Strategies for the Prevention of Oesophageal 
Adenocarcinoma. Int J Surg. 2014;12(9):931-5. 
• Weaver JM et al.; the OCCAMS Consortium. Ordering of mutations in 
preinvasive disease stages of esophageal carcinogenesis. Nat Genet. 
2014;46(8):837-43.  
• L. Max Almond, Oliver Old, Nick Stone, Catherine Kendall, Gavin Rhys 
Lloyd, Joanne Hutchings, John Horsnell, Charlotte Kallaway, Hugh Barr. 
Real-time disease detection using spectroscopic diagnosis. Biomedical 
Spectroscopy and imaging, 2014;3(3):197-202 
• Rowlands C et al.; on behalf of the Severn and Peninsula Audit and 
Research Collaborative for Surgeons (SPARCS); the Northwest 
Research Collaborative. Surgical ward rounds in England: a trainee-led 




• Old, OJ, Fullwood LM, Scott R, Lloyd GR, Almond LM, Shepherd NA, 
Stone N, Barr H, Kendall C. ‘Vibrational Spectroscopy for cancer 
diagnostics’ Anal. Methods, 2014;6:3901-17  
 
Book chapters 
• Old OJ, Almond LM, Barr H, Jankowski J. ‘Chemoprevention in 
esophageal carcinoma’, in Esophageal cancer Prevention, Diagnosis 
and Therapy, Springer, 2015. 
• Old OJ, Almond LM, Griggs R, Lloyd GR, Horsnell J, Kallaway C, 
Fullwood L, Das K, Hutchings J, Kendall C, Stone N, Barr H. In vivo 





• Old O. Early detection of Barrett’s dysplasia. St Michael’s Hospital, 
Toronto, October 2014. Invited talk.  
• Old O. Vibrational spectroscopy for detection of Barrett’s neoplasia. 
Princess Margaret Cancer Centre, Toronto, October 2014. Invited talk. 
• Old OJ, Almond LM, Lloyd GR, Kendall C, Stone N, Barr H. ‘Real-time 
diagnosis of high-grade dysplasia and early oesophageal cancer using 
Raman spectroscopy’. International Conference of Photodynamic 
Applications’. Dundee, May 2014. 
• Old OJ, Almond LM, Lloyd GR, Kendall C, Stone N, Barr H. ‘Real-time 
diagnosis of high-grade dysplasia and early oesophageal cancer using 
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Raman spectroscopy’. BioRaman workshop, Warsaw, Poland, May 
2014. 
• Old OJ, Almond LM, Lloyd GR, Hutchings J, Shepherd N, Barr H, 
Kendall C, Stone N. Novel fibre-optic Raman probe for real-time 
diagnosis of early oesophageal cancer. SPEC, Krakow, Poland, August 
2014. 
• Old O, Almond M, Lloyd G, Townsend D, Lenau K, Diem M, Barr H. 
Infrared spectral cytopathology as a diagnostic tool in screening for 
Barrett’s esophagus. International Society for Diseases of the 
Esophagus (ISDE), Vancouver, September 2014. Oral. 
• Old O, Stokes C, Woods S, Foy C, Hapeshi J, Barr H; on behalf of the 
BOSS team.  Successful recruitment to Barrett’s Oesophagus 
Surveillance Study (BOSS): you CAN randomize to ‘at need’ endoscopy. 
ISDE, Vancouver, September 2014. Oral. 
• Old OJ, Almond LM, Lloyd GR, Kendall C, Stone N, Barr H. Advanced 
endoscopic imaging of Barrett’s Esophagus: a feasibility study of Raman 
Spectroscopy in the presence of endoscopic white light and Narrow 
Band Imaging. ISDE, Vancouver, September 2014. Oral. 
 
National Presentations 
• Raman mapping to classify pathology in Barrett's oesophagus. O Old, M 




• Non-endoscopic screening: identifying Barrett's neoplasia with infrared 
spectroscopy. O Old, LM Almond, G Lloyd, C Kendall, A Shore, H Barr, 
N Stone. Barrett's Symposium, UCL, April 2015. Poster.  
• Dual modality endoscopic therapy in Barrett’s associated Oeosphageal 
Dysplasia in a Tertiary Centre: completing the audit cycle. C J Florance, 
M Almond, O Old, H Barr. DDF, London, June 2015. Poster. 
• Non-endoscopic screening for Barrett's oesophagus: identifying 
dysplasia with infrared spectroscopy. O Old, LM Almond, G Lloyd, C 
Kendall, A Shore, H Barr, N Stone. DDF, London, June 2015. Poster.  
• Raman mapping to classify pathology in the oesophagus. O Old, M 
Isabelle, G Lloyd, K Curtis, C Kendall, H Barr, N Stone. DDF, London, 
June 2015. Poster. 
• Selected to present on behalf of RCS Research Fellows at Freemasons, 
Newport, June 2015.  
• Old OJ, Barr H. Barrett’s oesophagus: current challenges. Invited 
speaker, Gastroenterology and Nutrition Symposium, Worcester, 
September 2014. 
• Old OJ, Almond LM, Lloyd GR, Kendall C, Stone N, Barr H. ‘Real-time 
diagnosis of high-grade dysplasia and early oesophageal cancer using 
Raman spectroscopy’. International Conference of Photodynamic 
Applications’. Dundee, May 2014. Oral presentation. 
• Old O, Stokes C, Woods S, Foy C, Hapeshi J, Barr H; on behalf of the 
BOSS team.  Barrett’s Oesophagus Surveillance Study (BOSS): 
overcoming the challenges of recruitment to a large Randomised 
Controlled Trial. AUGIS, Brighton, September 2014. Poster. 
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• Old O, Hardy T, Hewin D, Barr H, Brown J. Post-ERCP Pancreatitis In 
Secondary Care: Can We Predict Who Would Benefit From A 
Prophylactic Pancreatic Stent? BSG, Manchester, June 2014. 
• Old O, Almond M, Lloyd G, Townsend D, Lenau K, Diem M, Barr H. 
Barrett's Oesophagus Screening: Infrared Spectroscopy For Cytological 
Assessment. BSG, Manchester, June 2014. Awarded Poster Prize. 
• Old O, Stokes C, Woods S, Foy C, Hapeshi J, Barr H; on behalf of the 
BOSS team. Barrett's Oesophagus Surveillance Study (BOSS) Update: 
Successful Recruitment To A Long Follow-up RCT. BSG, Manchester, 
June 2014. 
• Old OJ, Almond LM, Lloyd GR, Diem M, Barr H. ‘Infrared spectroscopy 
for accurate detection of Barrett’s oesophagus and dysplasia’. ASGBI, 
Harrogate, April 2014. Oral presentation. 
 
COURSES 
• BEST Academia course: Endoscopic resection and RFA for Barrett's 
neoplasia. Cambridge, September 2015.  
• BioRaman workshop, Warsaw, May 2014 
• RCS Research Methods, RCS London, November 2013. 
• University of Exeter Professional Skills for Doctors in Specialty Training, 
Nov 2013-Oct 2014 
• Laser Safety Course, Gloucestershire Royal Hospital, December 2013 




OTHER RESEARCH ACTIVITY 
Clinical Trials 
• Local Investigator, Gloucestershire Hospitals NHS Foundation Trust, 
Barrett’s Oesophagus Surveillance Study (BOSS): multi-centre 
randomised controlled trial. 
• Local Investigator, Gloucestershire Hospitals NHS Foundation Trust, 
Aspirin Esomeprazole Chemoprevention Trial (AspECT): multi-centre 
randomised controlled trial. 
• Local Investigator, Gloucestershire Hospitals NHS Foundation Trust, 
Oesophageal Cancer Clinical and Molecular Strategy (OCCAMS): multi-
centre trial. 
• Local Investigator, Gloucestershire Hospitals NHS Foundation Trust, 




• I co-designed and supervised a project with a medical student (Avgi 
Loizidou) from the University of Bristol, who undertook a 4 week special 
study module in the Biophotonics Research Unit. 
• I set up an international collaboration with a group from the University of 
Toronto. I have co-designed and will co-supervise this project, which will 
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